

The International Society for Heart and Lung Transplantation
Twenty-Third Annual Meeting and Scientific Sessions
April 9-12, 2003
Convening at the Hofburg Congress Center
Vienna, Austria
Final Program

Board of Directors

President

Stephan Schueler, MD, Newcastle, United Kingdom

President-Elect

Jon Kobashigawa, MD, Los Angeles, CA

Past President

James B. Young, MD, Cleveland, OH

Secretary/Treasurer

Alec Patterson, MD, St. Louis, MO

Directors

Paul A. Corris, MB, FRCP, Newcastle, United Kingdom

Sabina M. De Geest, RN, PhD, Basel, Switzerland

F. Jay Fricker, MD, Gainesville, FL

Luigi Martinelli, MD, Genova, Italy

Soon J. Park, MD, Minneapolis, MN

Hermann Reichenspurner, MD, PhD, Hamburg, Germany

W. Steves Ring, MD, Dallas, TX

Robert C. Robbins, MD, Stanford, CA

Heather J. Ross, MD, Toronto, Canada

David O. Taylor, MD, Cleveland, OH

Adriana Zeevi, PhD, Pittsburgh, PA

JHLT Editor

James K. Kirklin, MD, Birmingham, AL

Heart and Lung Transplant Registry Medical Director

Marshall I. Hertz, MD, Minneapolis, MN

Mechanical Circulatory Support Device Database Medical Director

Mario C. Deng, MD, New York, NY

Staff

Amanda W. Rowe

Executive Director

Phyllis Glenn

Assistant Executive Director

Director of Membership Services

Lisa Edwards

Director of Meetings

LeeAnn Mills

Director of Operations

14673 Midway Road, Suite 200

Addison, TX 75001

Phone: 972-490-9495

Fax: 972-490-9499

www.ishlt.org

ishlt@ishlt.org

PAST PRESIDENTS

1981-1982	Michael Hess, MD
1982-1984	Jack Copeland, MD
1984-1986	Terence English, FRCS
1986-1988	Stuart Jamieson, MD
1988-1990	Bruno Reichart, MD
1990-1991	Margaret Billingham, MD
1991-1992	Christian Cabrol, MD
1992-1993	John O'Connell, MD
1993-1994	Eric Rose, MD
1994-1995	John Wallwork, FRCS
1995-1996	Sharon Hunt, MD
1996-1997	William Baumgartner, MD
1997-1998	Leslie Miller, MD
1998-1999	Alan Menkis, MD, FRCS(C)
1999-2000	Robert L. Kormos, MD
2000-2001	Anne Keogh, MBBS, MD
2001-2002	James B. Young, MD

AWARD RECIPIENTS

LIFETIME SERVICE AWARD

1996 Michael Kaye
1997 Jacques Losman

LIFETIME ACHIEVEMENT AWARD

1999 Keith Reemtsma, MD
1996 Norman Shumway, MD

ISHLT/ROCHE TRANSPLANT CAREER DEVELOPMENT AWARD

2002 Anthony Azakie, MD
2000 Gordon D. Wu, MD

ISHLT/ROCHE TRANSPLANT RESEARCH FELLOWSHIP GRANT

2002 Ruediger Hoebelt, MD
2001 Matteo Vatta, PhD
2001 Arnar Geirsson, MD
2000 Christopher H. Wigfield, FRCS
1999 Donald Wong, PhD
Sivasai Krovvidi, PhD
1998 Kelly S.A. Blair, MD
A.M. El Gamel, MD
1997 Jonathen Chen, MD
Anne K. Raisanen-Sokolowski, MD
1996 Tuija S. Ikonen, MD

ISHLT/NOVARTIS TRANSPLANT RESEARCH FELLOWSHIP GRANT

2000 Richard S. Lee, MD
1999 George Juang, MD
Satoshi Saito, MD
1998 Margaret L. Schwarze, MD

ISHLT TRANSPLANT RESEARCH FELLOWSHIP GRANT

1998 Scott D. Ross, MD

ISHLT/WYETH-AYERST TRANSPLANT RESEARCH FELLOWSHIP GRANT

1998 Christine L. Lau, MD

ISHLT/ORTHO BIOTECH TRANSPLANT RESEARCH FELLOWSHIP GRANT

1997 Owen T. Lawrence, MD
1996 Andrew F. Pierre, MD
1995 Frances L. Johnson, MD

ISHLT/FUJISAWA TRANSPLANT RESEARCH FELLOWSHIP GRANT

1997 Alyssa M. Krasinskas, MD

ISHLT NURSING RESEARCH GRANT

2002 Annette J. De Vito Dabbs, RN, MN, PhD
2001 Lynn Doering, RN, DNSc
2000 Nancy M. Albert, MSN, RN
1999 Jeanne Salyer, PhD

1998 Katherine St. Clair, RN, MSN
1997 Eileen Collins, RN, PhD

CAVES AWARD

2002 Peter Blaha, MD
2001 Alexander S. Krupnick, MD
2000 Michael P. Fischbein, MD
1999 Joerg Koglin, MD
1998 Carla C. Baan, MD
1997 Simon D. Eiref, MD
1996 Moninder S. Bhabra, MD
1995 Elizabeth A. Davis, MD
1994 Jobst Winter, MD
1994 Alain Chapelier, MD
1993 David Marshman, MD
1992 David P. Kapelanski, MD
1991 A. Jiminez, MD
1990 Andres J. Duncan, MD
1989 A.M. Wood, MD
1988 Charles D. Fraser, Jr., MD
1987 Wim Van Der Bij, MD
1986 Stuart J. Knechtle, MD
1985 Michael A. Breda, MD
1984 Hermann Reichensperner, MD
1983 Robbin G. Cohen, MD

SCIENTIFIC PROGRAM COMMITTEE

Bruce R. Rosengard, MD, Philadelphia, PA, 2003 Program Chair
Stephan Schueler, MD, Newcastle, United Kingdom, ISHLT President
Robert C. Robbins, MD, Stanford, CA, 2002 Chair
Mandeep R. Mehra, MD, New Orleans, LA, 2004 Program Chair
James K. Kirklin, MD, Birmingham, AL, JHLT Editor
Annalisa Angelini, Padova, Italy
Michael A. Acker, Philadelphia, PA
Selim M. Arcasoy, MD, New York, NY
Nancy P. Blumenthal, CRNP, Philadelphia, PA
Susan C. Brozena, Philadelphia, PA
John Dark, MB, FRCS, Newcastle, United Kingdom
Thomas J. Dengler, MD, Heidelberg, Germany
Mariell Jessup, MD, Philadelphia, PA
Asghar Khagani, FRCS, Amersham Bucks, United Kingdom
Robert L. Kormos, MD, Pittsburgh, PA
Walter Klepetko, MD, Vienna, Austria
Gunther Laufer, MD, Innsbruck, Austria
Robert B. Love, MD, Madison, WI
Joren C. Madsen, MD, Boston, MA
Bruno M. Meiser, MD, Munich, Germany
Carmelo A. Milano, MD, Durham, NC
Michael S. Mulligan, MD, Seattle, WA
Barry K. Rayburn, MD, Birmingham, AL
Doris A. Taylor, PhD, Durham, NC
George Tellides, MD, New Haven, CT
Carol Twomey, CRNP, Philadelphia, PA
Steven A. Webber, MB, ChB, Pittsburgh, PA
Lori J. West, MD, DPhil, Toronto, Canada
Thomas D. Wekerle, MD, Vienna, Austria

ABSTRACT REVIEWERS

Keith Aaronson, MD, Ann Arbor, MI
James S. Allan, MD, Boston, MA
Abbas Ardehali, MD, Los Angeles, CA
Estela Azeka, MD, San Pablo, Brazil
Carla C. Baan, MD, Rotterdam, The Netherlands
Mark L. Barr, MD, Los Angeles, CA
William A. Baumgartner, MD, Baltimore, MD
Sangeeta M. Bhorade, MD, Chicago, IL
Margaret Burke, MB, MRCPATH, Harefield, Middlesex, United Kingdom
Susan V. Chambers, CRNP, Philadelphia, PA
Roberto M. Colque, MD, Cordoba, Argentina
John V. Conte, MD, Baltimore, MD
Maria Crespo-Leiro, MD, La Coruna, Spain
Richard C. Daly, MD, Rochester, MN
John J. Dunning, FRCS, Cambridge, United Kingdom
Jim J. Egan, MD, Dublin, Ireland
Howard J. Eisen, MD, Philadelphia, PA
Marc Estenne, MD, Brussels, Belgium
Albert Faro, MD, Gainesville, FL
Michael C. Fishbein, MD, Los Angeles, CA
David M. Follette, MD, Sacramento, CA
J. Michael Gokel, MD, Krefeld, Germany
Lee R. Goldberg, MD, Philadelphia, PA
Kathleen L. Grady, RN, PhD, Chicago, IL
Edoardo G. Gronda, MD, Milan, Italy
Frederick L. Grover, MD, Denver, CO
Elizabeth Hammond, MD, Salt Lake City, UT
Paul Hendry, MD, Ottawa, ON, Canada

Roland Hetzer, MD, PhD, Berlin, Germany
Katherine Hoercher, RN, Cleveland, OH
Theresa Hollander, PhD, Philadelphia, PA
Daphne T. Hsu, MD, New York, NY
Charles B. Huddleston, MD, St. Louis, MO
Brian E. Jaski, MD, La Jolla, CA
Valluvan Jeevanandam, MD, Chicago, IL
Kirk R. Kanter, MD, Atlanta, GA
Edward K. Kasper, MD, Baltimore, MD
Anne Keogh, MBBS, MD, Sydney, Australia
Shaf Keshavjee, MD, Msc, FRCS, Toronto, ON, Canada
Christer Kjellstrom, MD, Goteborg, Sweden
Jon Kobashigawa, MD, Los Angeles, CA
Joerg Koglin, MD, Munich, Germany
Stephen R. Large, MS, FRCS, Cambridge, United Kingdom
Daniel Y. Loisanche, MD, Creteil, France
Keith McNeil, FRACP, Brisbane, Australia
Philippe Menasche, MD, PhD, Paris, France
Paul J. Mohacsi, MD, Berne, Switzerland
Johannes Mueller, MD, Berlin, Germany
Yoshifumi Naka, MD, PhD, New York, NY
Charles G. Orosz, PhD, Columbus, OH
Walter E. Pae, Jr., MD, Hershey, PA
Francis D. Pagani, MD, PhD, Ann Arbor, MI
Jayan Parameshwar, MRCP, Cambridge, United Kingdom
Soon J. Park, MD, Minneapolis, MN
Bill A. Pietra, MD, Boulder, CO
Hermann Reichenspurner, MD, PhD, Hamburg, Germany
Marlene Rose, PhD, Harefield, Middlesex, United Kingdom
Alan G. Rose, MD, FRCP, Minneapolis, MN
Stuart D. Russell, MD, Durham, NC
Jeanne Salyer, PhD, Richmond, VA
Ralph A. Schmid, MD, Berne, Switzerland
Marc A. Silver, MD, Oak Lawn, IL
Frank W. Smart, MD, New Orleans, LA
Nicholas G. Smedira, MD, Cleveland, OH
Andrew L. Smith, MD, Atlanta, GA
Keld Sorensen, MD, Aarhus, Denmark
Susan Stewart, FRCP, Cambridge, UK
Patricia Stutman, CRNP, Philadelphia, PA
Nicole Suciu-Foca, PhD, New York, NY
Benjamin C. Sun, MD, Columbus, OH
Alfred J. Tector, MD, Milwaukee, WI
Steven S.L. Tsui, MD, FRCS, Cambridge, United Kingdom
Hannah A. Valentine, MD, Stanford, CA
Dirk Van Raemdonck, MD, PhD, Leuven, Belgium
Florian Wagner, MD, Hamburg, Germany
Thorsten Wahlers, MD, Jena, Germany
John Wallwork, MBChB, FRCS, Cambridge, United Kingdom
Walter Weder, MD, Zurich, Switzerland
George Wieselthaler, MD, Vienna, Austria
Gayle L. Winters, MD, Boston, MA

LOCAL ORGANIZING COMMITTEE

Gunther Laufer, MD, Chair
Walter Klepetko, MD, Vice-Chair
Michael Grimm, MD, Vice-Chair
Andreas Zuckerman, MD, Secretary-General
Alfred Kocher, MD, Secretary-General
Herwig Antretter, MD
Florian Iberer, MD

Werner Klein, MD
Richard Pacher, MD
Othmar Pachinger, MD
Raimund Margreiter, MD
Ludwig Muller, MD
Gerald Maurer, MD
Heinz Schima, PhD
Karl-Heinz Tscheliessnigg, MD
George Wieselthaler, MD
Wilfried Wisser, MD
Ernst Wolner, MD

CONTINUING MEDICAL EDUCATION INFORMATION

Accreditation

This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education. The International Society for Heart and Lung Transplantation is accredited by the ACCME to provide continuing medical education for physicians. ISHLT designates this activity for a maximum of 32 hours in Category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Category I Continuing Education Points for Transplant Coordinators (CEPTs) have been applied for through the American Board of Transplant Coordinators (ABTC).

Continuing Education hours in CERP Category A have been applied for through the American Association of Critical Care Nurses (AACN).

Educational Objectives

The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in heart and lung transplantation. Because of the rapid advances in medicine in general and transplantation medicine specifically, transplant professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in transplant medicine. This meeting is designed to address their need.

Goals

To enable participants to learn about current practices, emerging technologies, and medical advances related to heart and lung transplantation and end-stage heart and lung disease; and to provide a forum for participants to engage in discussion, debate, and examination regarding the efficacy and applicability of these current practices, emerging technologies, and medical advances.

Target Audience

The audience for this program includes physicians, surgeons, scientists, nurses, and transplant coordinators engaged in the practice of heart and lung transplantation, the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields, or specialties which cause them to become involved in the treatment of transplant recipients or patients with end stage heart or lung disease.

Learning Objectives

At the conclusion of this meeting, participants should be able to:

- * identify, prevent, and treat post-transplant complications of immunosuppression including infection, renal dysfunction, and post-transplant malignancy
- * compare and evaluate the relative advantages and disadvantages of various pharmacologic, non-pharmacologic, and biologic immunosuppression techniques
- * understand current and developing organ preservation/reperfusion techniques and the impact of these on the transplanted organ, and use that knowledge to optimize donor selection and extend the donor pool
- * compare and evaluate the advantages and disadvantages of various mechanical circulatory support systems and their associated patient selection criteria
- * describe the state of the art in clinical heart and lung failure treatment and the criteria for the selection of patients for transplant therapy
- * understand current animal models of basic science immunology and their application to the transplant setting
- * evaluate issues of controversy, such as age, prior transplantation, and systemic diseases, in the selection of candidates for heart and lung transplantation
- * understand the pathology of acute and chronic rejection and its application in the formulation of a definitive diagnosis of rejection
- * identify the issues unique to pediatric transplantation, and apply to pediatric transplantation the relevant practices and therapies of adult transplantation
- * evaluate the current and developing alternatives to orthotopic transplantation, including mechanical circulatory support, xenotransplantation, and a variety of surgical alternatives; assess the future of these therapies; and compare the value of these therapies as alternatives and/or bridges to transplantation
- * evaluate and implement the use of alternative methods of monitoring and treating rejection
- * identify, prevent, and treat donor-transmitted diseases

Disclosure

Current guidelines state that participants in CME activities should be made aware of any affiliation or financial interest that may affect a speaker's presentation. Each speaker has been requested to complete a disclosure statement. The names of the speakers declaring such affiliations are shown below. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

FACULTY/PRESENTATION	COMPANY AFFILIATION	RELATIONSHIP
Herman Reichensperner, MD, PhD Abstract #10	Fujisawa	Consultant
David J. Farrar, PhD Abstract #29	Thoratec Corporation	Employee of company
Tofy Mussivand, MD Abstract #32	World Heart Corporation	Chairman & Chief Scientific Officer
Christopher GA McGregor, FRCS Abstract #47	Nextran Inc.	Direct research support provided by commercial organization
Sangeela M. Bhorade, MD Abstract #143	Fujisawa Healthcare Inc.	Research Support
Gregorio Rabago, MD Abstract #153	Roche	Research Support
Simon P. Hoerstrup, MD Abstract #159	Synetis, Inc.	Scientific Advisory Committee
Kathleen D. Lake, Pharm D Abstract #184	Roche	Research Support
Michel White, MD Abstract #205	Fujisawa Canada	Consultant Fujisawa Canada
Randall Starling, MD Abstract #206	Novartis Pharmaceuticals	Research Support
Steven M. Woolley, MD Abstract #213	Inotek Corporation	Subcontracted work for NIH grant
Jack G. Copeland, MD Abstract #229	Syncardia Systems, Inc.	Chairman of Board
Bronwyn J. Levvey, RN Abstract #238	Novartis Pharmaceuticals	Research Support
Michael D. McGoon, MD Abstract #245	Pfizer	Co-investigator of sponsored study
Alexander S. Farivar, MD Abstract #251	Inotek Corporation	Subcontracted work for NIH grant
David S. Feldman, MD, PhD Abstract #257	Scios	Consultant
Azei Rahmel, MD Abstract #261	Myocor	Research Support
Tofy Mussivand, MD Abstract #262	World Heart Corporation	Chairman & Chief Scientific Officer

Jason D. Christie, MD Abstract #266	Pfizer Pharmaceuticals	Consultant
Michael E. Bowdish, MD Abstract #272	Tularik Inc. & ChemoCentryx	Research Support
Jasmina I. Radeva, MD Abstract #287	Novartis Pharma AG	Research agreement
Steven K. Takmoto, PhD Abstract #299	Sangstat, Novartis	Research Grant
Stephen Dummer, MD Abstract #341	Pfizer	Lecture for Honoraria
Gregory Snell, FRACP Abstract #360	Novartis Pharmaceuticals	Research Support
Allan R. Glanville, MBBS, MD Abstract #410	Roche, Novartis Janssen	Research Support
Gregory Snell, FRACP Abstract #411	Novartis Pharmaceuticals	Research Support
Robert E. Shaddy, MD Abstract #432	Roche Pharmaceuticals	Research Grant
Hani N. Sabbah, PhD Abstract #444	Acorn Cardiovascular, Inc.	Research Grant, Consultant
William Abraham, MD Satellite Symposium: Heart Failure: Who Needs Drugs Anyway?	Medtronic, Guidant	Speaker honoraria, Research Grant
Michael Acker, MD Satellite Symposium: Heart Failure: Who Needs Drugs Anyway?	Acorn Cardiovascular Inc	Consultant
Martin R. Cowie, MD Joint ISHLT/HFSA/ESC Heart Failure Symposium	Roche, Biosite	Consultant
Jay A. Fishman, MD Roche Lunch Symposium	Roche, Fujisawa, Gilead, Pfizer, Pharmacia	Speaker's Bureau
Thomas Force, MD Joint ISHLT/HFSA/ESC Heart Failure Symposium	Vertex Pharmaceuticals	Lab Support
David Kass, MD Joint ISHLT/HFSA/ESC Heart Failure Symposium	Guidant	Consultant
Mandeep Mehra, MD Fujisawa Lunch Symposium	Fujisawa, Roche, Novartis	Consultant
Bruno M. Meiser, MD Fujisawa Lunch Symposium	Fujisawa GmbH	Consultant
Randall Morris, MD Novartis Satellite Symposium	Novartis	Employee

Branislav Radovancevic, MD How to Symposium: Expanding the Borders: How to Start or Rejuvenate a Thoracic Transplant or Device Program	Orgis Medical	Consultant
Marlene Rose, PhD Joint ISHLT/ASHI Symposium	Proteome Science	Consultant
Robert Shaddy, MD Satellite Symposium: Pediatric Thoracic Transplantation: Cutting Edge and Future Directions	Roche Pharmaceuticals	Research Grant
Randall Starling, MD Novartis Lunch Symposium	Novartis Pharmaceuticals	Sponsored & Clinical Research
Doria Taylor, PhD Satellite Symposium: Heart Failure: Who Needs Drugs Anyway?	Bioheart, Inc.	Consultant
Hannah Valentine, MD Roche Lunch Symposium	Roche Pharmaceuticals	Research Support

The International Society for Heart and Lung Transplantation is most grateful for the educational grants and the support of our corporate partners toward this Twenty-Third Annual Meeting and Scientific Sessions

PLATINUM PARTNER

Novartis

GOLD PARTNER

Roche

SILVER PARTNER

Fujisawa

BRONZE PARTNER

Actelion Pharmaceuticals

CORPORATE PARTNER

SangStat

FRIEND OF SOCIETY

Thoratec Corporation

GROUND LEVEL

HALLE
Registration

GARDEHALLE I
Posters

GARTENSALLE
Concurrent Sessions

PRINCE EUGEN SALLE
Concurrent Sessions

MEZZANINE LEVEL

PLATZL
Micromed Exhibit Booth

VORSAAL
Roche Exhibit Booth
SangStat Exhibit Booth
Scanlan Exhibit Booth

SEITENGALERIE
Actelion Exhibit Booth
Asanus Exhibit Booth
Medical Insight Research Exhibit Booth
Novartis Exhibit Booth
Thoratec Exhibit Booth
Vitrolife Exhibit Booth

FESTSAAL
Plenary Sessions
Concurrent Sessions
Lunch Symposia

ZEREMONIENSAAL
Concurrent Sessions

ANTEKAMMER
Fujisawa Exhibit Booth

MARMORSAAL
Acorn Exhibit Booth
Arrow Exhibit Booth
Berlin Heart Exhibit Booth
Terumo Exhibit Booth
WorldHeart Exhibit Booth

WINTERGARTEN
Biotest Exhibit Booth
Internet Cafe

RITTERSAAL
ISHLT Exhibit Booth
Elsevier Exhibit Booth
European Society for Organ Transplantation Exhibit Booth

SCIENTIFIC PROGRAM

Note: All meetings and activities will take place at the Hofburg Congress Center unless otherwise specified. All papers will be presented in English.

TUESDAY, APRIL 8, 2003

8:00 am-6:00 pm

Exhibit Hall Set Up (Seitengalerie, Vorsaal, Marmorsaal, Antekammer, Rittersaal)

1:00 pm-6:00 pm

ISHLT Board of Directors Meeting (Radetzky Appt II)

WEDNESDAY, APRIL 9, 2003

8:00 am-Noon

ISHLT Board of Directors Meeting (Radetzky Appt II)

Exhibitor Set Up (Seitengalerie, Vorsaal, Marmorsaal, Antekammer, Rittersaal, Wintergarten)

Poster Board Set Up (Gardehalle I)

8:00 am-6:00 pm

Speaker Ready Room Open (Kunstlerzimmer)

10:00 am-6:00 pm

Registration Desk Open (Halle)

Noon – 6:00 pm

Exhibit Hall Open (Seitengalerie, Vorsaal, Marmorsaal, Antekammer, Rittersaal, Wintergarten)

Poster Session 1 Set-Up (Gardehalle I)

12:30 pm-3:00 pm

Satellite Symposium: Heart Failure: Who Needs Drugs, Anyway? (Festsaal)

Chairs: Robert L. Kormos, MD and Ernst Wolner, MD

BiVentricular Pacing and ICDs

Robert Bourge, Univ of Alabama, Birmingham, AL

Girdling Devices for Left Ventricular Remodeling

Michael Acker, MD, University of Pennsylvania, Philadelphia, PA

New Therapeutic Horizons Using Cell Therapy for Heart Failure

Doris Taylor, PhD, Duke University Medical Center, Durham, NC

New Pulsatile Assist Systems: Ventricular and Total Heart

Aly El-Banayosy, Heart Center NRW, Bad Oeynhausen, Germany

Continuous Flow Devices: Axial and Centrifugal

George Wieselthaler, MD, University of Vienna, Vienna, Austria

Myocardial Recovery Strategies Using LVADs

Asghar Khagani, FRCS, Harefield Hospital, Harefield, United Kingdom

Surgical Remodeling

Vincent Dor, MD, Centre Cardio-Thoracique de Monaco, Monaco

12:30 pm-3:00 pm

Satellite Symposium: Pulmonary Hypertension (Zeremoniensaal)

(supported by an educational grant from Actelion)

Chairs: Paul Corris, MD and Keith McNeil, MD

Genetic Screening - Possibilities and Pitfalls

Richard Trembath, BSc, MB, BS, FRCP, Leicester, United Kingdom

Screening for PAH in those at Risk: What is Best?

Jean Luc Vachiery, MD, Erasme University Hospital, Brussels, Belgium

Combination Therapy - Which and When: The Evidence

Anne Keogh, MBBS, MD, St. Vincent's Hospital, Sydney, Australia

Septostomy and Transplantation - Indications and Timing

Paul Corris, MB FRCP, Freeman Hospital, Newcastle upon Tyne, United Kingdom

12:30 pm-3:00 pm

Joint ISHLT/ASHI Symposium: Clinical Significance of HLA and non-HLA Antibodies in Heart and Lung Transplantation (Prince Eugen Saal)

Chair: Adriana Zeevi, PhD

Opening Remarks and Introduction

Adriana Zeevi, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA

Clinically Relevant Alloantibodies in Heart Transplant Patients

Ron H. Kerman, PhD, University of Texas Medical School, Houston, TX

Clinically Relevant Alloantibodies in Lung Transplant Recipients

Nancy Reinsmoen, PhD, Duke University Medical Center, Durham, NC

Determination and Clinical Significance of Non-HLA Specific Antibodies

Marlene Rose, PhD, Harefield Hospital, Harefield, United Kingdom

3:00 pm - 3:30 pm

Coffee Break (Exhibit Halls)

3:30 pm-6:00 pm

Novartis Symposium: Immunosuppression Pathways for Prolongation of Graft Survival (Festsaal)

Chair: Anne Keogh, MBBS, MD

Factors Contributing to Graft Failure in Heart and Lung Transplantation

Anne Keogh, MBBS, MD, St. Vincent's Hospital, Sydney, Australia

Post-Transplant Vasculopathies in Cardiac Transplantation

Jayan Parameshwar, MRCP, Papworth Hospital, Cambridge, United Kingdom

Advances in Immunomodulation: Potential Targets for the Future

Randall E. Morris, MD, Novartis Pharma AG, Basel, Switzerland

3:30 pm-6:00 pm

Satellite Symposium: Nursing Satellite (Zeremoniensaal)

Chairs: Katherine J. Hoercher, RN and Sandra A. Cupples, DNSc, RN

Homeward Bound: IV Milrinone and Status 1B Patients Waiting at Home

Carol Twomey, CRNP, University of Pennsylvania Medical Center, Philadelphia, PA

Management of LVAD Patients at Home: Challenges and Strategies

Karl Nelson, MD, Salt Lake City, UT

How Sick Is Too Sick? Taking the High-Risk Lung Transplant Recipient to Surgery

Jean B. Rea, RN, MS, CCTC, Duke University Medical Center, Durham, NC

Complications of Immunosuppression

Robert Bourge, MD, University of Alabama, Birmingham, AL

Panel Discussion: Clinical and Quality of Life Outcomes in Cardiothoracic Transplantation: Emerging Issues and Future Directions

Sandra A. Cupples, DNSc, RN, Washington Hospital Center, Washington, DC

Mary Amanda Dew, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA

Sabina M. DeGeest, PhD, RN, University of Basel, Basel, Switzerland

Fabienne Dobbels, Msc, University Hospital Leuven, Leuven, Belgium

Kathleen L. Grady, PhD, RN, Rush Presbyterian-St. Lukes Medical Center, Chicago, IL

Dorothy M. Lanuza, PhD, RN, Loyola University of Chicago, Maywood, IL

Wayne D. Paris, MSW, Nazih Zuhdi Transplantation Institute, Oklahoma City, OK

Panel Discussion: Transplant as a Venue for Career Development: 2 Year, 10 Year And 20 Year Perspectives

Kathleen L. Grady, PhD, RN, Rush-Presbyterian-St Luke's Medical Center, Chicago, IL

Nancy P. Blumenthal, MSN, CS, CRNP, University of Pennsylvania Medical Center, Philadelphia, PA

Wouter Tack, Onze Lieve Vrouw Clinic, Oust, Belgium

3:30 pm-6:00 pm

Satellite Symposium: Pediatric Thoracic Transplantation: Cutting Edge and Future Directions

(Prince Eugen Saal)

Chairs: Keld Sorensen, MD and TBD

ABO Incompatible Heart Transplantation

Lori West, MD, DPhil, Hospital for Sick Children, Toronto, Canada

Future Directions in Pediatric Immunosuppression

Bill A. Pietra, University of Colorado Children's Hospital, Littleton, CO

Experimental Approaches to Tolerance Directed Towards Children

Joren C. Madsen, MD, Massachusetts General Hospital, Boston, MA

Options for the Sensitized Heart Transplant Candidate

Robert E. Shaddy, MD, Primary Children's Medical Center, Salt Lake City, UT

Living Related Lung Transplantation: First or Last Choice?

Marlyn S. Woo, University of Southern California, Los Angeles, CA

6:00 pm – 7:00 pm

Registry Executive Committee Meeting (Radetzky Appt II)

6:00 pm-8:00 pm

How-To Symposium: Expanding the Borders: How to Start or Rejuvenate a Thoracic Transplant or Device Program (Prince Eugen Saal)

Chairs: Branislav Radovancevic, MD and Stephan Schueler, MD

Introduction

Marian Zembala, MD, Silesian Medical School, Zabrze, Poland

Heart Failure Program: Role in Patient Recruitment for Transplantation, Devices or Alternatives

Mandeep R. Mehra, MD, Ochsner Medical Institutions, New Orleans, LA

Overcoming and Simplifying the Donor Issue

Bruce Rosengard, MD, University of Pennsylvania, Philadelphia, PA

Optimal and Affordable Transplant Programs

Guenther Laufer, MD, University Hospital Innsbruck, Innsbruck, Austria

Why Should a Lung Transplant Program be Developed in Parallel to a Heart Program?

Walter Klepetko, MD, University of Vienna, Vienna, Austria

Mechanical Replacement or Assistance

Branislav Radovancevic, MD, Texas Heart Institute, Houston, TX

THURSDAY, APRIL 10, 2003

7:00 am-5:30 pm

Speaker Ready Room Open (Kunstlerzimmer)

7:30 am-8:30 am

Morning Coffee (Exhibit Halls)

7:30 am-10:00 am

Poster Session 1 Set-Up (Gardehalle I)

7:30 am-6:30 pm

Registration Desk Open (Halle)

Exhibits Open (Seitengalerie, Vorsaal, Marmorsaal, Antekammer, Rittersaal, Wintergarten)

8:00 am-10:00 am

OPENING PLENARY SESSION (Festsaal)

Chairs: Stephan Schueler, MD and Bruce R. Rosengard, MD

8:00 am Welcome, Stephan Schueler, MD, ISHLT President, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

8:05 am Scientific Program Report, Bruce R. Rosengard, MD, University of Pennsylvania, Philadelphia, PA

8:10 am Registry Report, Marshall I. Hertz, MD, Medical Director, ISHLT International Heart and Lung Transplant Registry, University of Minnesota, Minneapolis, MN

8:35 am Presidential Address, Stephan Schueler, MD, ISHLT President, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

Featured Abstracts

9:00 am (1) Non-Invasive Molecular Screening for Acute Cardiac Rejection: A Multicenter Prospective Clinical Study

H.J. Eisen,¹ M.C. Deng,² M. Mehra,³ S. Hunt,⁴ F. Johnson,⁴ R. Robbins,⁴ M. Autieri,¹ S. Itescu,² J. Giacomini,⁴ D. Ahern,² G. Berry,⁴ C. Marboe,² I. Mahmood,⁵ R. Woodward,⁵ J. Wohlgenuth,⁵ ¹Advanced Heart Failure and Transplant Center, Temple

University, Philadelphia, PA; ²Circulatory Physiology, Columbia University, New York, NY; ³Cardiology, Ochsner Clinic, New Orleans, LA; ⁴Heart Transplant Program, Stanford University, Palo Alto, CA; ⁵Expression Diagnostics, XDX Inc., South San Francisco, CA

9:15 am (2) Serial Echocardiography Increases Donor Heart Utilization

W.D. Babcock,¹ R.L. Menza,¹ J.G. Zaroff,² ¹Clinical Services, California Transplant Donor Network, Oakland, CA; ²Division of Cardiology, University of California; San Francisco, San Francisco, CA

9:30 am Invited Lecture: State of the Art of Molecular Diagnosis for Rejection and Tolerance

Vicki Seyfert-Margolis, PhD, Immune Tolerance Network, Bethesda, MD

10:00 am-10:30 am

Coffee Break/Visit Exhibits/Visit Posters

10:30 am – Noon

CONCURRENT SESSION 1

Clinical Heart Transplantation 1: Cardiac Allograft Vasculopathy (Festsaal)

Chairs: Asghar Khagani, FRCS and George Tellides, MD

10:30 am (3) Elevated Homocysteine Levels Accelerate Cardiac Allograft Vasculopathy

I. Kutschka,¹ K. Pethig,² W. Harringer,¹ A. Haverich,² M. Strueber,² ¹Department of Thoracic and Cardiovascular Surgery, Klinikum Braunschweig, Braunschweig, Germany; ²Department of Thoracic and Cardiovascular Surgery, Hannover Medical School, Hannover, Germany

10:45 am (4) Effect of Folate Administration on Heart Allograft Atherosclerosis One Year after Transplant: A Prospective Randomized Study

L. Potena,¹ G. Magnani,¹ S. Sorbello,¹ F. Grigioni,¹ S. Sassi,² P. Ortolani,¹ F. Coccolo,¹ S. Carigi,¹ A. Marzocchi,¹ C. Magelli,¹ A. Branzi,¹ ¹Institute of Cardiology, University of Bologna, Bologna, Italy; ²Institute of Angiology, University of Bologna, Bologna, Italy

11:00 am (5) Improved Survival after Diagnosis of Cardiac Allograft Vasculopathy (CAV) through Extreme Reduction of Cholesterol and Fibrinogen

B.R. Jaeger,¹ P. Braun,² D. Nagel,¹ L. Bennett Edwards,³ M. Oberhoffer,⁴ J.W. Park,⁵ M.C. Deng,⁶ D.B. Gysan,⁷ E. Kreuzer,⁴ S. Schueler,⁸ B. Reichart,⁴ D. Seidel,¹ ¹Institute of Clinical Chemistry, Ludwig-Maximilians-University, Munich, Germany; ²Cardiology, Ev.Kaiser-Wilhelm-KHK, Duisburg, Germany; ³ISHLT Registry/MCSD Database, ISHLT, Richmond/New York, VA/NY; ⁴Abteilung f. Herzchirurgie, Ludwig-Maximilians-University, Munich, Germany; ⁵Cardiology, Klinikum Hoyerswerda, Hoyerswerda, Germany; ⁶Kardiologie, Roelshover Hof, Koeln, Germany; ⁷Cardiac Surgery, Freeman Hospital, Newcastle upon Tyne, United Kingdom

11:15 am (6) Paraoxonase-1 M55L Single Nucleotide Polymorphism: A New Mutation Associated with Transplant Coronary Artery Disease?

S.G. Miriuka, P.C. Chan, E. Keren, B. Wong, D.H. Delgado, D.E. Cole, H.J. Ross, Heart Transplant, Toronto General Hospital - University of Toronto, Toronto, ON, Canada

11:30 am (7) May Preservation Solution Affect the Incidence of Graft Vasculopathy in Transplanted Heart?

M. Garlicki,¹ ¹Cardiosurgery Department, MSWiA Hospital, Warsaw, Poland

11:45 am (8) Donor Intracranial Bleeding is Associated with Advanced Transplant Coronary Vasculopathy: Evidence from Intravascular Ultrasound

M.H. Yamani,¹ R.C. Starling,¹ E.M. Tuzcu,¹ S.A. Haji,¹ D.J. Cook,² A.S. Abdo,² N.B. Ratliff,³ M.M. Yousufuddin,¹ P.M. McCarthy,⁴ J.B. Young,¹ ¹Cardiology, Cleveland Clinic, Cleveland, OH; ²Allogen Laboratory; ³Anatomic Pathology; ⁴Cardiovascular Thoracic surgery, Cleveland Clinic, Cleveland, OH

10:30 am-Noon

CONCURRENT SESSION 2

Lung Heart/Lung Transplantation 1: Immunosuppression and Chronic Rejection in Lung Transplantation

(Zeremoniensaal)

Chairs: John Dark, MB, FRCS and Bruno Reichart, MD

10:30 am (9) Long Term Follow-Up of a Prospective Randomized Trial Comparing Tacrolimus Versus Cyclosporine in Combination with MMF after Lung Transplantation

A. Zuckermann,¹ H. Reichenspurner,² P. Jaksch,¹ H. Treede,² W. Wisser,¹ J. Groetzner,³ B. Reichart,³ W. Klepetko,¹ ¹Department of Cardio-Thoracic Surgery, University of Vienna, Vienna, Austria; ²Department of Cardiac Surgery, Universitaetsklinikum Eppendorf Hamburg, Hamburg, Germany; ³Department of Cardiac Surgery, Ludwig-Maximilian University Munich, Munich, Germany

10:45 am (10) Prospective Randomized International Multi-Center Investigator Driven Study Comparing TAC and CSA (+MMF / Steroids) after Lung Transplantation - Interim Analysis of 110 Patients

H. Reichenspurner,¹ A. Glanville,² W. Klepetko,³ R. Lama,⁴ G.M. Verleden,⁵ C. Bravo,⁶ M. Estenne,⁷ B. Reichart,⁸ S. Hirt,⁹ F.Z. Goni,¹⁰ J. Aubert,¹¹ J.M. Borro,¹² P. Usetti,¹³ T. Wahlers,¹⁴ H. Treede,¹ the European and Australian Investigators in Lung Transplantation, ¹Department of Cardiovascular Surgery, University Hospital Hamburg-Eppendorf, Hamburg, Germany; ²University of Sydney, Sydney, Australia; ³University of Vienna, Vienna, Austria; ⁴University of Cordoba, Cordoba, Spain; ⁵University of Leuven, Leuven, Belgium; ⁶University of Barcelona, Barcelona, Spain; ⁷University of Bruxelles, Bruxelles, Belgium; ⁸University of Munich, Munich, Germany; ⁹University of Kiel, Kiel, Germany; ¹⁰University of Santander, Santander, Spain; ¹¹University of Lausanne, Lausanne, Switzerland; ¹²University La Coruna, La Coruna, Spain; ¹³University of Madrid, Madrid, Spain; ¹⁴University of Jena, Jena, Germany

11:00 am (11) Aerosol Cyclosporine Provides Dose Dependent Improvement in Lung Function after Lung Transplantation

T.E. Corcoran,¹ G.C. Smaldone,² J.H. Dauber,¹ D.A. Smith,¹ K.R. McCurry,³ G.J. Burckart,³ B.P. Griffith,⁴ W.F. Grgurich,¹ A.T. Iacono,¹ ¹Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA; ²Pulmonary and Critical Care Medicine, State University of New York at Stony Brook, Stony Brook, NY; ³Division of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA; ⁴Division of Cardiac Surgery and Cardiopulmonary Transplantation, University of Maryland Medical Center, Baltimore, MD

11:15 am (12) IL-10 High Genotype Is Protective Against Acute Persistent Rejection after Lung Transplantation

H.X. Zheng,¹ G.J. Burckart,¹ K. McCurry,¹ S. Webber,¹ D. Zaltonis,¹ J. Ristich,¹ A. Iacono,¹ J. Dauber,¹ W. Grgurich,¹ K. McDade,¹ A. Zeevi,¹ ¹Pharmacy, Surgery, Pediatrics, Medicine, and Pathology, University of Pittsburgh, Pittsburgh, PA

11:30 am (13) Bronchiolitis Obliterans Syndrome/Obliterative Bronchiolitis Ameliorated by Azithromycin

S.G. Gerhardt,¹ J.S. McDyer,¹ R.E. Girgis,¹ J.V. Conte,² S.C. Yang,³ M. Khalid,⁴ J.B. Orens,¹ ¹Division of Pulmonary and Critical Care Medicine, The Johns Hopkins Hospital; ²Division of Cardiac Surgery; ³Division of Thoracic Surgery, The Johns Hopkins Hospital, Baltimore, MD; ⁴Division of Pulmonary Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

11:45 am (14) The Predictive Value of Bronchiolitis Obliterans Syndrome Stage 0-P

F. Fernandez, R.R. Hachem, G.A. Patterson, E.P. Trulock. Lung Transplant Program, Washington University School of Medicine, St Louis, MO

10:30 am-Noon

CONCURRENT SESSION 3

New/Alternative Therapies: Cell Transplantation for the Failing Myocardium (Prince Eugen Saal)

Chairs: Alfred Kocher, MD and Doris A. Taylor, PhD

10:30 am (15) Autologous Skeletal Myoblasts Transplanted to Infarcted Human Myocardium: Histological Analysis of Cell Survival and Differentiation

F.D. Pagani,¹ H. DerSimonian,² A. Zawadzka,² D.B. Jacoby,² J. Dinsmore,² S. Wright,¹ T.H. Aretz,³ K. Wetzel,² K.D. Aaronson,⁴ ¹Section of Cardiac Surgery, University of Michigan, Ann Arbor, MI; ²Department of Cell Transplantation, Diacrin, Inc, Charlestown, MA; ³Department of Pathology, Massachusetts General Hospital, Boston, MA; ⁴Division of Cardiology, University of Michigan, Ann Arbor, MI

10:45 am (16) Bone Marrow Cell Enhances the Efficacy of Skeletal Myoblast Transplantation in Rats with Ischemic Cardiomyopathy

G. Sakaguchi,¹ Y. Sakakibara,¹ K. Tambara,¹ G. Premaratne,¹ X. Lin,¹ K. Nishimura,¹ M. Komeda,¹ ¹Cardiovascular Surgery, Kyoto University, Kyoto, Japan

11:00 am (17) Electrophysiological Properties of Myoblasts Injected into the Infarcted Myocardium of Rats

H.C. Ott,¹ S.A. Berjukow,² R. Marksteiner,² E. Margreiter,² B. Podesser,⁴ G. Laufer,³ S. Hering,² ¹Cardiology, University of Innsbruck, Innsbruck, Austria; ²Biochemical Pharmacology, University of Innsbruck, Innsbruck, Austria; ³Cardiac Surgery, University of Innsbruck, Innsbruck, Austria; ⁴Ludwig Boltzman Institute for Cardiovascular Research, University of Vienna, Vienna, Austria

11:15 am (18) A Novel Sub-Population of Bone Marrow Derived Myocardial Stem Cells: Potential Autologous Cell Therapy in Myocardial Infarction

H.J. Soukiasian,¹ L.S.C. Czer,¹ I. Avital,¹ T. Aoki,¹ Y. KIM,¹ Y. Umehara,¹ J. Pass,¹ R. Tabrizi,¹ K. Magliato,¹ G.P. Fontana,¹ W. Cheng,¹ A.A. Demetriou,¹ A. Trento,¹ ¹Cardiothoracic Surgery, Cedars-Sinai Medical Center, Los Angeles, CA

11:30 am (19) Transplantation of a Mixed Population of Bone Marrow-Derived Progenitor Cells Improves Regional Systolic Function in a Rabbit Model of Cryoinjured Myocardium

R.B. Thompson,¹ S. Emani,¹ S. Colgrove,² B.H. Davis,² D. Craig,¹ Y. Morimoto,² D. Glower,¹ D.A. Taylor,² ¹Department of Surgery, Duke University Medical Center, Durham, NC; ²Department of Medicine, Duke University Medical Center, Durham, NC

11:45 am (20) Cellular Cardiomyoplasty Using Skeletal Myoblasts Overexpressing IL-1 Receptor Antagonist Enhances Effects on Adverse Post-Infarction Remodeling

B. Murtuza,¹ K. Suzuki,¹ M.H. Yacoub,¹ ¹Gene Therapy, Harefield Hospital, United Kingdom

10:30 am-Noon

CONCURRENT SESSION 4

Basic Science and Immunobiology 1: Tolerance and Immunomodulation (Gartensaal)

Chairs: Charles G. Orosz, PhD and Thomas D. Wekerle, MD

10:30 am (21) Interleukin-4 and -10 Combined Gene Therapy Induces Cardiac Allograft Tolerance by Promoting the Alloreactive T Cells Apoptosis and Preventing Myocytes Apoptosis Via FAS/FASL Pathway

H. Furukawa,¹ K. Oshima,¹ H. Russell,¹ T. Tung,¹ J. Xu,¹ G. Cui,¹ H. Laks,¹ L. Sen,¹ ¹Surgery, UCLA Medical Center/UCLA School of Medicine, Los Angeles, CA

10:45 am (22) IL-10 Induces Suppressor of Cytokine Secretion-3 (SOCS-3) and ILT-3 in Human Endothelial Cells and Inhibits T Cell Costimulation

C. Gleissner,¹ A. Zastrow,¹ R. Klingenberg,¹ N. Xia,¹ T.J. Dengler,¹ ¹Cardiology, Medizinische Universitätsklinik III, Heidelberg, Germany

11:00 am (23) Influence of an Anti-CD25 MAB on Tolerance Induction through BMT with Costimulation Blockade

S. Bigenzahn,¹ P. Blaha,¹ Z. Koporc,¹ M. Schmid,¹ E. Selzer,¹ H. Bergmeister,¹ C. Heusser,² K. Wagner,² F. Muehlbacher,¹ T. Wekerle,¹ ¹Vienna General Hospital, Vienna, Austria; ²Novartis Pharma, Basel, Switzerland

11:15 am (24) Donor-Derived Suppressor Macrophages for Recipient-Specific Immunosuppression in Lung Transplantation in Minipigs

G. Warnecke,¹ F. Faendrich,² S.P. Sommer,¹ T. Steinkamp,¹ G. Zehle,² M. Ruhnke,² A.R. Simon,¹ J.M. Hohlfeld,¹ J. Niedermeyer,¹ A. Haverich,¹ M. Strueber,¹ ¹Division of T&CV Surgery, Hannover Medical School, Hannover, Germany; ²Department of Surgery, University Kiel, Kiel, Germany

11:30 am (25) Indirect Allorecognition of MHC Class II Peptides Accelerates Cardiac Allograft Rejection in Miniature Swine

D.R. Johnston,¹ J.D. Mezrich,¹ R. Hoerbelt,¹ L.C. Benjamin,¹ T. Shoji,¹ R.S. Lee,¹ S.L. Houser,¹ L.G. Ledgerwood,¹ R.S. Hasse,¹ J.S. Allan,¹ M.H. Sayegh,² J.C. Madsen,¹ ¹Transplantation Biology Research Center, Massachusetts General Hospital, Boston, MA; ²Department of Nephrology, Brigham and Women's Hospital, Boston, MA

11:45 am (26) Induction of Tolerance to a Minor Histocompatibility Antigen Prevents Post-Transplant Obliterative Airway Disease in Mouse Tracheal Allografts

T. Mohanakumar,¹ A. Jaramillo,¹ T. Higuchi,¹ W. Lu,¹ Z. Kaleem,² G.A. Patterson,¹ ¹Department of Surgery, Washington University School of Medicine, St. Louis, MO; ²Department of Pathology, Creighton University, Omaha, NE

Noon– 2:00 pm

ISHLT Editorial Board Meeting (Radetzky Appt II)

12:15 pm-1:45 pm

Novartis Lunch Symposium: Transplant Coronary Artery Disease: Intravascular Ultrasound, Surrogate Markers and Treatment (Zeremoniensaal)

Chair: Jon Kobashigawa, MD

Panel: Randall Starling, MD, Cleveland Clinic, Cleveland, OH and Howard Eisen, MD, Temple University, Philadelphia, PA

2:00 pm-3:30 pm

CONCURRENT SESSION 5

Mechanical Circulatory Support 1: Mechanical Assist as Destination Therapy for End Stage Heart Failure (Festsaal)

Chairs: Michael A. Acker, MD and Ernst Wolner, MD

(27) 2:00 pm Infection in Permanent Circulatory Support: Experience from the Randomized Evaluation of Mechanical Assistance in the Treatment of Congestive Heart Failure (REMATCH) Trial

W. Holman,¹ S. Park,³ J. Long,² A. Weinberg,⁴ R. Adamson,⁵ E. Raines,⁶ G. Couper,⁷ F. Pagani,⁸ N. Burton,⁹ L. Miller,³ Y. Naka,⁴ ¹Department of Surgery, University of Alabama, Birmingham, AL; ²Department of Surgery, LDS Hospital, Salt Lake City, UT; ³Department of Surgery, University of Minnesota, Minneapolis, MN; ⁴Department of Surgery, Columbia University, New York, NY; ⁵Department of Surgery, Sharp Memorial Hospital, San Diego, CA; ⁶Department of Surgery, Bryan LGH Heart Institute, Lincoln, NE; ⁷Department of Surgery, Brigham and Women's Hospital, Boston, MA; ⁸Department of Surgery, University of Michigan Hospital, Ann Arbor, MI; ⁹Department of Surgery, Inova Fairfax Hospital, Annandale, VA

(28) 2:15 pm Initial European Experience with the Lionheart(TM) LVAS (Left Ventricular Assist System) for Destination Therapy

W.E. Pae,¹ R. Koerfer,² A. El-Banayosy,² L. Arusoglu,² R. Hetzer,³ Y. Weng,³ M. Jurmann,³ M. Vigano,⁴ M. Rinaldi,⁴ A. Pavie,⁵ P. LaPrince,⁵ E. Wolner,⁶ G. Wieselthaler,⁶ L. vonSegesser,⁷ T. Whaler,⁸ U. Franke,⁸ S.R. Scholl,⁹ M.T. Swartz,⁹ O. Fey,⁹ M. Reeders,⁹ J. Lewis,⁹ D. Frank,⁹ ¹Cardiothoracic Surgery, Penn State Milton S Hershey Med Ctr, Hershey, PA; ²Cardiac Surgery, Bad Oeynhausen Heart Center, Bad Oeynhausen, Germany; ³Cardiac Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; ⁴Cardiac Surgery, Policlinico San Matteo, Pavia, Italy; ⁵Cardiac Surgery, La Pitie Hospital, Paris, France; ⁶Cardiac Surgery, University of Vienna, Vienna, Austria; ⁷Cardiac Surgery, CHUV Hospital Vaudois, Luusanne, Switzerland; ⁸Cardiac Surgery, Klinikum der Friderich Schiller Universita, Jena, Germany; ⁹All Representatives, Arrow International, Reading, PA

(29) 2:30 pm Design Improvements of the Heartmate VE LVAS and Their Effectiveness in Reducing Adverse Events

D.J. Farrar,¹ O. Bataille,¹ C. Cotter,¹ K. Kwan,¹ C. Aulenbach,¹ V.L. Poirier,¹ ¹Research and Development, Thoratec Corporation, Pleasanton, CA

(30) 2:45 pm Left Ventricular Assist Device Replacement

J.W. Long,¹ W. Dembitsky,² R. Khodaverdian,¹ A.J. Powers,¹ R. Adamson,² ¹Utah Artificial Heart Program, LDS Hospital, Salt Lake City, UT; ²Mechanical Assist Device, Sharp Memorial Hospital, San Diego, CA

(31) 3:00 pm Scoring System Determines Successful RVAD Explant Following BIVAD Support: Implications for Destination Therapy

H.J. Patel,¹ S. Wright,¹ D.B. Dyke,² K.D. Aaronson,² F.D. Pagani,¹ ¹Section of Cardiac Surgery, University of Michigan, Ann Arbor, MI; ²Division of Cardiology, University of Michigan, Ann Arbor, MI

(32) 3:15 pm Clinical Results with EPTFE Inflow Conduit for Mechanical Circulatory Support

T. Mussivand,¹ P. Portner,² R. Hetzer,³ P. Noirhomme,⁴ E. Vitali,⁵ M. Rinaldi,⁶ J.-N. Fabiani,⁷ E. Wolner,⁸ B. Meyns,⁹ R. Koerfer,¹⁰ F. Beyersdorf,¹¹ A. Pavie,¹² ¹Cardiovascular Devices Division, University of Ottawa Heart Institute, Ottawa, ON, Canada; ²Stanford University Medical School, Stanford, CA; ³German Heart Center, Berlin, Germany; ⁴Cliniques Universitaires St. Luc, Brussels, Belgium; ⁵Hospital Niguarda Ca' Granda, Milano, Italy; ⁶Policlinico San Matteo - University of Pavia, Pavia, Italy; ⁷HEGP Broussais, Paris, France; ⁸AKH des Stast, Vienna, Austria; ⁹UZ Gasthuisberg, Leuven, Belgium; ¹⁰Heart Center NRW, Bad Oeynhausen, Germany; ¹¹Albert-Ludwigs University, Freiburg, Germany; ¹²Hopital La Pitie Salpetiere, Creteil, France

2:00 pm-3:30 pm

CONCURRENT SESSION 6

Clinical Heart Failure 1: Prognostic Markers in Heart Failure (Zeremoniensaal)

Chairs: Robert Bourge, MD and Edoardo Gronda, MD

2:00 pm (33) Dilutional Anemia in Patients with Advanced Heart Failure Is Associated with Poor Outcome

D.M. Mancini,¹ S.A. Androne,² J. LaManca,¹ S.P. Pinney,¹ A. Christian,¹ L. Lund,¹ S.D. Katz,² ¹Medicine, Columbia University, New York, NY; ²Medicine, Yale University, New Haven, CT

2:15 pm (34) Obesity and Advanced Heart Failure: The Differential Impact of Body Weight on B-Type Natriuretic Peptide and Proinflammatory Cytokine Expression

M.R. Mehra,¹ P.A. Uber,¹ P.F. Nasca,¹ M.H. Park,¹ J.R. Becker,¹ M.E. Keebler,¹ R.L. Scott,¹ ¹Cardiomyopathy and Heart Transplantation Ctr, Ochsner Clinic Foundation, New Orleans, LA

2:30 pm (35) N-Terminal Brain Natriuretic Peptide: The New Gold Standard in Predicting Mortality in Patients with Advanced Heart Failure

R.S. Gardner,¹ F. Ozalp,¹ A.J. Murday,¹ S.D. Robb,² T.A. McDonagh,² ¹Scottish Cardiopulmonary Transplant Unit, Glasgow Royal Infirmary, Glasgow, United Kingdom; ²Department of Cardiology, University of Glasgow, Glasgow, United Kingdom

2:45 pm (36) Interleukin-6 Is the Most Potent Predictor for Worsening of Heart Failure in Patients with Congestive Heart Failure

M. Gwechenberger, M. Huelsmann, R. Berger, Ch. Springer, B. Stanek, R. Pacher, Department of Cardiology, University of Vienna, Vienna, Austria

3:00 pm (37) Chronotropic Reserve Beyond Anerobic Threshold (CR_{AT}) Predicts Survival in Advanced Heart Failure

M.R. Mehra, P.A. Uber, C.J. Lavie, R.L. Scott, M.H. Park, R.V. Milani, Cardiomyopathy and Heart Transplantation, Ochsner Clinic Foundation, New Orleans, LA

3:15 pm (38) Sublingual Sildenafil and Reversibility of Pulmonary Hypertension in Candidates to Heart Transplant

M.A. Gomez Sanchez,¹ M. Lazaro,¹ P. Escribano,¹ J.F. Delgado,¹ A. Albarran,¹ L. Cea-Calvo,¹ M.J. Ruiz Cano,¹ M.T. Velazquez,¹ R. Tello,¹ F. Hernandez,¹ C. Saenz de la Calzada,¹ ¹Cardiology, Hospital Universitario Doce de Octubre, Madrid, Spain

2:00 pm-3:30 pm

CONCURRENT SESSION 7

Donor Management 1: Strategies to Increase Donor Utilization (Prince Eugen Saal)

Chairs: Alec Patterson, MD and Walter Weder, MD

2:00 pm (39) Screening Potential Donors for Living Donor Lobar Lung Transplantation

F.A. Schenkel,¹ M.V. Horn,² M.S. Woo,² M.L. Barr,¹ V.A. Starnes,¹ ¹Cardiothoracic Surgery, Keck-USC School of Medicine, Los Angeles, CA; ²Cardiothoracic Surgery, Childrens Hospital Los Angeles, Los Angeles, CA

2:15 pm (40) Ten Year Experience with Human Lung Transplantation from Non-Heart Beating Donors

R.B. Love,¹ A.M. D'Allesandro,¹ R.A. Cornwell,² K.M. Meyer,² ¹Surgery, University of Wisconsin, Madison, WI; ²Medicine, University of Wisconsin, Madison, WI

2:30 pm (41) Outcome of Heart Transplantation Using Refurbished Allografts

J. Odum,¹ C. Gleason,¹ B. Zaia,¹ D. Mulder,¹ J. Kobashigawa,¹ A. Alikhani,¹ H. Laks,¹ UCLA Heart/Lung Transplant Team,¹ ¹Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA

2:45 pm (42) Lung Transplantation with Donors 60 Years of Age and Older

A. Patterson, M. de Perrot, T.K. Waddell, Y. Shargall, F. D'Ovidio, A. Pierre, S. Keshavjee, Toronto Lung Transplant Program, University of Toronto, Toronto, ON, Canada

3:00 pm (43) Increased Thoracic Organ Utilization Using an Advanced Practice Organ Procurement Coordinator

W.D. Babcock,¹ R.L. Menza,¹ A.R. Richardson,¹ D.A. Kinder,¹ E.W. Osborne,¹ P. Weber,¹ ¹Department of Clinical Services, California Transplant Donor Network, Oakland, CA

3:15 pm (44) Donor Designation on the Driver's License: Friend or Foe?

A.G. Kfoury,¹ K.A. Myer,² J.R. Stanzone,² C.G. Tribble,¹ J.D. Bergin,¹ ¹The Heart Center, University of Virginia Health System, Charlottesville, VA; ²LifeNet, Richmond, VA

2:00 pm-3:30 pm

CONCURRENT SESSION 8

Basic Science and Immunobiology 2: From Pigs to People (Gartensaal)

Chairs: Michael Schmoekkel, MD and Andre R. Simon, MD

2:00 pm (45) En-Bloc Vascularized Thymus and Heart Transplantation in Miniature Swine

D.R. Johnston,¹ R. Hoerbelt,¹ T. Shoji,¹ J.D. Mezrich,¹ S.L. Houser,¹ J.S. Allan,¹ L.G. Ledgerwood,¹ R.S. Hasse,¹ D.H. Sachs,¹ J.C. Madsen,¹ ¹Transplantation Biology Research Center, Massachusetts General Hospital, Boston, MA

2:15 pm (46) Vascularized Thymic Lobe Transplantation: Experience with an Allogeneic and Xenogeneic Large Animal Model of Transplantation

P.A. Vagefi,¹ S. Yamamoto,¹ C. Kamano,¹ H. Arakawa,¹ K. Teranishi,¹ D.H. Sachs,¹ K. Yamada,¹ ¹Department of Surgery, Transplantation Biology Research Center, Massachusetts General Hospital/Harvard Medical School, Boston, MA

2:30 pm (47) Advances in Preclinical Cardiac Xenotransplantation

C.G. McGregor,¹ S.S. Teotia,¹ J.M. Schirmer,¹ H.D. Tazelaar,¹ R.C. Walker,¹ R.P. Frantz,¹ G.W. Byrne,² J.M. Risdahl,² J.S. Logan,² ¹William J von Liebig Transplant Center, Mayo Clinic, Rochester, MN; ²Nextran, Inc., Princeton, NJ

2:45 pm (48) Natural Killer Cell-Derived Cytokines are Central in Monocyte Infiltration and Rejection of Porcine Xenografts

S. Itescu,¹ P. Kwiatkowski,² J.H. Artrip,¹ R.E. Michler,² ¹Department of Surgery, Columbia University, New York, NY; ²Division of Cardiothoracic Surgery, Ohio State University, Columbus, OH

3:00 pm (49) Gene Expression in Cardiac and Lung Xenografts

T.K. Waddell,¹ T. Tabata,¹ D. Wigle,¹ M. Liu,¹ S.H. Keshavjee,¹ G.P. Downey,² ¹Thoracic Surgery, Toronto General Hospital, Toronto, ON, Canada; ²Respiratory Medicine, Toronto General Hospital, Toronto, ON, Canada

3:15 pm (50) Inhibition of Human Nk Cell Mediated Cytotoxicity to Pig Endothelial Cells by over Expression of Human ECTO-5'-Nucleotidase

F.N. Osborne,¹ C. Lawson,¹ M.H. Yacoub,¹ K.K. Kalsi,¹ R.T. Smolenski,¹ M.L. Rose,¹ ¹National Heart and Lung Institute, Harefield Hospital, Harefield, Middlesex, United Kingdom

3:30 pm-4:00 pm

Coffee Break/Visit Exhibits/Visit Posters

4:00 pm-5:30 pm

CONCURRENT SESSION 9

Clinical Heart Transplantation 2: Cardiac Rejection: Diagnostics and Outcomes (Festsaal)

Chairs: John S. Dunning, FRCS and Valluvan Jeevanandam, MD

4:00 pm (51) Presence of Donor-Derived DNA in the Plasma of Sex-Mismatched Cardiac Transplant Recipients: A Potential Novel Strategy for Monitoring Graft Rejection

K.S. Woo,¹ L. Chan,¹ P.N. Ruygrok,² J.J. Edmond,² E. Chau,³ Y.M.D. Lo,¹ ¹Cardiology, The Chinese University, Hong Kong, Hong Kong, China; ²Cardiology, Green Lane Hospital, Auckland, Auckland, New Zealand; ³Cardiology, Grantham Hospital, Hong Kong, Hong Kong, China

4:15 pm (52) Non-Invasive Screening by Tissue Doppler for Late Post-Transplant Cardiac Rejection Surveillance

M. Dandel,¹ H.B. Lehmkuhl,¹ M. Hummel,¹ R. Meyer,¹ R. Hetzer,¹ ¹Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Berlin, Germany

4:30 pm (53) Rejection with Hemodynamic Compromise: A Dismal Prognosis

R. Lee,² R.N. Brown, N. Moazami, J. Young, B. Clemson, J. Hill, B. Czarska, J. O'Donnell, E. Kasper, J.K. Kirklin, for the Cardiac Transplant Research Database(CTRD), ¹CTRD, University of Alabama at Birmingham, Birmingham, AL; ²Roche Young Investigator's Award

4:45 pm (54) Magnetic Resonance Measurements of Coronary Flow Reserve: Relationship to Coronary Angiographic Findings

K. Kennedy,¹ A. Dick,² A. Raval,² M. Drangova,³ C. Mahoney,¹ W.J. Kostuk,² P.W. Pflugfelder,² ¹Department of Radiology, LHSC University Campus, London, ON, Canada; ²Division of Cardiology, LHSC University Campus, London, ON, Canada; ³Robarts Research Institute, London, ON, Canada

5:00 pm (55) The Impact of a Positive Donor-Specific Crossmatch on Outcome after Heart Transplantation

S.S. Schmitz,¹ S.A. Moore,¹ T.C. Fuller,¹ J.W. Long,¹ M.E. Hagan,¹ S.M. Belleville,¹ B.K. Campbell,¹ J.W. Folsom,¹ E.M. Gilbert,¹ D.G. Renlund,¹ ¹UTAH Cardiac Transplant Program, University of Utah School of Medicine, LDS Hospital, and the Veterans Affairs Medical Center, Salt Lake City, UT

5:15 pm (56) Efficacy and Safety of Tacrolimus (TAC) Vs. Cyclosporine Microemulsion (CME) in De Novo Cardiac Transplant Recipients: 6-Month Results

M. Grimm,¹ M. Rinaldi,² N.A. Yonan,³ the European Tacrolimus Heart Study Group, ¹Department of Cardiothoracic Surgery, Allgemeines Krankenhaus Wien, Vienna, Austria; ²Cardiac Surgery Division, Ospedale Policlinico San Matteo, Pavia, Italy; ³Cardiac Transplantation Unit, Wythenshawe Hospital, Manchester, United Kingdom

4:00 pm-5:30 pm

CONCURRENT SESSION 10

Lung/Heart-Lung Transplantation 2: Outcomes in Lung Transplantation (Zeremoniensaal)

Chairs: Selim M. Arcasoy, MD and Andreas Zuckermann, MD

4:00 pm (57) Double Lung Transplantation Does Not Confer a Survival Advantage over Single Lung Transplantation in COPD

Marshall Hertz,¹ M. Valapour,¹ S.M. Studer,² P.B. Terry,³ ¹Division of Pulmonary, Allergy & Critical Care Medicine and Center for Bioethics, University of Minnesota, Minneapolis, MN; ²Recanati/Miller Transplant Institute, Mount Sinai Medical Center, New York, NY; ³Division of Pulmonary and Critical Care, Johns Hopkins University, Baltimore, MD

4:15 pm (58) Effect of Transplant Operation on Survival after Development of Bronchiolitis Obliterans Syndrome (BOS) in Patients with Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF)

D. Hadjiliadis,¹ C. Chaparro,¹ R.H. Messier,² C. Gutierrez,¹ T.K. Waddell,¹ M.P. Steele,² L.G. Singer,¹ R.D. Davis,² M.A. Hutcheon,¹ S.M. Palmer,² S. Keshavjee,¹ ¹Toronto Lung Transplant Program, University of Toronto, Toronto, ON, Canada; ²Duke Lung Transplant Program, Duke University, Durham, NC

4:30 pm (59) Survival Benefit of Lung Transplantation in Cystic Fibrosis Patients Infected with B. Cepacia

C.A. Gutierrez,^{1,5} A. Dupuis,^{2,5} C. Chaparro,^{1,5} E. Tullis,^{3,5} L. Singer,^{1,5} T.K. Waddell,^{4,5} M. Hutcheon,^{1,5} S. Keshavjee,^{4,5} M. Corey,^{2,5} ¹Medicine, Toronto Lung Transplant Program, Toronto General Hospital, Canada; ²Medicine, Hospital for Sick Children, Canada; ³Medicine, Adult CF Program, St Michael's Hospital, Canada; ⁴Surgery, Toronto Lung Transplant Program, Toronto General Hospital, Canada; ⁵University of Toronto, Toronto, ON, Canada

5:15 pm (62) Long-Term Functional Outcome after Living-Donor Lung Transplantation in Adults

M.E. Bowdish,¹ R. Pessotto,¹ F.A. Schenkel,¹ C.J. Baker,¹ R.G. Barbers,² R.M. Bremner,¹ R.G. Cohen,¹ V.A. Starnes,¹ M.L. Barr,¹ ¹Department of Cardiothoracic Surgery, University of Southern California, Los Angeles, CA; ²Department of Medicine, University of Southern California, Los Angeles, CA

5:00 pm (61) Predicting Death Following Lung Transplantation: Development of a Prognostic Model

I. Saeed, C.A. Rogers, S. Ganesh, A.J. Murday, and the Steering Group, UK Cardiothoracic Transplant Audit, CEU, The Royal College of Surgeons of England, London, United Kingdom

4:45 pm (60) Functional Outcomes of Lobar and Double Lung Transplant Recipients

J.S. Rodrigues,¹ ¹Biokinesiology and Physical Therapy, University of Southern California, Los Angeles, CA

4:00 pm-5:30 pm

CONCURRENT SESSION 11

Immunosuppression 1: Novel Effects of Immunosuppression in Experimental Models (Prince Eugen Saal)

Chairs: Joren C. Madsen, MD, PhD and Hermann Reichenspurner, MD, PhD

4:00 pm (63) A Novel Selective Inhibitor of JNK Suppresses Alloreactivity and Prolongs Cardiac Allograft Survival

M. Morikawa,¹ A. Tabata,¹ Y. Satoh,² B.L. Bennett,² T. Abe,¹ ¹Thoracic and Cardiovascular Surgery, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan; ²Signal Research Division, Celgene Corporation, San Diego, CA

4:15 pm (64) FK 778, A Novel Immunosuppressive Agent Reduces Early Adhesion Molecule Upregulation after Cardiac Transplantation

T. Deuse,¹ S. Schrepfer,¹ C. Detter,¹ F. Wagner,¹ C. Pahrman,¹ D. Boehm,¹ H. Reichenspurner,¹ ¹Department of Cardiovascular Surgery, University Hamburg-Eppendorf, Hamburg, Germany

4:30 pm (65) Reduction of Pecam-1 at Graft Endothelium after Cardiac Transplantation is Accompanied by the Reduction of Leukocyte Infiltration into the Perivascular Space of Arteries. A Comparative Study with CSa, FK506 and MMF

M.H.C. Richter,¹ K. Kafchitsas,² H.R. Richter,² J.F. Gummert,¹ F.W. Mohr,¹ ¹Cardiac Surgery, Heartcenter, Leipzig, Germany; ²Experimental Heart Transplant Group, University of Frankfurt, Frankfurt, Germany

4:45 pm (66) Different Cyclosporine Regimens and Their Influences on Transplant Vasculopathy

M.H.C. Richter,^{1/2} D. Schramm,² H.R. Richter,² ¹Cardiac Surgery, Heartcenter, Leipzig, Germany; ²Experimental Heart Transplant Group, Goethe-University, Frankfurt, Germany

5:00 pm (67) Effects of FK506 Inhalant on the Suppression of Acute Rejection in Lung Transplantation: Use of Rat Orthotopic Lung Transplantation Model

A. Ingu,¹ K. Komatsu,¹ M. Morikawa,¹ T. Abe,¹ S. Ichimiya,² Y. Hirayama,³ ¹Thoracic and Cardiovascular Surgery, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan; ²Pathology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan; ³Immunology and Inflammation Medical Biology Research Laboratories, Kashima Institution, Osaka, Osaka, Japan

5:15 pm (68) Tacrolimus: In Vitro Effects on Neutrophil Production and Apoptosis

F. J. Fricker, J.M. Koenig, N. Matharoo, J.J. Stegner, K.O. Schowengerdt. Pediatrics, University of Florida, Gainesville, FL

4:00 pm-5:30 pm

CONCURRENT SESSION 12

Pathology 1: Heart and Lung Transplantation (Gartensaal)

Chairs: Annalisa Angelini, MD and Martin Goddard, FRCS

4:00 pm (69) Inter-Reader and Intra-Reader Agreement for Grading Acute Rejection and Airway Inflammation after Lung Transplantation, Based on the Lung Rejection Study Group Revised Working Formulation

F. Fernandez, M.M. Chakinala,¹ J. Ritter,² B.F. Gage,¹ A.A. Aloush,¹ E.P. Trulock,¹ ¹Internal Medicine, Washington University School of Medicine, Saint Louis, MO; ²Pathology, Washington University School of Medicine, Saint Louis, MO

4:15 pm (70) Inter-Observer Variability in Grading Acute Rejection in Endomyocardial Biopsies

G.B.M. Lindop,¹ M.M. Burke,¹ S. Ogston,¹ P. Bishop,¹ C. Corbishley,¹ M. Goddard,¹ R. Harrison,¹ C. Kjellstrom,¹ A. McPhaden,¹ M. Malone,¹ D. Parums,¹ K. Suvarna,¹ S. Stewart,¹ ¹UK Heart Lung Transplant Pathology Group, Papworth Hospital, Cambridge, United Kingdom

4:30 pm (71) Apoptotic Death of Infiltrating Cells in Human Cardiac Allografts Is Regulated by IL-2

H.A. de Groot-Kruseman,¹ C.C. Baan,¹ P.E. Zondervan,² R.A. de Weger,³ A.H. Balk,⁵ W. Weimar,¹ ¹Internal Medicine, Erasmus MC, Rotterdam, Netherlands; ²Pathology; ³Pathology, (University Medical Center Utrecht); ⁴Cardiology, Rotterdam, Netherlands

4:45 pm (72) Detection of Cardiac Allograft Rejection by Multi-Parameter Gene Expression Analysis on Circulating Mononuclear Cells Using Real-Time RT-PCR

M. Schoels,¹ T.J. Dengler,² R. Klingenberg,² R. Richter,¹ T. Giese,¹ S.C. Meuer,¹ ¹Immunology, University of Heidelberg, Heidelberg, Germany; ²Cardiology, University of Heidelberg, Heidelberg, Germany

5:00 pm (73) Distribution of Collagen Subtypes and Matrix Metalloproteinases in Coronary Artery Vasculopathy

C. Atkinson,¹ R. Pitman,¹ C.J. Phillpotts,² S.C. Charman,¹ J. Wallwork,¹ M. Goddard,¹ ¹Pathology Department, Papworth NHS Trust Hospital, Cambridge, Cambridgeshire, United Kingdom; ²Faculty of Applied Sciences, University of the West of England, Bristol, Bristol, United Kingdom

5:15 pm (74) Elevated Levels of the CXCR3 Chemokine Ligand Itac Is Associated with the Development of Severe Transplant Coronary Artery Disease in Humans

J. Kao,¹ M.C. Fishbein,² J.A. Kobashigawa,¹ J.K. Patel,¹ R.C. McLellan,¹ M. Burdick,³ J. Belperio,³ R.M. Strieter,³ ¹Cardiology, The David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Pathology, The David Geffen School of Medicine at UCLA, Los Angeles, CA; ³Pulmonary, The David Geffen School of Medicine at UCLA, Los Angeles, CA

5:30 pm-6:30 pm

ISHLT Registry Meeting (Festsaal)

Heart Failure and Transplant Medicine Scientific Council Meeting (Zeremoniensaal)

Pathology and Basic Science Scientific Council Meeting (Gartensaal)

Pulmonary Hypertension Scientific Council Meeting (Prince Eugen Saal)

Cell Transplantation/Tissue Engineering Scientific Council Meeting (Radetzky Appt II)

5:30 pm-6:30 pm

GENERAL POSTER SESSION 1/Wine and Cheese Reception (Gardehalle I)

(Please see page ??? of this program booklet for the list of Poster Session I abstract titles and authors – Abstracts 75 – 204)

6:30 pm-7:30 pm

Poster Display Session 1 Tear-Down (Gardehalle I)

7:30 pm-10:00 pm

President's Gala Reception (City Hall)

FRIDAY, APRIL 11, 2003

7:00 am-5:30 pm

Speaker Ready Room Open (Kunstlerzimmer)

7:30 am-8:30 am

Morning Coffee (Exhibit Halls)

7:30 am-10:00 am

Poster Display Session 2 Set-Up (Gardehalle I)

7:30 am-5:00 pm

Registration Desk Open (Halle)

7:30 pm-6:30 pm

Exhibits Open (Seitengalerie, Vorsaal, Marmorsaal, Antekammer, Rittersaal, Wintergarten)

8:00 am-10:00 am

PLENARY SESSION: JOINT ISHLT/HFSA/ESC WORKING GROUP ON HEART FAILURE SYMPOSIUM (Festsaal)

Chairs: Stephan Schueler, MD, Helmut Drexler, MD, Marvin A. Konstam, MD

8:00 am Epidemiology

John J. Cleland, MD, University of Hull, Kingston-upon-Hull, United Kingdom, on behalf of the European Society for Cardiology Working Group on Heart Failure

8:20 am Novel Diagnostics

Martin R. Cowie, MD, Imperial College, London, United Kingdom, on behalf of the European Society for Cardiology Working Group on Heart Failure

8:40 am Systolic and Diastolic Dysfunction? Time for a New Paradigm

Marvin Konstam, MD, New England Med Center, Boston, MA on behalf of the Heart Failure Society of America

9:00 am Cellular Signaling Pathways as Drug Targets

Thomas L. Force, MD, Tufts University, Boston, MA, on behalf of the Heart Failure Society of America

9:20 am Ventricular Remodeling Surgery

Nicholas G. Smedira, MD, Cleveland Clinic Foundation, Cleveland, OH, on behalf of ISHLT

9:40 am Cellular Therapies

Philippe Menasche, MD, PhD, Hopital Bichat, Paris, France, on behalf of ISHLT

10:00 am-10:30 am

Coffee Break/Visit Exhibits/Visit Posters

10:30 am-Noon

CONCURRENT SESSION 13

Clinical Heart Transplantation 3: Clinical Immunosuppressive Strategies (Festsaal)

Chairs: Francis D. Pagani, MD, PhD and Yoshifumi Naka, MD, PhD

10:30 am (205) Prograf Decreases Plasma Cholesterol in Heart Transplant Recipients with Treated but Persisting Mild Dyslipidemia: The Canadian Multicenter Randomized Trial of Prograf Versus Neoral

Michel White, on Behalf of the Canadian Heart Transplant Group, Research Center, Montreal Heart Institute, Montreal, QC, Canada

10:45 am (206) Everolimus Dose Recommendations in De Novo Heart Transplantation - TDM Simulations

R.C. Starling,¹ J. Hare,² D. Renlund,³ D. Mancini,⁴ H.W. Mayer,⁵ H. Schmidli,⁵ ¹Transplant Unit, Cleveland Clinic Foundation, Cleveland, OH; ²Transplant Unit, Johns Hopkins, Baltimore, ML; ³Transplant Unit, Utah Transplant Affiliated Hospitals, Salt Lake City, UT; ⁴Transplant Unit, Columbia Presbyterian Medical Center, New York, NY; ⁵BU Transplantation, Novartis Pharma, Basel, Basel, Switzerland

11:00 am (207) Everolimus in De Novo Cardiac Transplant Recipients: 24-Month Follow-Up

A. Haverich,¹ E.M. Tuzcu,² M. Viganò,³ L. Pulpon,⁴ R.B. Love,⁵ R. Dorent,⁶ H.J. Eisen,⁷ J. Murphy,⁸ K.H. Abeywickrama,⁸ P. Bernhardt,⁸ the RADB 253Study Group, ¹Med Hochschule, Thoraxchir., Hannover, Germany; ²Cleveland Clinic Foundation, Department Cardiol, Cleveland, OH; ³Policlinico San Matteo, IRCCS, Pavia, Italy; ⁴Clinica Puerta de Hierro, Cardiology, Madrid, Spain; ⁵University of Wisconsin, Cardiothor.Division., Madison, WI; ⁶Hopital Pitie Salpetriere, Service Chir., Paris, France; ⁷Temple University, Cardiology Sect., Philadelphia, PA; ⁸Novartis Pharma AG, BU Transplantation, Basel, Switzerland

11:15 am (208) Study of the Safety and Tolerability of Simulect (Basiliximab) Versus OKT3 in Heart Transplantation

M.G. Crespo-Leiro,¹ J.L. Rodriguez-Lambert,² J.L. Segovia,³ L. Almenar,⁴ E. Roig,⁵ M.A. Gómez-Sánchez,⁶ E. Lage,⁷ N. Manito,⁸ L.A. Pulpon,³ ¹Heart Transplant, H.Juan Canalejo, A Coruna, Spain; ²Heart Transplant, H.Central de Asturias, Oviedo, Spain; ³Heart Transplant, H.Clinica Puerta de Hierro, Madrid, Spain; ⁴Heart Transplant, H.La Fe, Valencia, Spain; ⁵Heart Transplant, H.Clinic i Provincial, Barcelona, Spain; ⁶Heart Transplant, H.12 de Octubre, Madrid, Spain; ⁷Heart Transplant, H.Virgen del Rocio, Sevilla, Spain; ⁸Heart Transplant, H.de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain

11:30 am (209) The Impact of Pharmacogenomic Factors on Steroid Weaning in Pediatric Heart Transplant Patients Using Logistic Regression Analysis

H.X. Zheng,¹ S. Webber,¹ A. Zeevi,¹ E. Schuetz,² J. Zhang,² P. Bowman,¹ J. Lamba,² G.J. Burckart,¹ ¹Pharmacy, Pediatrics, and Pathology, University of Pittsburgh, Pittsburgh, PA; ²Pharmacology, St. Jude Children's Research Hospital, Memphis, TN

11:45 am (210) Everolimus Is Associated with a Reduced Incidence of CMV Infection in Heart Transplantation

R. Dorent, H. Valantine, J. Parameshwar, J. Hill, N. Cretin, Cardiovascular Surgery, Hopital La Pitie Salpetriere, Paris, France; Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA; Transplant Unit, Papworth Hospital, Cambridge, United Kingdom; Cardiovascular Center, Shands Hospital Health Science Center, Gainesville, FL; Pharma, Novartis Pharma AG, Basel, Switzerland

10:30 am-Noon

CONCURRENT SESSION 14

Donor Management 2: Donor Organ Preservation (Zeremoniensaal)

Chairs: James K. Kirklin, MD and Daniel Y. Loisance, MD

10:30 am (211) Hormonal Therapy Stabilizes Hemodynamics during Donor Procurement

A.B. Van Bakel,¹ S. Pitzer,² P. Drake,² N.A. Kay,² R. Sade,² ¹Medicine/Cardiology, Medical University of South Carolina, Charleston, SC; ²LifePoint, Inc, Charleston, SC

10:45 am (212) Exogenous Surfactant Instillation in Lung Donors to Reduce Early Graft Dysfunction

M. Strueber,¹ J. Niedermeyer,² G. Warnecke,¹ B. Gohrbandt,¹ S. Fischer,¹ B. Lindenberg,¹ A.R. Simon,¹ J.M. Hohlfeld,² ¹T&CV Surgery, Hannover Medical School, Hannover, Germany; ²Respiratory Medicine, Hannover Medical School, Hannover, Germany

11:00 am (213) The Role of Poly(ADP)Ribose Synthetase in Lung Ischemia-Reperfusion Injury

S.M. Woolley,¹ B.V. Naidu,¹ A.S. Farivar,¹ A.L. Salzman,² C. Szabo,² M.S. Mulligan,¹ ¹Cardiothoracic Surgery, University of Washington, Seattle, WA; ²Inotek Corporation, Beverly, MA

11:15 am (214) Effects of P38 Mitogen-Activated Protein Kinase Inhibitor as an Additive to Celsior Solution on Canine Heart Transplantation from Non-Heart-Beating Donors

N. Koike,¹ I. Takeyoshi,¹ S. Ohki,¹ M. Tokumine,¹ K. Matsumoto,² Y. Morishita,¹ ¹Second Department of Surgery, Gunma University Faculty of Medicine, Maebashi, Gunma, Japan; ²Department of Pathology, Nippon Medical School Second Hospital, Kawasaki, Kanagawa, Japan

11:30 am (215) Poly-ADP-Ribose Polymerase-Inhibition Protects Against Myocardial and Endothelial Reperfusion Injury after Heart Transplantation

G. Szabo,¹ N. Stumpf,¹ S. Baehrle,¹ S. Hagl,¹ ¹Cardiac Surgery, University of Heidelberg, Heidelberg, BW, Germany

11:45 am (216) Hearts Transfected with Inducible Nitric Oxide Synthase Have Accelerated Restoration of Cardiac Function Following Ischemia/Reperfusion Associated with Cardiac Transplantation

L.L. Shears,¹ S. Kanno,¹ T.R. Billiar,¹ R. Mahidara,¹ K.R. McCurry,¹ R.L. Kormos,¹ ¹Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA

10:30 am-Noon

CONCURRENT SESSION 15

Pediatrics 1: Thoracic Transplant Outcomes (Prince Eugen Saal)

Chairs: Albert Faro, MD and Robert Shaddy, MD

10:30 am (217) Lung Transplantation in Infancy

E.N. Mendeloff,¹ S.C. Sweet,² M.T. de la Morena,² P.M. Schuler,² T.J. Guthrie,¹ C.B. Huddleston,¹ ¹Surgery/Pediatric Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO; ²Pediatric Allergy and Pulmonary Medicine, Washington University, St. Louis, MO

10:45 am (218) Exercise Assessment in Children after Cardiac Transplant in Infancy: Effect of Chronotropic Incompetence

G.L. Abarbanell,¹ N.F. Mulla, R.E. Chinnock, R.L. Larsen, ¹Department of Pediatrics, Loma Linda University Children Hospital, Loma Linda, CA

11:00 am (219) Long-Term Neuropsychological Sequelae of Infant Cardiac Transplant Recipients: Trends and Predictors of Outcome

T. Babikian,¹ M.C. Freier,^{1,2} T.R. Burley Aen,¹ J. Pivonka,¹ J.M. Gardner,¹ M. Baum,² L.L. Bailey,³ R.E. Chinnock,² ¹Psychology, Loma Linda University; ²Pediatrics; ³Surgery, Loma Linda University Medical Center, Loma Linda, CA

11:15 am (220) A Longitudinal Perspective on Neurodevelopmental Outcome Following Infant Cardiac Transplantation
M.C. Freier,^{1,2} J. Pivonka,¹ J.M. Gardner,¹ T. Babikian,¹ T.R. Burley Aaen,¹ M. Baum,² L.L. Bailey,³ R.E. Chinnock,²
¹Psychology, Loma Linda University; ²Pediatrics; ³Surgery, Loma Linda University Medical Center, Loma Linda, CA

11:30 am (221) The Effect of Oversizing Cardiac Allografts on Survival in Pediatric Patients with Congenital Heart Disease

A.J. Razzouk,¹ J.K. Johnston,¹ R.L. Larsen,¹ R.E. Chinnock,¹ L.L. Bailey,¹ ¹Cardiothoracic Surgery and Pediatrics, Loma Linda University Children's Hospital & Medical Center, Loma Linda, CA

11:45 am (222) Single Center Comparison of Pediatric Living Donor Lobar and Cadaveric Lung Transplant
S.C. Sweet,¹ M.T. de la Morena,¹ P.M. Schuler,² G.A. Patterson,² B.F. Meyers,² D. Schuller,³ C.B. Huddleston,² E.N. Mendeloff,² ¹Pediatric Allergy and Pulmonary Medicine, Washington University, St. Louis, MO; ²Cardiothoracic Surgery, Washington University, St. Louis, MO; ³Pulmonary and Critical Care Medicine, Washington University, St. Louis, MO

10:30 am-Noon (Gartensaal)

CONCURRENT SESSION 16

Nursing/Social Science/Health Economics 1: Calculating the Risks Pre- and Post-Heart and Lung Transplantation

Chairs: Sabina M. DeGeest, RN, PhD, NFESC and Carol Twomey, CRNP

10:30 am (223) Should We Transplant UNOS Status 2 Patients?

J. Jimenez,¹ L. Bennett Edwards,² R. Higgins,³ S. Pham,¹ J. Bauerlein,¹ S. Mallon,¹ ¹Cardiology, Jackson Memorial Medical Center, Miami, FL; ²United Network Organ Sharing, Richmond, VA; ³Cardiothoracic Surgery, Medical College of Virginia, Richmond, VA; ⁴Cardiothoracic Surgery, Jackson Memorial Medical Center, Miami, FL

10:45 am (224) Time-Dependent Mortality Risk of Lung Transplantation Compared with Remaining on the Waitlist
K.P. McCullough,¹ R. Bustami,¹ S. Murray,^{1,2} T.M. Egan,³ R.M. Merion,^{1,2} ¹SRTR, URREA, Ann Arbor, MI; ²Department Surgery, University of Michigan, Ann Arbor, MI; ³Department Surgery, University of North Carolina, Chapel Hill, NC

11:00 am (225) Risk Factors for Death after Lung Transplant in the US

T. Egan,¹ K. McCullough,² S. Murray,² R. Bustami,² R. Merion,² E. Garrity,³ F. Grover,⁴ W. Ring,⁵ R. Robbins,⁶ E. Trulock,⁷ D. Wood,⁸ L. Edwards,⁹ ¹University of North Carolina, Chapel Hill, NC; ²SRTR/URREA, Ann Arbor, MI; ³Loyola University, Maywood, IL; ⁴University of Colorado, Denver, CO; ⁵University of Texas Southwestern, Dallas, TX; ⁶Stanford University, Palo Alto, CA; ⁷Washington University, St. Louis, MO; ⁸University of Washington, Seattle, WA; ⁹UNOS, Richmond, VA

11:15 am (226) Predictors of Death on the UNOS Lung Transplant Waiting List

T. Egan,¹ K. McCullough,² S. Murray,² R. Bastrami,² R. Merion,² E. Garrity,³ F. Grover,⁴ W. Ring,⁵ R. Robbins,⁶ E. Trulock,⁷ D. Wood,⁸ L. Edwards,⁹ ¹UNC, NC; ²SRTR-URREA, MI; ³Loyola, IL; ⁴University of Colorado, Denver, CO; ⁵University of Texas Southwestern, Dallas, TX; ⁶Stanford University, Palo Alto, CA; ⁷Washington University, St. Louis, MO; ⁸University of Washington, Seattle, WA; ⁹UNOS, Richmond, VA

11:30 am (227) Time-Dependent Mortality Risk of Heart Transplantation Compared with Remaining on the Waitlist

R.M. Merion,^{1,2} K.P. McCullough,² S. Murray,^{1,2} R. Bustami,² F.L. Grover,³ ¹Department Surgery, University of Michigan, Ann Arbor, MI; ²SRTR, URREA, Ann Arbor, MI; ³Department Surgery, University of Colorado, Denver, CO

11:45 am (228) Medication Noncompliance > 1 Year after Heart Transplantation Predicts Posttransplant Outcome: A 5 Years Follow-Up Survival Analysis Study

F. Dobbels,^{1,3} S. De Geest,^{1,2} W. Droogne,³ J. Van Cleemput,³ J. Vanhaecke,³ ¹Center for Health Services and Nursing Research, Katholieke Universiteit Leuven, Leuven, Belgium; ²Institute of Nursing Science, University of Basel, Basel, Switzerland; ³Department of Cardiology, Katholieke Universiteit Leuven, Leuven, Belgium

Noon-12:15 pm

ANNUAL BUSINESS MEETING (Members only) (Zeremoniensaal)

12:15 pm-1:45 pm

Roche Lunch Symposium: New Perspectives on Cytomegalovirus in Heart and Lung Transplantation (Festsaal)

Chair: Jay A. Fishman, MD

12:15 pm Opening Remarks and Overview

Jay A. Fishman, MD, Massachusetts General Hospital, Boston, MA

12:25 pm Current Treatment and Prevention Options for CMV Infection in Lung Transplantation

R Duane Davis, MD, Duke University, Durham, NC

12:45 pm Pathophysiology and Role of CMV in Cardiac Allograft Vasculopathy

Hannah A. Valentine, MD, Stanford University School of Medicine, Stanford, CA

1:05 pm ValGanciclovir vs Oral Ganciclovir as a Preventive Strategy for CMV Infection in Heart, Liver, and Renal Transplantation

Jay A. Fishman, MD, Massachusetts General Hospital, Boston, MA

1:25 pm Discussion

12:15 pm-2:00 pm

ISHLT Board of Directors Meeting (Radetzky Appt II)

2:00 pm-3:30 pm

CONCURRENT SESSION 17

Mechanical Circulatory Support 2: Clinical Challenges in Mechanical Support (Festsaal)

Chairs: Robert C. Robbins, MD and TBD

2:00 pm (229) Total Artificial Heart Bridge to Transplantation: A 9 Year Experience in 61 Patients

J.G. Copeland,¹ R.G. Smith,¹ F.A. Arabia,¹ P.E. Nolan,¹ D. McClellan,¹ P. Tsau,¹ G.K. Sethi,¹ R.K. Bose,¹ M.E. Banchy,¹ M.J. Slepian,² ¹Surgery, University of Arizona, Tucson, AZ; ²Cardiology, University of Arizona, Tucson, AZ

2:15 pm (230) Heart Failure Demands More Biventricular Mechanical Circulatory Support

J.S. Sapirstein,¹ L.L. Shears,¹ K.R. McCurry,¹ L.J. Carozza,¹ E.A. Stanford,¹ S. Winowich,¹ S. Murali,² R.L. Kormos,¹ ¹Department of Surgery, University of Pittsburgh, Pittsburgh, PA; ²Department of Medicine, University of Pittsburgh, Pittsburgh, PA

2:30 pm (231) Emergent Mechanical Support in the Community: Improvement with Early Transplant Center Referral

R.J. Morris,¹ A. Pochettino,¹ M. O'Hara,¹ T.J. Gardner,¹ M.A. Acker,¹ ¹Division of Cardiothoracic Surgery, University of Pennsylvania, Philadelphia, PA

2:45 pm (232) Cardiac Transplantation without Prospective Crossmatch in HLA-Sensitized Ventricular Assist Device Patients

S.W. Etoch,^{1,3} A.S. Ghaly,¹ R.D. Dowling,^{1,3} D. Pidwell,³ G. Bhat,^{2,3} ¹Surgery, Division of Cardiothoracic Surgery, University of Louisville, Louisville, KY; ²Medicine, Division of Cardiology, University of Louisville, Louisville, KY; ³Jewish Hospital, Louisville, KY

3:00 pm (233) Inhaled Milrinone and Prostacyclin for Ventricular Assist Device Recipients: Effectiveness and Cost

S.W. Etoch,¹ A.S. Ghaly,¹ D. Barber,¹ K. Thielmeier,¹ M. Bouvette,¹ R.D. Dowling,¹ ¹Surgery, Division of Cardiothoracic Surgery, University of Louisville, Louisville, KY

3:15 pm (234) Do Implantable Left Ventricular Assist Devices Affect Posttransplant Survival in the Modern Era (2000-2002): An Analysis of the US Scientific Registry of Transplant Recipients

K.D. Aaronson,¹ A.H. Wu,¹ T.M. Koelling,¹ H.J. Patel,¹ S.M. Wright,¹ D.B. Dyke,¹ F.D. Pagani,¹ ¹Division of Cardiology and Section of Cardiac Surgery, University of Michigan, Ann Arbor, MI

2:00 pm-3:30 pm

CONCURRENT SESSION 18

Immunosuppression 2: Better Immunosuppression with Fewer Complications (Zeremoniensaal)

Chairs: James S. Allan, MD and Bruno M. Meiser, MD

2:00 pm (235) Effects of Differing Calcineurin Based Immune Therapies on Homocysteine Levels in Cardiac Transplant Patients

L.M. Fedoruk,¹ L. Ding,² R.C. Cook,¹ L. Straatman,² ¹Department of Cardiac Surgery, University of British Columbia, Vancouver, BC, Canada; ²Department of Cardiology, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada

2:15 pm (236) Tacrolimus in Heart Transplantation: Monotherapy Vs. Steroid Requiring Patients

I.D. Galin,¹ D.A. Baran,¹ R. Correa,¹ M.C. Courtney,¹ M. Chan,¹ D. Spielvogel,¹ S.L. Lansman,¹ J.T. Fallon,¹ A.L. Gass,¹ ¹Zena and Michael A. Wiener Cardiovascular Institute, The Mount Sinai Hospital, New York, NY

2:30 pm (237) Calcineurin-Inhibitor-Free Immunosuppression with Mycophenolatmofetil and Sirolimus after Cardiac Transplantation Is Safe and Improves Renal Function Significantly

J. Groetzner,¹ I. Kaczmarek,¹ L. Buehse,¹ M. Muller,¹ P. Landwehr,¹ M. Vogeser,² B. Meiser,¹ B. Reichart,¹ ¹Cardiac Surgery, Ludwigs Maximilians University Hospital Grosshadern, Munich, Germany; ²Institute for Clinical Chemistry, LMU Hospital Grosshadern, Munich, Germany

2:45 pm (238) A Retrospective Analysis of 2 Years Experience Using Basiliximab (BMAB) in High Risk Lung Transplant Recipients(LTR) at a Single Institution

B.J. Levvey,¹ H.M. Whitford,¹ T.J. McWilliams,¹ T.C. Kotsimbos,¹ G.I. Snell,¹ T.J. Williams,¹ ¹Respiratory Medicine, The Alfred, Melbourne, Australia

3:00 pm (239) The Risk of Bronchiolitis Obliterans Syndrome Is Reduced in Lung Transplant Patients Who Receive Mycophenolate Mofetil Based Immunosuppression

J.M. Dunitz,¹ M.I. Hertz,¹ S.K. Savik,² S.J. Park,³ ¹Department of Medicine, University of Minnesota, Minneapolis, MN; ²Department of Nursing, University of Minnesota, Minneapolis, MN; ³Department of Thoracic Surgery, University of Minnesota, Minneapolis, MN

3:15 pm (240) The Tolerability and Efficacy of Total Lymphoid Irradiation (TLI) in the Control of Rapidly Progressive Bronchiolitis Obliterans Syndrome

A.J. Fisher,¹ J.M. Bozzino,² R.M. Rutherford,¹ G. Parry,¹ J.H. Dark,¹ P.A. Corris,¹ ¹Cardiopulmonary Transplantation, Freeman Hospital; ²Northern Centre for Cancer Treatment, University of Newcastle, Newcastle upon Tyne, United Kingdom

2:00 pm-3:30 pm

CONCURRENT SESSION 19

Lung/Heart-Lung Transplantation 3: Pulmonary Hypertension (Prince Eugen Saal)

(supported by an educational grant from Actelion)

Chairs: Michael Mulligan, MD and Jean-Luc Vachiery, MD

2:00 pm (241) The Use of Bosentan and a Prostacyclin Analog in the Treatment of Primary Pulmonary Hypertension

B.K. Rayburn, R.L. Benza, J.A. Tallaj, B.A. Foley, L.J. Pinderski, K.L. Thomas, R.C. Bourge. Medicine, University of Alabama at Birmingham, Birmingham, AL

2:15 pm (242) The Safety and Efficacy of Bosentan in Pulmonary Hypertension Due to Congenital Heart Disease

R.L. Benza, B.K. Rayburn, J.A. Tallaj, B.A. Foley, L.J. Pinderski, K.L. Thomas, R.C. Bourge. Medicine, University of Alabama at Birmingham, Birmingham, AL

2:30 pm (243) Differential Protein Expression in Plexogenic Pulmonary Hypertensive Lung Lesions

M. Southwood,¹ C. Atkinson,¹ L. Long,² R. Pitman,¹ S. Stewart,¹ N. Morrell,² ¹Pathology Department, Papworth Hospital, Cambridge, Cambridgeshire, United Kingdom; ²Respiratory Medicine Unit, University of Cambridge, Cambridge, Cambridgeshire, United Kingdom

2:45 pm (244) Nebulised Iloprost in Pulmonary Arterial Hypertension Due to Eisenmengers Syndrome

F. Reichenberger,¹ L. Howard,¹ J. Parameshwar,¹ N.W. Morrell,¹ J. Pepke-Zaba,¹ ¹Pulmonary Vascular Diseases Unit, Papworth Hospital, Cambridge, United Kingdom

3:00 pm (245) Acute and Short-Term Hemodynamic and Clinical Effect of Sildenafil in Pulmonary Arterial Hypertension

M.D. McGoon,¹ R.P. Frantz,¹ C.J. Severson,¹ L.A. Durst,¹ S.K. Tointon,¹ ¹Cardiovascular Diseases, Mayo Clinic, Rochester, MN

3:15 pm (246) Utility of Neurohumoral Profiles in Pulmonary Hypertension: Clinical and Hemodynamic Correlations

R.P. Frantz,¹ M.D. McGoon,¹ C.J. Severson,¹ S.K. Tointon,¹ L.A. Durst,¹ K.V. Ballman,¹ K.R. Bailey,¹ J.C. Burnett,¹ ¹Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN

2:00 pm-3:30 pm

CONCURRENT SESSION 20

Basic Science and Immunobiology 3: Immune Mechanisms of Post Transplantation Vasculopathy and Obliterative Airway Disease (Gartensaal)

Chairs: Carla C. Baan, MD and Thomas J. Dengler, MD

2:00 pm (247) MIG/CXCL9 Neutralization Attenuates Chronic Rejection of Transplanted Hearts

D. Whiting,¹ S. Chun,¹ H. Laks,¹ J. Yun,¹ X. Gan,² W. Yao,¹ B. Bonavida,² A. Ardehali,¹ ¹Division of Cardiothoracic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA

(248) 2:15 pm Natural Killer Cells Can Mediate Cardiac Allograft Vasculopathy in Murine Allografts

H.S. Rose,¹ W.H. Kitchens,¹ C.M. Chase,¹ R.B. Colvin,² P.S. Russell,¹ J.C. Madsen,¹ ¹Department of Surgery, Massachusetts General Hospital, Boston, MA; ²Department of Pathology, Massachusetts General Hospital, Boston, MA

2:30 pm (249) Gamma-Interferon-Dependent T Cell-Mediated Injury and Remodeling of Human Coronary Arteries
Y. Wang,¹ W. Burns,¹ P. Tang,¹ Y. Bai,¹ T. Yi,¹ J.S. Schechner,¹ M.I. Lorber,¹ J.S. Pober,¹ G. Tellides,¹ ¹Interdepartmental Program in Vascular Biology and Transplantation, Yale University School of Medicine, New Haven, CT

2:45 pm (250) Granzyme B, a Cytotoxic Immune Protease, Induces Apoptosis of Smooth Muscle Cells in the Absence of Perforin

J.C. Choy,¹ V.H. Hung,¹ J. Myers,¹ B. Motyka,² I.S. Goping,² T. Sawchuck,² R.C. Bleackley,² B.M. McManus,¹ D.J. Granville,^{1,3}
¹McDonald Research Laboratories/The iCAPTUR4E Centre, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; ²Department of Biochemistry, University of Alberta, Edmonton, AB, Canada;
³Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA

3:00 pm (251) Inhibition of Poly (ADP) Ribose Synthetase Ameliorates Experimental Obliterative Bronchiolitis in Rat Tracheal Allografts

A.S. Farivar,¹ B.V. Naidu,¹ S.M. Woolley,¹ A.L. Salzman,² C.S. Szabo,² M.S. Mulligan,¹ ¹Cardiothoracic Surgery, University of Washington, Seattle, WA; ²Inotek Corporation, Beverly, MA

3:15 pm (252) Role of the ICOS/ICOS Ligand Costimulating System in Endothelial Cell-Dependent T Cell Activation

R. Klingenberg,¹ U. Heidl,¹ W. Nottmeyer,¹ N. Xia,¹ G. Richter,² T.J. Dengler,¹ ¹Cardiology/Heart Transplant Center, University Hospital Heidelberg, Heidelberg, Germany; ²Hematology, University Hospital Halle, Halle, Germany

3:30 pm-4:00 pm

Coffee Break/Visit Exhibits/Visit Posters

4:00 pm-5:30 pm

CONCURRENT SESSION 21

Clinical Heart Transplantation 4: Heart Transplant Complications (Festsaal)

Chairs: Steven S. L. Tsui, MD, FRCS and TBD

4:00 pm (253) Transplantation Using Hearts from Primary Pulmonary Hypertensive Donors for Recipients with High Pulmonary Vascular Resistance

E.J. Birks,¹ A. Anyanwu,¹ F. De Robertis,¹ J. Jayakumar,¹ R. Radley Smith,¹ N.R. Banner,¹ M.H. Yacoub,¹ A. Khaghani,¹
¹Cardiology & Cardiothoracic Surgery, Royal Brompton & Harefield Hospital, Harefield, Middlesex, United Kingdom

4:15 pm (254) Combined Prophylaxis of CMV-Immune Globulin Plus Ganciclovir Versus CMV-Immune Globulin Alone in High Risk Heart Transplant Recipients

N.E. Bonaros,¹ A.A. Kocher,² M. Ehrlich,² M. Grimm,² E. Wolner,² G. Laufer,¹ ¹Cardiac Surgery, University of Innsbruck, Innsbruck, Austria; ²Cardiothoracic Surgery, University of Vienna, Vienna, Austria

4:30 pm (255) Prevention of Bone Loss after Cardiac Transplantation with Alendronate or Calcitriol: Efficacy and Safety

S. Maybaum,¹ V. Adesso,¹ P. Namerow,¹ R.B. Staron,¹ S.H. Lo,¹ M. Zucker,² S. Pardi,² D.M. Mancini,¹ E. Shane,¹ ¹Medicine, Columbia University, College of Physicians & Surgeons, New York, NY; ²Medicine, Newark-Beth Israel Medical Center, Newark, NJ

4:45 pm (256) Temporal Alteration in B-Type Natriuretic Peptide Expression Predicts Allograft Failure in Heart Transplantation

M.H. Park,¹ P.A. Uber,¹ P.F. Nasca,¹ R.L. Scott,¹ M.R. Mehra,¹ ¹Cardiomyopathy and Heart Transplantation Center, Ochsner Clinic Foundation, New Orleans, LA

5:00 pm (257) B-Natriuretic Peptide Improves Hemodynamics and Renal Function in Heart Transplant Patients Immediately after Surgery

S.M. Tann,¹ J.S. Ikonomidis,¹ W. Uber,¹ A.B. VanBakel,¹ N.L. Pereria,¹ A. Crumbley,¹ D.S. Feldman,¹ ¹Cardiovascular Institute, Medical University of South Carolina, Charleston, SC

5:15 pm (258) Does Prophylactic Ganciclovir Therapy after Heart Transplantation Decrease CMV-Infection Properly?

M. Mueller,¹ J. Groetzner,¹ I. Kaczmarek,¹ F. Reisch,¹ P. Landwehr,¹ P. Ueberfuhr,¹ B. Meiser,¹ B. Reichart,¹ ¹Department of Cardiac Surgery, University of Munich, Klinikum Grosshadern, Munich, Bavaria, Germany

4:00 pm-5:30 pm

CONCURRENT SESSION 22

Clinical Heart Failure 2: Novel Therapy in Heart Failure (Zeremoniensaal)

Chairs: Wolfgang F. Konertz, Jr., MD and Mandeep R. Mehra, MD

4:00 pm (259) Stable Left Ventricular Volumes and Function Following Dor Ventriculoplasty

H.J. Patel,¹ M.M. Kirsh,¹ R. Cody,² J. Corbett,^{2,3} F.D. Pagani,¹ ¹Section of Cardiac Surgery, University of Michigan, Ann Arbor, MI; ²Division of Cardiology, University of Michigan, Ann Arbor, MI; ³Department of Radiology, University of Michigan, Ann Arbor, MI

4:15 pm (260) Implantation of a Cardiac Support Device as Adjunct to CABG in Ischemic Cardiomyopathy

M.A. Castel,¹ N. Kotetishvili,² R. Schomburg,¹ M. Lass,² ¹Cardiology, St. Georg Hospital, Hamburg, Hamburg, Germany; ²Cardiac Surgery, St. Georg Hospital, Hamburg, Hamburg, Germany

4:30 pm (261) Left Ventricular Shape Change with Myosplint Implantation in Dilative Cardiomyopathy: Clinical Experience in 9 Patients

A. Rahmel,¹ R. Krakor,¹ J. Schneider,¹ T. Bossert,¹ F.W. Mohr,¹ ¹Department of Cardiac Surgery, University of Leipzig - Heart Center, Leipzig, Germany

4:45 pm (262) Does Extended Duration of Mechanical Circulatory Support Impact Clinical Outcomes ?

T. Mussivand,¹ ¹Cardiovascular Devices Division, University of Ottawa Heart Institute, Ottawa, ON, Canada

5:00 pm (263) Tissue Doppler Echocardiography Predicts Positive Left Ventricular Remodeling after Biventricular Pacing in Severe Heart Failure

M. Penicka,¹ J. Bartunek,¹ M. Vanderheyden,¹ B. De Bruyne,¹ M. De Zutter,¹ P. Geelen,¹ E. Barbato,¹ M. Goethals,¹ ¹Cardiovascular Center, OLV Ziekenhuis, Aalst, Aalst, Belgium

5:15 pm (264) Improved Survival with Statin Therapy in Ischemic and Non-Ischemic Heart Failure

T.B. Horwich,¹ J.K. Patel,¹ M.A. Hamilton,¹ W.R. MacLellan,¹ M. Lesniewski,¹ G.C. Fonarow,¹ ¹Cardiology, The David Geffen School of Medicine at UCLA, Los Angeles, CA

4:00 pm-5:30 pm

23) Lung/Heart-Lung Transplantation 4: Complications and Lung Injury in Lung Transplantation (Prince Eugen Saal)

Chairs: Walter Klepetko, MD and TBD

4:00 pm (265) Medium Term Results of ECMO for Severe Acute Lung Injury Following Lung Transplantation

P.S. Dahlberg,¹ M.E. Prekker,¹ M.I. Hertz,² C.S. Herrington,¹ S.J. Park,¹ ¹Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN; ²Pulmonary Medicine, University of Minnesota, Minneapolis, MN

4:15 pm (266) A Simple Clinical Predictive Model for Primary Graft Failure Following Lung Transplantation

J.D. Christie, V.N. Ahya, A. Pochettino, E. Demissie, C. Gaughan, D.A. Zisman, D.A. Lipson, B.R. Rosengard, R.M. Kotloff, Departments of Medicine and Surgery, University of Pennsylvania, Philadelphia, PA

4:30 pm (267) Maternal and Foetal Outcome Following Pregnancy after Intrathoracic Organ Transplantation: Single Centre Experience in 21 Patients

K.S. Nair,¹ K.A. Ghosh,¹ A. Mooney,¹ E.J. Birks,¹ N.R. Banner,¹ M. Hodgson,¹ A. Khaghani,¹ ¹Department of Cardiothoracic Surgery and Transplantation, Harefield Hospital, Harefield, Middlesex, United Kingdom

4:45 pm (268) Lymphoproliferative Disease Following Lung Transplant: Positive Results with Rituximab as Primary Therapy

D.C. Lien,¹ K.B. Jackson,¹ M.J. Bentley,¹ J.C. Mullen,¹ K.C. Stewart,¹ T.L. Winton,¹ D.L. Modry,¹ ¹Lung Transplant Program, University of Alberta, Edmonton, AB, Canada

5:00 pm (269) Impact of Bronchogenic Carcinoma in Patients Undergoing Lung Transplantation. Results of an International Survey

A. Patterson, M. de Perrot, S. Chernenko, T.K. Waddell, Y. Shargall, A. Pierre, L. Singer, M. Hutcheon, S. Keshavjee, Toronto Lung Transplant Program, University of Toronto, Toronto, ON, Canada

5:15 pm (270) Negative Effect of CMV Donor Status on Graft Survival after Lung but Not Heart Transplantation Is Restricted to HLA-A2 Negative Recipients

H. Bonatti,¹ W. Tabarelli,³ D. Hofer,³ R. Kafka,¹ A. Klaus,¹ G. Lauffer,³ C. Larcher,² G. Geltner,¹ R. Margreiter,¹ H. Antretter,³ L. Mueller,³ ¹Surgery, General Surgery, Innsbruck, Tirol, Austria; ²Hygiene, Virology, Innsbruck, Tirol, Austria; ³Surgery, Cardiac Surgery, Innsbruck, Tirol, Austria

4:00 pm-5:30 pm

CONCURRENT SESSION 24

Basic Science and Immunobiology 4: Cellular and Molecular Events in Acute Rejection (Gartensaal)

Chairs: Paul J. Mohacsi, MD and Thalachallor Mohanakumar, PhD

4:00 pm (271) Visualization of Alloreactive CD4 T Cell Responses and Tolerance Induction In Vivo

S. Sandner,¹ A. Salama,¹ E. Palmer,² L.A. Turka,³ M.H. Sayegh,¹ ¹Immunogenetics and Transplantation, Brigham & Women's Hospital and Children's Hospital, Harvard Medical School, Boston, MA; ²Transplantation Immunology, University Hospital Basel, Basel, Switzerland; ³Medicine, University of Pennsylvania, Philadelphia, PA

4:15 pm (272) Evaluation of an Oral CXCR3 Antagonist in a Rat Model of Acute Cardiac Allograft Rejection

M.E. Bowdish,¹ M.L. Barr,¹ S.M. Quardt,¹ J. Medina,³ T. Collins,³ M. Johnson,³ G. Tonn,³ D. Newland,⁴ D. Dairaghi,⁴ G.D. Wu,¹ R. Mencil,¹ N. Mitsuhashi,¹ M. Watanabe,¹ M.N. Koss,² V.A. Starnes,¹ D.V. Cramer,¹ ¹Department of Cardiothoracic Surgery, University of Southern California, Los Angeles, CA; ²Department of Pathology, University of Southern California, Los Angeles, CA; ³Tularik, Inc., South San Francisco, CA; ⁴ChemoCentryx, San Carlos, CA

4:30 pm (273) Role of the Thymus in Heterotopic Cardiac Allograft Survival in Miniature Swine: Evidence for the Need of Thymic Emigrants Immediately Post-Transplantation, and Thymic Immigrants for Long Term Tolerance Induction

S. Yamamoto,¹ P.A. Vagefi,¹ J.D. Mezrich,¹ S.L. Houser,¹ C. Kamano,¹ H. Arakawa,¹ K. Teranishi,¹ J.C. Madsen,¹ D.H. Sachs,¹ K. Yamada,¹ ¹Department of Surgery, Transplantation Biology Research Center, Massachusetts General Hospital/Harvard Medical School, Boston, MA

4:45 pm (274) Increased Incidence of Severe Lung Allograft Acute Rejection in Patients Exhibiting HLA-Specific Antibodies

A. Zeevi,¹ A.L. Girmita,¹ K. McCurry,² M. Awad,¹ G. Burckart,³ R. Duquesnoy,¹ J. Dauber,¹ B. Griffith,² A. Iacono,⁴ ¹Pathology; ²Surgery; ³Pharmacology; ⁴Pneumology, University of Pittsburgh Medical Center, Pittsburgh, PA

5:00 pm (275) Vascular Endothelial Growth Factor Gene Polymorphism Are Associated with Acute Rejection after Heart Transplantation

S. Datta,¹ J. Fildes,¹ A.K. Deiraniya,¹ N. Yonan,¹ I.V. Hutchinson,² ¹Transplant Research Laboratory, Wythenshawe Hospital, Manchester, Manchester, United Kingdom; ²Department of Immunology, School of Biological Sciences, University of Manchester, Manchester, Manchester, United Kingdom

5:15 pm (276) Sequential Expression of Three Known Protective Genes in Cardiac Biopsies after Transplantation

A.I. De Souza,¹ L.E. Felkin,¹ P.J. Barton,¹ N.R. Banner,¹ M.L. Rose,¹ ¹National Heart and Lung Institute, Imperial College School of Medicine, Harefield, Middlesex, United Kingdom

5:30 pm-6:30 pm

Pediatric Transplantation Scientific Council Meeting (Zeremoniensaal)
Pulmonary Transplantation Scientific Council Meeting (Prince Eugen Saal)
Mechanical Circulatory Support Scientific Council Meeting (Festsaal)
Infectious Diseases Scientific Council Meeting (Radetzky Appt II)
Nursing and Social Sciences Scientific Council Meeting (Gartensaal)

5:30 pm-6:30 pm

GENERAL POSTER SESSION 2/Wine and Cheese Reception (Gardehalle I)

(Please see page ??? of this program booklet for the list of Poster Session I abstract titles and authors – Abstracts 277 – 409)

6:30 pm-Midnight

Exhibit Hall Teardown (Seitengalerie, Vorsaal, Marmorsaal, Antekammer, Rittersaal, Wintergarten)
Poster Teardown (Gardehalle I)

SATURDAY APRIL 12, 2003

7:00 am-5:00 pm

Speaker Ready Room Open (Kunstlerzimmer)

7:30 am-8:30 am

Morning Coffee (Seitengalerie)

7:30 am-10:30 am

Registration Desk Open (Halle)

8:00 am-9:00 am

PLENARY SESSION (Festsaal)

Chairs: Walter Klepetko, MD and Guenther Laufer, MD

Research Grant Awards Presentations

Caves Award Winner Presentation

Featured Abstracts

8:30 am (410) Mycophenolate Mofetil (MMF) vs Azathioprine (AZA) in Lung Transplantation for the Prevention of Bronchiolitis Obliterans Syndrome (BOS): Results of A 3 Year International Randomized Trial

A.R. Glanville¹, P.A. Corris², K.D. McNeil³, Th. Wahlers and on Behalf of the International MMF Lung Study Group. ¹Thoracic Medicine, St. Vincent's Hospital Sydney, Darlinghurst, NSW, Australia; ²Freeman Hospital, Newcastle upon Tyne, United Kingdom; ³Prince Charles Hospital, Brisbane, Australia

8:45 am (411) One-Year Results of an International, Randomized, Double-Blind Study of Everolimus vs Azathioprine as Adjunctive Therapy to Inhibit the Decline of Pulmonary Function in Stable Lung or Heart/Lung Transplant Recipients

G.I. Snell¹, V.G. Valentine², R.B. Love³, P. Vitulo⁴, A.R. Glanville⁵, U. Pirron⁶. ¹Lung Transplantation Service, Alfred Hospital, Melbourne, Australia; ²Lung Transplantation, Ochsner Clinic Foundation, New Orleans, LA; ³Lung Transplant Unit, University of Wisconsin, Madison, WI; ⁴Division of Pneumology, IRCCS Policlinico San Matteo, Pavia, Italy; ⁵The Lung Transplant Unit, St. Vincent's Hospital, Sydney, Australia and ⁶BU Transplantation and Immunology, Novartis Pharma AG, Basel, Switzerland.

9:00 am Invited Lecture: Chronic Rejection

Marshall Hertz, MD, University of Minnesota, Minneapolis, MN

9:30 am Invited Lecture: Tolerance is a Clinical Reality

David H. Sachs, MD, Massachusetts General Hospital, Boston, MA

10:00 am-10:30 am

Coffee Break (Seitengalerie)

10:30 am-Noon

CONCURRENT SESSION 25

Clinical Heart Transplantation 5: Outcomes After Cardiac Transplantation (Festsaal)

Chairs: Carmelo A. Milano, MD and Hannah A. Valentine, MD

10:30 am (412) Diagnostic Accuracy of Coronary Angiography and Risk Factors for Post-Heart Transplant Coronary Artery Vasculopathy (CAV)

L.D. Sharples¹, C.H. Jackson¹, J. Parameshwar², J. Wallwork², S.R. Large². ¹MRC Biostatistics Unit, Institute of Public Health, Cambridge, Cambridgeshire, United Kingdom; ²Transplant Unit, Papworth Hospital HNS Trust, Cambridge, Cambridgeshire, United Kingdom

10:45 am (413) QTC Interval Prolongation Predicts Mortality in Patients with Transplant Coronary Artery Disease

B. Vrtovec¹, B. Radovancevic¹, A.P. Yazdanbakhsh¹, R. Radovancevic¹, C.D. Thomas¹, O.H. Frazier¹. ¹Cardiopulmonary Transplantation, Texas Heart Institute, Houston, TX

11:00 am (414) Impact of Health Insurance and Black Race on Outcome after Cardiac Transplantation: Analysis of the Cardiac Transplant Research Database

M.C. Montpetit², R.N. Brown, S.V. Pamboukian, T. Stevens, G.W. Dec, C. Leier, A. VanBakel, B. Jaski, A. Heroux, J.K. Kirklin, for the Cardiac Transplant Research Database(CTRD), ¹CTRD, University of Alabama at Birmingham, Birmingham, AL; ²Roche Young Investigator Award

11:15 am (415) Pre-Existing Renal Failure Doubles 30 Day Mortality after Cardiac Transplantation

M.E. Ostermann¹, C.A. Rogers², I. Saeed², S.R. Nelson¹, A.J. Murday², the Steering Group of the UK Intrathoracic Transplant Audit, ¹Department of Nephrology & Transplantation, St George's Hospital, London, United Kingdom; ²UK Cardiothoracic Transplant Audit, The Royal College of Surgeons of England, London, United Kingdom

11:30 am (416) Outcome after Cardiac Transplantation - Influence of Allocation Modus

A. Costard-Jäckle¹, S.W. Hirt¹, B. Fischer¹, T. Spahr¹, U. Struckmeyer¹, R. Stahl¹, J. Cremer¹. ¹Cardiac Surgery, University Kiel, Kiel, Germany

11:45 am (417) Heart Transplantation in Diabetic Recipients: A Decade Review of 161 Patients at Columbia Presbyterian

J.A. Morgan¹, N.J. Colletti¹, K.W. Hollingsworth¹, F.H. Cheema¹, A.R. Kherani¹, D.W. Vigilance¹, M. Argenziano¹, Y. Naka¹, M.C. Oz¹, D. Mancini¹, N.M. Edwards¹. ¹Surgery, Division of Cardiothoracic Surgery, Columbia University, New York, NY

10:30 am-Noon

CONCURRENT SESSION 26

Mechanical Circulatory Support 3: The Science of Myocardial Recovery with LVADs (Zeremoniensaal)

Chairs: Gilles Dreyfus, MD and O. H. Frazier, MD

10:30 am (418) Effect of Mechanical Ventricular Unloading on Mast Cells in Failing Myocardium

C.A. Skrabal,¹ L.O. Thompson,¹ K.A. Youker,¹ J.A. Lafuente,¹ G.P. Noon,¹ M. Loebe,¹ ¹Michael E. DeBaKey Department of Surgery, Baylor College of Medicine, Houston, TX

10:45 am (419) Myocardial Structural Recovery Is Associated with Apoptosis Inactivation in Biomechanical Unloaded Heart by LVAD Therapy

M. Vatta, S. Jimenez, S.J. Stetson, K. Becker, J.A. Towbin, G. Torre-Amione, N.E. Bowles, Pediatrics (Cardiology), Baylor College of Medicine, Houston, TX; Medicine (Cardiology), Baylor College of Medicine, Houston, TX

11:00 am (420) Improved Right Ventricular Structure Following LVAD Support in Patients with End-Stage Cardiomyopathy

S.A. Kucuker,¹ S.J. Stetson,¹ K.A. Becker,¹ A. Akgul,¹ M. Loebe,¹ J.A. LaFuente,¹ G.P. Noon,¹ M.M. Koerner,¹ M.L. Entman,¹ G. Torre-Amione,¹ ¹DeBaKey Heart Center at the Methodist Hospital, Baylor College of Medicine, Houston, TX

11:15 am (421) Long Term Survival Following Left Ventricular Assist and Comprehensive Medical Management as Bridge to Recovery Therapy for Advanced Heart Failure

M.A. Silver,¹ M.S. Slaughter,¹ P.S. Pappas,¹ A.J. Tatoes,¹ S. Szabo,¹ ¹Heart Failure Institute/ LVAD Program, Advocate Christ Medical Center, Oak Lawn, IL

11:30 am (422) Assessment of Myocardial Blood Flow and Coronary Bypass Graft Patency during LVAD Support

S. Maybaum,¹ S. Pinney,¹ Y. Naka,² D. Mancini,¹ M. Oz,² S. Bergmann,¹ ¹Medicine, Columbia University, New York, NY; ²Surgery, Columbia University, New York, NY

11:45 am (423) Experience of Severe Fulminant Myocarditis with Shock by Extracorporeal Membrane Oxygenation - What Mechanical Support Should be Considered First?

Y.S. Chen,¹ S.C. Huang,¹ W.J. Ko,¹ H.Y. Yu,¹ S.S. Wang,¹ K.M. Chiu,² F.Y. Lin,¹ S.H. Chu,² ¹Cardiovascular Surgery, National Taiwan University Hospital, Taipei, Taiwan; ²Far-East Memorial Hospital, Taiwan

10:30 am-Noon

CONCURRENT SESSION 27

Donor Management 4: Extended Donors and Other Issues (Prince Eugen Saal)

Chairs: Robert B. Love, MD and Florian Wagner, MD

10:30 am (424) Donor Intracranial Bleeding Is Associated with Upregulation of the Angiotensin Receptor

M.H. Yamani,¹ D.J. Cook,² A.S. Abdo,² M. Yousufuddin,¹ R.C. Starling,¹ Y. Yu,¹ E.M. Tuzcu,¹ N.B. Ratliff,³ P. Paul,² P.M. McCarthy,⁴ J.B. Young,¹ ¹Cardiovascular Medicine, Cleveland Clinic; ²Allogen Laboratory; ³Anatomic Pathology; ⁴Cardiovascular Thoracic surgery, Cleveland Clinic, Cleveland, OH

10:45 am (425) Role of Interleukin-8 in Predicting Outcome of Donor Lungs

A. Patterson, M. de Perrot, H. Kaneda, M. Yamane, Y. Imai, M. Quadri, T.K. Waddell, M. Liu, S. Keshavjee, Thoracic Surgery Research Laboratory, University of Toronto, Toronto, ON, Canada

11:00 am (426) Liberalization of Donor Criteria Does Not Compromise Outcomes Three Years after Lung Transplantation

S.M. Bhorade,¹ A.M. Jordan,¹ W.T. Vigneswaran,² E.R. Garrity,¹ ¹Pulmonary and Critical Care, Loyola University Medical Center, Maywood, IL; ²Cardiothoracic Surgery, Loyola University Medical Center, Maywood, IL

11:15 am (427) IL-1 α in Broncho-Alveolar Lavage Is a Non-Invasive Predictor of the Viability of the Pulmonary Graft from the Non-Heart-Beating Donor

F. Rega,¹ B. Vanaudenaerde,² W. Wuyts,² N. Jannis,¹ G. Verleden,² T. Lerut,³ D. Van Raemdonck,^{1,3} ¹Center for Experimental Surgery and Anaesthesiology, Katholieke Universiteit Leuven, Leuven, Belgium; ²Laboratory for Pneumology, Katholieke Universiteit Leuven, Leuven, Belgium; ³Department of Thoracic Surgery, University Hospital Gasthuisberg, Leuven, Belgium

11:30 am (428) The Risk of Transmission of Hepatitis B from Donors with Hepatitis B Core Antibody Positivity Is Low

S.P. Pinney,¹ F.H. Cheema,² K.M. Hammond,¹ J.M. Chen,² N.M. Edwards,² M.C. Oz,² D.M. Mancini,¹ ¹Medicine, Columbia University, New York, NY; ²Surgery, Columbia University, New York, NY

11:45 am (429) Impact of Donor-Transmitted Coronary Atherosclerosis

O. Grauhan,¹ D. Kemper,¹ H. Krieglner,¹ H. Lehmkühl,¹ C. Knossala,¹ M. Dandel,¹ R. Meyer,¹ M. Pasic,¹ Y. Weng,¹ R. Hetzer,¹
¹Cardiothoracic Surgery, German Heart Institute, Berlin, Germany

10:30 am-Noon

CONCURRENT SESSION 28

Pediatrics 2: General Topics (Gartensaal)

Chairs: Asif Hasan, MD, and Lori West, MD, DPhil

10:30 am (430) Tissue Doppler Echocardiography - New Insights into Cardiac Allograft Function in Children

L.B. Pauliks,¹ L.M. Valdes-Cruz,¹ B.A. Pietra,¹ C.G. DeGroof,¹ L. Logan,¹ O.A. Knudson,¹ M.M. Boucek,¹ ¹The Children's Hospital Denver, University of Colorado Health Sciences Center, Denver, CO

10:45 am (431) Cystic Fibrosis and Lung Transplantation - Determination of the Survival Benefit

C. Aigner,¹ P. Jaksch,¹ G. Seebacher,¹ S. Mazhar,¹ W. Wisser,¹ W. Klepetko,¹ ¹Department of Cardio-Thoracic Surgery, University of Vienna, Vienna, Austria

11:00 am (432) Mycophenolic Mofetil Reduces the Alloimmune Response of Children to Surgical Valved Allograft Implantation

R.E. Shaddy,¹ T.C. Fuller,² J.B. Anderson,¹ L.M. Lambert,³ M.K. Brinkman,¹ T. Profaizer,² J.A. Hawkins,³ ¹Pediatrics, University of Utah School of Medicine; ²Pathology; ³Surgery, University of Utah School of Medicine, Salt Lake City, UT

11:15 am (433) Extracorporeal Membrane Oxygenation (ECMO) as a Bridge to Heart Transplantation in Children

R. Perez,¹ A. Campbell,¹ D. Edgell,¹ L. West,¹ J. Coles,¹ B. McCrindle,¹ G. VanArsdell,¹ A. Dipchand,¹ ¹Paediatric Cardiology, Cardiovascular Surgery, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

11:30 am (434) Growth Hormone Therapy Following Pediatric Cardiac Transplantation

S. Mital,¹ A. Andron,¹ B. Softness,¹ J.M. Lamour,¹ D.T. Hsu,¹ L.J. Addonizio,¹ ¹Pediatrics, Columbia University, New York, NY

11:45 am (435) Is Interstitial Lung Disease a Risk Factor for Mortality in Pediatric Lung Transplantation?

K.J. Guleserian,¹ E.N. Mendeloff,¹ S.C. Sweet,² M.T. de la Morena,² C.B. Huddleston,¹ ¹Cardiothoracic Surgery, St. Louis Children's Hospital, St. Louis, MO; ²Pulmonary Medicine, St. Louis Children's Hospital, St. Louis, MO

12:15 pm-1:45 pm

Fujisawa Lunch Symposium: Non-immunological Risks of Immunosuppressive Therapy in Heart Transplantation
(Zeremoniensaal)

Chair: Mandeep R. Mehra, MD

12:15 pm How Do We Define "Success" Following Heart Transplantation?

Mandeep R. Mehra, MD, Ochsner Medical Institutions, New Orleans, LA

12:40 pm Rationale for Focusing on Non-Immunological Outcomes: Mechanisms and Clinical Impact

Bruno M. Meiser, MD, University of Munich/Grosshadern, Munich, Germany

1:05 pm Results of a Multi-Center Study of Metabolic and Renal Factors Influencing Survival in Heart Transplantation

Jon Kobashigawa, MD, UCLA Medical Center, Los Angeles, CA

1:30 pm Panel Discussion and Closing Remarks

2:00 pm-3:30 pm

CONCURRENT SESSION 29

Clinical Heart Transplantation 5: Optimizing Outcomes After Cardiac Transplantation (Festsaal)

Chairs: Richard C. Daly, MD and Mariell Jessup, MD

2:00 pm (436) Time Course of Physical Reconditioning during Exercise Rehabilitation Late after Heart Transplantation

U. Tegtbur,¹ K. Pethig,² H. Machold,³ A. Haverich,⁴ M.W. Busse,⁵ ¹Sportsmedicine, Hannover Medical School, Hannover, Germany; ²Cardiology, University of Jena, Jena, Germany; ³Pfaffenhofen, Germany; ⁴Thoracic and Cardiovascular Surgery, Hannover Medical School, Hannover, Germany; ⁵Sportsmedicine, University of Leipzig, Leipzig, Germany

2:15 pm (437) Heart Failure Survival Score Continues to Predict Death or UNOS 1 Transplant in Heart Failure Patients Receiving Beta Blockers

T.M. Koelling,¹ S. Joseph,¹ K.D. Aaronson,¹ ¹Division of Cardiology, University of Michigan, Ann Arbor, MI

2:30 pm (438) IL-6 and TNF α Cytokine Genotypes Are Associated with Acute Rejection and Lower Survival in African American Heart Transplant Recipients

B.L. Coleman,¹ L.S.C. Czer,¹ S.C. Jordan,² J.M. Mirocha,³ M.G. Gillaspie,⁴ C. Blanche,¹ A. Hickey,¹ K.E. Magliato,¹ D.B. Tyan,⁵ ¹Cardiothoracic Surgery, Cedars Sinai Medical Center, Los Angeles, CA; ²Pediatrics / Transplant Immunology, Cedars Sinai Medical Center, Los Angeles, CA; ³Cardiology / Biostatistics, Cedars Sinai Medical Center, Los Angeles, CA; ⁴Outcomes Management, Cedars Sinai Medical Center, Los Angeles, CA; ⁵Medical Genetics, Cedars Sinai Medical Center, Los Angeles, CA

2:45 pm (439) Is There a Need for a Tailored Immunosuppression in Elderly Heart Transplant Recipients ?

I. Kaczmarek, B. Meiser, J. Groetzner, M. Mueller, P. Landwehr, P. Ueberfuhr, G. Nollert, F. Reisch, B. Reichart, Department of Cardiac Surgery, Ludwig-Maximilians University, Munich, Germany

3:00 pm (440) Patient Factors Influencing Waiting Time to Heart Transplant in the UK and Republic of Ireland

A.J. Hudson,¹ F.M. Seeney,¹ J. Wallwork,² C.J. Rudge,¹ ¹Medical Directorate, UK Transplant on Behalf of the UK Transplant Cardiothoracic Advisory Group, Bristol, United Kingdom; ²Papworth Hospital, Papworth, United Kingdom

3:15 pm (441) Neurohormonal Activation in Congestive Heart Failure: Does It Normalize after Heart Transplantation?

E. Ferrer,¹ F. Perez-Villa,¹ E. Roig,¹ A. Cuppoletti,¹ I. Vallejo,¹ J. Orus,¹ G. Sanz,¹ ¹Cardiovascular Institute, Hospital Clinic, Barcelona, Spain

2:00 pm-3:30 pm

CONCURRENT SESSION 30

Mechanical Circulatory Support 4: Impact of New LVAD Technology (Zeremoniensaal)

Chairs: Robert L. Kormos, MD and George Wieselthaler, MD

2:00 pm (442) Vascular Thrombosis in Patients with Long Term Jarvik 2000 VAD Support

R.M. Delgado,¹ B. Kar,¹ T.J. Myers,¹ G. Letsou,² I. Riaz,¹ R. Metcalfe,³ M.T. Harting,² O.H. Frazier,¹ ¹Cardiopulmonary Transplantation, Texas Heart Institute, Houston, TX; ²Cardiology, University of Texas Health Science Center Houston, Houston, TX; ³Mechanical Engineering, University of Houston, Houston, TX

2:15 pm (443) The Micromed-DeBakey VAD: Initial American Experience

D.J. Goldstein,¹ M. Zucker,¹ L. Arroyo,¹ P. McCarthy,² G. Noon,³ ¹Cardiothoracic Surgery, Newark Beth Israel Medical Center, Newark, NJ; ²Cardiothoracic Surgery, Cleveland Clinic Foundation, Cleveland, OH; ³Cardiothoracic Surgery, Methodist Hospital, Houston, TX

2:30 pm (444) Chronic Therapy with the Acorn Cardiac Support Device Normalizes Gene Expression of Vascular Endothelial and Basic Fibroblast Growth Factors in Dogs with Heart Failure

S. Rastogi, S. Mishra, R.C. Gupta, H. Morita, H.N. Sabbah, Medicine and Surgery, Henry Ford Health System, Detroit, MI

2:45 pm (445) The Differences in Hemodynamics, Cardiac Function and Myocardial Structure Associated with Chronic Mechanical Circulatory in Patients Support with Either Pulsatile or Continuous Flow Left Ventricular Assist Devices

V. Thohan,¹ M. Loebe,¹ J. LaFuente,¹ M. Koerner,¹ G.P. Noon,¹ G. Torre-Amione,¹ ¹DeBakey Heart Center at the Methodist Hospital, Baylor College of Medicine, Houston, TX

(446) 3:00 pm Mechanical Circulatory Assistance with Pulsatile or Continuous Flow Devices Leads to Molecular Remodeling of Dystrophin: Evidence for Improvement in the Failing Left and Right Ventricle

M. Vatta,¹ S.J. Stetson,² J.A. Towbin,¹ M.M. Koerner,² G.P. Noon,² G. Torre-Amione,² ¹Pediatric Cardiology at Texas Children's Hospital, Baylor College of Medicine, Houston, TX; ²DeBakey Heart Center at The Methodist Hospital, Baylor College of Medicine, Houston, TX

3:15 pm (447) Liver Failure Following Mechanical Circulatory Support: Improving Outcome with Application of Mars Technique

A. El-Banayosy,¹ L. Kizner,¹ L. Arusoglu,¹ S. Bergmeier,¹ R. Koerfer,¹ ¹Cardiac Surgery, Heart Center NRW, Bad Oeynhausen, Germany

2:00 pm-3:30 pm

CONCURRENT SESSION 31

Nursing, Social Science, Health Economics 2: Reclaiming Function and Quality (Prince Eugen Saal)

Chairs: Nancy P. Blumenthal, CRNP and TBD

2:00 pm (448) Does Functional Ability and Return To Work Improve from 1 to 3 Years after Heart Transplantation?

C. White-Williams,¹ A. Jalowiec,² K. Grady,³ ¹Nursing, University of Alabama, Birmingham, Birmingham, AL; ²Niehoff SON, Loyola University, Chicago, IL; ³Cardiology, Rush-Presbyterian-St. Luke's, Chicago, IL

2:15 pm (449) Predictors of Quality of Life at 5 to 6 Years after Heart Transplantation

K.L. Grady,¹ D.C. Naftel,² C. White-Williams,² A.J. Bellg,³ J. Young,⁴ D. Pelegrin,⁴ K. Patton-Schroeder,⁴ J. Kobashigawa,⁵ J. Chait,⁵ J. Kirklin,² W. Piccione, Jr.,¹ M. McLeod,¹ A. Heroux,¹ ¹Cardiology, Rush University, Chicago, IL; ²Cardiothoracic Surgery, University of Alabama, Birmingham, AL; ³Cardiology, Appleton Cardiology Associates, Appleton, WI; ⁴Cardiology, Cleveland Clinic Foundation, Cleveland, OH; ⁵Cardiology, University of California, Los Angeles, CA

2:30 pm (450) Measuring Physical Activity among Female Heart Transplant Recipients

L.S. Evangelista,¹ L.V. Doering,¹ K. Dracup,² J. Kobashigawa,³ ¹School of Nursing, University of California, Los Angeles, Los Angeles, CA; ²School of Nursing, University of California, San Francisco, San Francisco, CA; ³School of Medicine, University of California, Los Angeles, Los Angeles, CA

2:45 pm (451) Perception Is Deceiving; the Real Gender Specific Exercise Capacity of Heart Transplant Recipients

B.T. Cole,¹ J.A. Kobashigawa,¹ J.K. Patel,¹ J. Moriguchi,¹ M. Espejo Vassilakis,¹ S.E. Go,¹ J. Chait,¹ H. Laks,² ¹Cardiology, The David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cardiothoracic Surgery, The David Geffen School of Medicine at UCLA, Los Angeles, CA

3:00 pm (452) Quality of Life after Lung Transplantation for Lymphangiomyomatosis (LAM)

S.M. Pollock-BarZiv,^{1,2} M.M. Cohen,^{1,2} H. Maclean,^{1,2} G.P. Downey,^{1,3} ¹Medical Sciences, University of Toronto, Toronto, ON, Canada; ²Centre for Research in Women's Health, Sunnybrook & Women's College Health Science Centre, Toronto, ON, Canada; ³Respirology, University Health Network, Toronto, ON, Canada

3:15 pm (453) Relation between Quality of Life and Functional Variables in Heart Transplant Recipients

U. Tegtbur,¹ K. Pethig,⁴ U. Brinkmeier,² A. Haverich,³ M.W. Busse,⁵ ¹Sportsmedicine, Medical School Hannover, Hannover; ²Psychology, Medical School Hannover, Hannover; ³Thoracic and Cardiovascular Surgery, Medical School Hannover, Hannover, Germany; ⁴Cardiology, University of Jena, Jena, Germany; ⁵Sportsmedicine, University of Leipzig, Leipzig, Germany

4:00 pm – 5:30 pm

CLOSING PLENARY SESSION (Festsaal)

Moderators: Jon Kobashigawa, MD and Mandeep Mehra, MD

4:00 pm Late Breaking Clinical Trial: Efficacy and Safety of Daclizumab with Background Immunosuppressive Regimen in Primary Cardiac Recipients: 12 Month Analysis

Randall C. Starling, MD, Cleveland Clinic Foundation, Cleveland, OH

4:15 pm Invited Lecture/Panel Discussion

Panelists:

Randall C. Starling, MD, Cleveland Clinic Foundation, Cleveland, OH

Howard Eisen, MD, Temple University, Philadelphia, PA

Jon Kobashigawa, MD, University of California, Los Angeles, CA

Bruce Rosengard, MD, University of Pennsylvania Health System, Philadelphia, PA

4:30 pm Debate: Resolved: Heart Transplantation Has No Future

Pro: James Kirklin, Univ of Alabama, Birmingham, AL

Con: TBD

5:00 pm Debate: Resolved: Transplant Programs Should be Run by Surgeons, Not Physicians

Pro: Jack G. Copeland, MD, University of Arizona Health Science Center, Tucson, AZ

Con: Maria Rosa Constanzo, MD, Wheaton, IL

**GENERAL POSTER SESSION 1
(Gardehalle 1)**

**THURSDAY, APRIL 10, 2003
5:30 pm – 6:30 pm**

Basic Science and Immunobiology

(75) Cyclosporin-Induced Endothelial Dysfunction: Is Tetrahydrobiopterin the Solution?

I. El-Hamamsy,¹ M. Grant,² L.M. Stevens,¹ O. Malo,² L.P. Perrault,¹ ¹Cardiovascular Surgery, Montreal Heart Institute, Montreal, QC, Canada; ²Research Department, Montreal Heart Institute, Montreal, QC, Canada

(76) Deregulation of Cell Cycle Protein Expression by Constitutive Overexpression of AIF-1 in Human Coronary Artery Smooth Muscle Cells

M.V. Autieri,¹ *¹Physiology, Temple University School of Medicine, Philadelphia, PA*

(77) Differential Expression of the Novel Immuno-Regulatory Growth Factors IL-11 and IL-17 in Lung Transplant Recipients

L. Zheng,¹ M. Al Kerithy,² B. Orsida,¹ H. Walters,¹ T.J. Williams,¹ Q. Hamid,² T. Kotsimbos,¹ G.I. Snell,¹ ¹Respiratory Med. & Lung Transplant Service, Alfred Hospital, Melb., Australia; ²Meakins Christie Labs., McGill University, Montreal, Canada

(78) Specific Dysregulation of Troponins and Inflammatory Marker Genes in Endomyocardial Biopsies from Heart Transplant Recipients

S.E. Kelemen,¹ D.P. Bednarik,³ M.V. Autieri,² K.B. Margulies,¹ H.J. Eisen,¹ ¹Cardiology, Temple University, Philadelphia, PA; ²Physiology, Temple University, Philadelphia, PA; ³GeneLogic, Inc., Gaithersburg, MD

(79) Single Cell Detection of IFN-Gamma Production Identifies Lung Recipients at High Risk for Early Immune Complications

K. Mohler,¹ A. Burnette,¹ K. Savik,² M. Hertz,² M. Steele,¹ S. Palmer,¹ D. Davis,¹ N. Reinsmoen,¹ ¹Pathology, Medicine and Surgery, Duke Medical Center, Durham, NC; ²Medicine, University of Minnesota, Minneapolis, MN

(80) The Role of Epithelial Cell Apoptosis in Allograft Transplant-Induced Airway Obliteration

L.E. Segall,¹ M. Liu,¹ S.M. Quadri,¹ A. Dutly,¹ T.K. Waddell,¹ S.H. Keshavjee,¹ ¹Thoracic Surgery Research Laboratory, Toronto General Hospital Research Institute, Toronto, ON, Canada

(81) WITHDRAWN

(82) Blockade of Receptor for Age (RAGE) Suppresses T Lymphocyte Proliferation in Mixed Lymphocyte Culture

B. Moser,¹ T.M. Wendt,¹ J.H. Ankersmit,² M. Hofmann,¹ L.G. Bucciarelli,¹ B.I. Hudson,¹ M. Schuster,¹ M.T. Goova,¹ M.J. Szabolcs,³ A.M. Schmidt,¹ S. Itescu,¹ ¹Surgery, Columbia University, New York, NY; ²CT Surgery, University of Vienna, Vienna, Austria, Austria; ³Pathology, Columbia University, New York, NY

(83) 25 Days of Baboons after Orthotopic Xenotransplantation of HDAF Transgenic Pig Hearts Using a Moderate Immunosuppression

U. Brandl,^{1,4} S. Michel,¹ M. Erhardt,¹ H. Baschnegger,³ A. Bauer,³ I. Bittmann,² C. Hammer,⁴ M. Schmoeckel,¹ B. Reichart,¹ ¹Cardiac Surgery, Ludwig-Maximilians-University, Munich, Germany; ²Pathology, Ludwig-Maximilians-University, Munich, Germany; ³Anesthesiology, Ludwig-Maximilians-University, Munich, Germany; ⁴Surgical Research, Ludwig-Maximilians-University, Munich, Germany

(84) Expression of Connective Tissue Growth Factor Is Upregulated in Post-Transplant Obliterative Airway Disease

M. Thanikachalam,¹ M. Pang,¹ S. Li,¹ R. Vazquez-Padron,¹ A. Aitouche,¹ G.R. Grotendorst,¹ S.M. Pham,¹ ¹Surgery, University of Miami School Of Medicine, Miami, FL

(85) Transcriptional Profiling of the Vascular Smooth Muscle Cell Response to Allograft Injury

M.V. Autieri,¹ S.E. Kelemen,² D.P. Bednarik,³ H.J. Eisen,² ¹Physiology, Temple University School of Medicine, Philadelphia, PA; ²Cardiology, Temple University, Philadelphia, PA; ³GeneLogic, Inc., Gaithersburg, MD

(86) High Potassium Lung Preservation Solutions Increase Production of NADPH Oxidase-Dependent Reactive Oxygen Species

J. Murar,¹ Z.G. Hong,² F.X. Hong,² O. Boning,³ D.P. Nelson,² E.K. Weir,² R.F. Kelly,¹ ¹Surgery, VA Medical Center and University of Minnesota, Minneapolis, MN; ²Medicine, VA Medical Center and University of Minnesota, Minneapolis, MN; ³Anesthesiology, Justus Liebig University, Giessen, Germany

(87) Expression of Allograft Inflammatory Factor-1 in T-Lymphocytes: A Role in T-Cell Activation and Allograft Rejection

S.E. Kelemen,¹ H.J. Eisen,¹ M.V. Autieri,² ¹Cardiology, Temple University School of Medicine, Philadelphia, PA; ²Physiology, Temple University School of Medicine, Philadelphia, PA

(88) Intracoronary Interferon- γ Promotes Vasculopathy in Tolerant Miniature Swine Bearing MHC Class I Disparate Hearts

R. Hoerbelt,¹ L.C. Benjamin,¹ D.R. Johnston,¹ T. Shoji,¹ J.A. Allan,¹ L.G. Ledgerwood,¹ R.S. Hasse,¹ D.H. Sachs,¹ J.C. Madsen,¹ ¹Department of Surgery, Massachusetts General Hospital, Transplantation Biology Research Center, Boston, MA

(89) Impact of Anticoagulant and Antiplatelet Regimens on Graft Survival in Pig-To-Primate Cardiac Xenotransplantation

J.M. Schirmer,¹ D.N. Fass,¹ S.S. Teotia,¹ J.S. Logan,² C.G.A. McGregor,¹ ¹Mayo Clinic William J von Liebig Transplant Center, Mayo Clinic, Rochester, MN; ²Nextran Inc., Princeton, NJ

(90) Progress Towards a More Physiologic Approach to Heart Preservation: The Advantages of Hyperpolarized Arrest

M.D. Diodato,¹ N.R. Shah,¹ S.M. Prasad,¹ S. Mizutani,¹ E.L. Racen,¹ J.L. Lawton,¹ R.J. Damiano, Jr.,¹ ¹Cardiothoracic Surgery, Washington University in St. Louis, St. Louis, MO

(91) C4D as a Diagnostic Adjunct in Lung Allograft Biopsies

A. Pope-Harman,² P. Ross, Jr.,¹ C. Magro,³ M. Kelsey,¹ ¹Cardiovascular and Thoracic Surgery, The Ohio State University, Columbus, OH; ²Pulmonary and Critical Care Medicine, The Ohio State University, Columbus, OH; ³Pathology, The Ohio State University, Columbus, OH

(92) PX3.102, a Novel Immunosuppressant, Slows Tracheal Allograft Rejection in the Mouse Model of Obliterative Bronchiolitis

W. Chalermkulrat,¹ I.P. Neuringer,¹ R.C.W. Park,¹ R.A. Braeckman,² R.M. Aris,¹ ¹Pulmonary Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; ²Pan Pacific Pharmaceuticals, Inc., Lincoln, RI

(93) Site of Heterotopic Tracheal Allograft Implantation Affects Graft Rejection Pattern

F. Sadegh Beigi,¹ L.J. West,¹ ¹Pediatrics, Hospital for Sick Children, Toronto, ON, Canada

(94) Bone Marrow Inhibits Allospecific T Cell Proliferation and Clonal Expansion

J.F. George,¹ A. Lu,¹ J.K. Kirklin,¹ L.J. Pinderski,² ¹Surgery, Division of Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL; ²Medicine, Division of Cardiovascular Diseases, University of Alabama at Birmingham, Birmingham, AL

(95) Differential Trafficking of Tolerizing Cells in Neonatal Tolerance Induction: Fate Depends on Cell Source

N.E. Lobach,¹ K. Tao,¹ L. Mai,¹ M. Seyed,² X. Fan,¹ L.J. West,¹ ¹Pediatrics, Hospital for Sick Children, Toronto, ON, Canada; ²Chicago Medical School, Finch University of Health Sciences, Chicago, IL

(96) Effects of Porcine Gal-Negative Hematopoietic Progenitor Cells on Primate Platelet Aggregation and Endothelial Cell Activation - Implications for the Induction of Mixed Hematopoietic Chimerism in the Pig-To-Primate Model

C. Knosalla,^{1,2} M.A. Giorvino,³ E. Kaczmarek,⁴ B. Gollackner,¹ D. Harper,³ M. Awwad,³ D.K.C. Cooper,¹ S. Robson,⁴ ¹Transplantation Biology Research Center, Massachusetts General Hospital-Harvard Medical School, Boston, MA; ²Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; ³Immerge BioTherapeutics, Charlestown, MA; ⁴Center for Immunobiology, Beth Israel-Deaconess Medical Center- Harvard Medical School, Boston, MA

(97) Monocyte-Induced Endothelial Calcium Signaling Mediates E-Selectin and VCAM-1 Expression on Xenogeneic Endothelium

M.D. Peterson,¹ E.V. Vlasova,¹ S. Keshavjee,¹ T.K. Waddell,¹ ¹Thoracic Surgery, University of Toronto, Toronto, ON, Canada

(98) Inhibition of Poly-Adp Ribose Synthase (PARS) Increases Cardiac Myocyte Survival during Acute Cardiac Allograft Rejection in Rats

M.J. Szabolcs,¹ N. Ma,² N. Edwards,² N. Son,³ Y. Liu,³ A. Albala,³ R.R. Sciacca,³ P.J. Cannon,³ ¹Pathology, College of Physicians and Surgeons, New York, NY; ²Surgery, College of Physicians and Surgeons, New York, NY; ³Medicine, College of Physicians and Surgeons, New York, NY

(99) Clonally-Expanded Gamma-Chain TCR Transcripts Are Present in the Coronary Arteries of Cardiac Allografts from Patients with Chronic Rejection

W.J. Jung,¹ S. Lu,¹ A. Afolabi,¹ C. Slachta,¹ J.E. Fincke,¹ B.I. Goldman,² V. Jeevanandam,³ C.D. Platsoucas,¹ ¹Microbiology & Immunology, Temple University School of Medicine, Philadelphia, PA; ²Pathology & Laboratory Medicine, Temple University School of Medicine, Philadelphia, PA; ³Surgery, Temple University School of Medicine, Philadelphia, PA

(100) Increased Expression of Single-Strand DNA-Binding Proteins Represses Alpha-Myosin Heavy Chain (MHC) Gene Expression in Heart Failure

J. Raman,¹ M.P. Gupta,¹ M. Gupta,² V. Jeevanandam,¹ ¹Department of Cardiac & Thoracic Surgery, The University of Chicago Medical Center, Chicago, IL; ²Department of Physiology, University of Illinois- Chicago, Chicago, IL

(101) Characterization of Regulatory CD8+CD28- T Cells in Heart Transplant Recipients

A.I. Colovai,¹ M. Mirza,¹ G. Vlad,¹ S. Wang,¹ R. Cortesini,² N. Suciu-Foca,¹ ¹Department of Pathology, Columbia University, New York, NY; ²Servizio Trapianti d'Organo, Università degli Studi di Roma "La Sapienza", Rome, Italy

(102) Optimization of a Novel Low-Strength Electroporation System for Ex Vivo Gene Transfer in Human Heart

L. Sen,¹ G. Guanggen,¹ H. Russell,¹ H. Furukawa,¹ J. Xu,¹ S. Zhang,¹ H. Laks,¹ ¹Surgery, UCLA Medical Center/UCLA School of Medicine, Los Angeles, CA

(103) Immunology Properties of Rat Vascular Endothelium

M. Riha,¹ D. Kreisel,¹ A.S. Krupnick,¹ K.R. Balsara,¹ B.R. Rosengard,¹ ¹Harrison Department of Surgical Research, University of Pennsylvania, Philadelphia, PA

Medical Management of Heart Failure and Candidate Selection

(104) Evaluation of Changes in Functional Capacity, Quality of Life and Hospital Days Following Participation in Cardiopulmonary Rehab in Patients with Congestive Heart Failure

L. Houston-Feenstra,¹ J.T. Heywood,¹ K. Jutzy,¹ R.V. Jutzy,¹ ¹Cardiology, Loma Linda University Medical Center, Loma Linda, CA

(105) Can Changes over Time in Echocardiographic Measurements; Cardiopulmonary Exercise Testing and Radionuclide Ventriculography Predict Outcome in Patients with Chronic Heart Failure?

H.-U. Stempfle,¹ A. Alt,¹ P. Überfuhr,² B. Reichart,² K. Theisen,¹ ¹Cardiology, Med. Klinik - Innenstadt, Munich, Germany; ²Cardiac Surgery, Klinikum Grosshadern, Munich, Germany

(106) WITHDRAWN

(107) The Differential Impact of Spironolactone on Patterns of Pro-Inflammatory Cytokine Expression in Advanced Heart Failure

J.R. Becker,¹ M.E. Keebler,¹ P.A. Uber,¹ M.H. Park,¹ R.L. Scott,¹ M.R. Mehra,¹ ¹Cardiomyopathy and Heart Transplantation Ctr, Ochsner Clinic Foundation, New Orleans, LA

(108) The Intrinsic Mitochondrial Oxidative Capacity of the Failing Heart Is Depressed and Relates to Markers of Disease Severity

B. Mettauer,² J. Zoll,¹ B. Guesson,¹ F. Ribera,¹ O. Roth,² J.P. Mazzucotelli,⁴ E. Epailly,⁴ E. Lampert,¹ R. Ventura-Clapier,³ B. Geny,¹ ¹Physiology, Faculty of Medicine, Strasbourg, France; ²Cardiology, Hopitaux Civils de Colmar, Colmar, France; ³ISERM U446, Faculty of Pharmacy, Chatenay-Malabry, France; ⁴Cardiovascular Surgery, University Hospital, Strasbourg, France

(109) Does QRS Width Really Impact on Cardiac Resynchronization Benefit in Heart Failure Patients?

E. Gronda,¹ A. Mucinò,¹ L. Genovese,¹ M. Mangiavacchi,¹ B. Andreuzzi,¹ D. Pini,¹ P. Galimberti,¹ C. Klersy,² F. Faletra,¹ M. Gasparini,¹ ¹Cardiology Department, Istituto Clinico Humanitas, Rozzano (Milano), Italy; ²Biometry and Clinical Epidemiology Department, Policlinico San Matteo, Pavia, Italy

(110) Elevated Troponin I in Heart Failure: A Marker for Poor Prognosis

T.H. Horwich,¹ J.K. Patel,¹ W.R. McLellan,¹ M.A. Hamilton,¹ D. Rourke,¹ G.C. Fonarow,¹ ¹Cardiology, The David Geffen School of Medicine at UCLA, Los Angeles, CA

(111) Hemodynamic Impact of Biventricular Pacing in Candidates For Heart Transplantation

H. Naegele,¹ M.A. Castel,¹ S. Schrepfer,¹ W. Roediger,¹ H. Reichenspurner,¹ ¹Cardiovascular Surgery, University Clinic Eppendorf, Hamburg, Hamburg, Germany

(112) Long-Term Outcome of Coronary Artery Surgery for Ischemic Cardiomyopathy - A Multi-Institutional Experience

J. Raman,¹ P.J. Shah,² D.L. Hare,² B.F. Buxton,² P. Mather,³ S. Furokawa,³ V. Jeevanandam,¹ ¹Department of Cardiac & Thoracic Surgery, The University of Chicago Medical Center, Chicago, IL; ²Department of Cardiac Surgery, Austin &

Repatriation Medical Centre - University of Melbourne, Melbourne, VIC, Australia; ³Department of Cardiac Surgery, Temple University Medical Center, Philadelphia, PA

(113) Nesiritide Use in End Stage Heart Failure

K.M. Truong,³ A.F. Bernabei,² B. Czerska,¹ ¹Cardiology, Henry Ford Hospital, Detroit, MI; ²Cardiothoracic Surgery, Henry Ford Hospital, Detroit, MI; ³Pharmacy, Henry Ford Hospital, Detroit, MI

(114) Comparison of the Calcium Sensitizer Levosimendan and Prostaglandin E1 as a Bridge to Increased Beta - Blockade in Patients with Refractory, Decompensated Chronic Heart Failure

R. Berger,¹ M. Huelsmann,¹ D. Moertl,¹ A. Bojic,¹ R. Pacher,¹ ¹Department of Cardiology, University Hospital of Vienna, Vienna, Austria

Donor Management, Organ Preservation, Organ Distribution

(115) The Prostacycline Derivative "Iloprost" as an Additive to Low Potassium Dextran (LPD) Preservation Solution Improves Early Graft Function Following Porcine Lung Transplantation after 24 Hours of Cold Ischemia

B. Gohrbandt,¹ S.P. Sommer,¹ G. Warnecke,¹ S. Fischer,¹ T. Steinkamp,¹ A. Haverich,¹ M. Strüber,¹ ¹Division of Thoracic and Cardiovascular Surgery, Hanover Medical School, Hannover, Germany

(116) Impact of Donor Serum Sodium Levels on Outcome after Heart Transplantation

I. Kaczmarek, B. Meiser, J. Groetzner, M. Mueller, G. Nollert, P. Landwehr, F. Reisch, P. Ueberfuhr, B. Reichart, Department of Cardiac Surgery, Ludwig-Maximilians-University, Grosshadern, Munich, Germany

(117) Switch From Euro-Collins to Perfadex for Pulmonary Graft Preservation Resulted in Superior Outcome in Transplant Recipients

F. Rega,¹ G. Verleden,¹ J. Vanhaecke,¹ W. Daenen,¹ D. Van Raemdonck,¹ ¹The Leuven Lung Transplant Group, University Hospital Gasthuisberg, Leuven, Belgium

(118) Asthma Donors Are Not a Contraindication for Lung Transplantation(LTx): A 12 Year Single Centre Experience

A.P. Griffiths,¹ T. Oto,¹ B.J. Levvey,¹ H.M. Whitford,¹ T.C. Kotsimbos,¹ D.S. Esmore,¹ M. Rabinov,¹ T.J. Williams,¹ G.I. Snell,¹ ¹Heart & Lung Transplant Service, The Alfred, Melbourne, VIC, Australia

(119) Preclinical Experience in Transplant with Lung Obtained from Non Heart Beating Donors

A. Varela,¹ P. Gamez,¹ J.R. Nuñez,² F. Rio,² J. Calatayud,² ¹Cardiothoracic Surgery, Puerta de Hierro Hospital, Madrid, Madrid, Spain; ²Transplant Unit, Clinico San Carlos Hospital, Madrid, Madrid, Spain

(120) Successful Outcome in Lung Transplant Recipients Who Receive Organs from Donors with Rapid Onset Fatal Asthma

P.M.A. Hopkins,¹ H. Luckraz,¹ J. Wallwork,¹ ¹Heart-Lung Transplant Unit, Papworth Hospital NHS Trust, Papworth, Cambridgeshire, United Kingdom

(121) Donor Intracranial Hemorrhage Is Associated with Graft Dysfunction and Poorer Survival Following Heart Transplantation

A.M. McNeill,¹ A.S. Abdo,² D.J. Cook,² R.C. Starling,¹ N.B. Ratliff,³ P.M. McCarthy,⁴ J.B. Young,¹ M.H. Yamani,¹ ¹Cardiology, Cleveland Clinic; ²Allogen Laboratory; ³Anatomic Pathology; ⁴Cardiovascular Thoracic Surgery, Cleveland Clinic, Cleveland, OH

(122) Reperfusion with Blood at 30 Deg C Improves Heart Function after Myocardial Ischemia/Reperfusion (I/R) Injury. Novel Mechanism to Enhance Donor Heart

D. Jayakar,¹ U. Williams,¹ V. Jeevanandam,¹ ¹Cardiac Surgery, University of Chicago, Chicago, IL

(123) Sodium-Hydrogen Exchanger Inhibition Is Superior to Pharmacological Preconditioning for Extended Cardiac Allograft Preservation

J.B. Ryan,^{1,2} M. Hicks,¹ J.R. Cropper,² S.R. Garlick,¹ S.H. Kesteven,^{1,2} M.K. Wilson,¹ M.P. Feneley,^{1,2} P.S. Macdonald,^{1,2} ¹Heart & Lung Transplant Unit, St Vincents Hospital, Sydney, Australia; ²Heart & Lung Transplant Research Laboratory, Victor Chang Cardiac Research Institute, Sydney, Australia

(124) L-Arginine Improves Endothelial and Myocardial Function after Brain Death

G. Szabo,¹ V. Buhmann,¹ A. Graf,¹ T.B. Andrasi,¹ C.F. Vahl,¹ S. Hagl,¹ ¹Cardiac Surgery, University of Heidelberg, Heidelberg, BW, Germany

(125) Full Viability of the Myocardium after Twenty-Four Hour Organ Conservation

J. Martin,¹ C. Yerebakan,¹ H. Goebel,² M. Krause,¹ M. Siegenthaler,¹ F. Beyersdorf,¹ ¹Department of Cardiovascular Surgery, Albert Ludwigs University Freiburg, Freiburg, Breisgau, Germany; ²Institut for Pathology, Albert Ludwigs University Freiburg, Freiburg, Breisgau, Germany

(126) The Efficacy of Partial Liquid Ventilation on Lung Protection during Hypotension and Cardiac Arrest

Y. Sekine,¹ S. Yoshida,¹ N. Shinozuka,¹ J. Sato,¹ K. Yasufuku,¹ Y. Saitoh,¹ T. Fujisawa,¹ Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan

(127) Impact of Donor Smoking on Survival after Lung Transplantation

T.K. Waddell,¹ M. DePerrot,¹ A. Pierre,¹ S.H. Keshavjee,¹ L.B. Edwards,² ¹Thoracic Surgery, Toronto General Hospital, Toronto, ON, Canada; ²UNOS/ISHLT Registry, UNOS, Richmond, VA

(128) Ischemic Reperfusion Injury to Donor Lung Endothelium Is Mediated through Gene Promoter NF- κ B and Upstream IKK Kinase

I.S. Bhullar,¹ D. Kapelanski,¹ J. Shyy,² S. Chien,² ¹Cardiothoracic Surgery, University of California Medical Center, San Diego, CA; ²Biomedical Engineering, University of California Graduate School, San Diego, CA

(129) Effect of Brain Death on Release of Brain and Atrium Natriuretic Peptides in an Animal Model

E.V. Potapov,¹ T. Blömer,¹ R. Michael,² M. Loebe,³ C. Skrabal,³ F. Hennig,¹ R. Hetzer,¹ ¹Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; ²Nuclear Medicine, Humboldt University, Charite, Berlin, Germany; ³Michael E. DeBakey Department of Surgery, Division of Transplantation and Assist Devices, Baylor College of Medicine, Houston, TX

(130) Utility of the Natriuretic Peptides, ANP and BNP in the Diagnosis of Impaired Cardiac Function in Organ Donors

B. Nyawo, M. Buckley, M. Koban, N.R. Banner, M.H. Yacoub, Academic Department of Cardiothoracic Surgery, National Heart and Lung Institute, The Royal Brompton & Harefield NHS Trust, London, United Kingdom

(131) Short and Long Term Outcomes Using Marginal Pulmonary Allograft Donors

H. Luckraz,¹ P. White,¹ L.D. Sharples,² P. Hopkins,¹ J. Wallwork,¹ ¹Transplant Unit, Papworth Hospital, Cambridge, United Kingdom; ²MRC Biostatistics Unit, Cambridge, United Kingdom

(132) Marginal Donors in Shortage Era: Impact on Recipient's Long-Term Outcomes

A. Gambino, G. Feltrin, G. Gerosa, G. Nesseris, G. Tarantini, D. Casarotto, Cardiovasc Surgery, University Padua, Italy

(133) Lobectomy to Downsize Donor Lungs for Use in Small Recipients

C.L. Lau,¹ T.J. Guthrie,¹ M. Scavuzzo,¹ E.P. Trulock,¹ J.D. Cooper,¹ G.A. Patterson,¹ B.F. Meyers,¹ ¹Department of Surgery/ Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO

(134) Donor Pretreatment Using the Aerosolized Prostacyclin Analogue Iloprost Optimizes Postischemic Function of Non Heart Beating Donor Lungs

T. Wittwer,¹ U.F.W. Franke,¹ T. Sandhaus,¹ A. Schuette,¹ S. Richter,¹ J.M. Albes,¹ T. Mueller,¹ H. Schubert,¹ T. Wahlers,¹ ¹Cardiothoracic and Vascular Surgery, Friedrich Schiller University, Jena, Germany

Immunosuppression

(135) C2 Targets and Multivariate Predictors of C2 Levels in Stable Heart Transplant Patients Immunosuppressed on a C0-Based Regimen

A.L.P. Caforio,¹ F. Tona,¹ S. Piaserico,² A. Gambino,³ G. Feltrin,³ A. Belloni Fortina,² A. Angelini,⁴ A. Peserico,² G. Thiene,⁴ S. Iliceto,¹ D. Casarotto,³ ¹Cardiology-Department Exp Clinical Medicine, University of Padua, Padua, PD, Italy; ²Dermatology, University of Padua, Padua, PD, Italy; ³Cardiac Surgery, University of Padua, Padua, PD, Italy; ⁴Cardiac Pathology, University of Padua, Padua, PD, Italy

(136) Rapamycin (SIROLIMUS) AUC Estimation in Heart Transplant Recipients with Chronic Renal Impairment

E.D. Moloney,¹ U. O'Mahony,² M. Kirwan,² J. McCarthy,² J. Hurley,² A.E. Wood,² J.J. Egan,² ¹Adult ICU, Royal Brompton and Harefield NHS Trust, London, United Kingdom; ²Heart Lung Transplant Programme, Mater Misericordiae Hospital, Dublin, Ireland

(137) Rapamycin-Based and Late FK506-Light Immunosuppression in Heart Transplant Recipients

B.P. Griffith,¹ S.M. Augustine,¹ C. Wade,¹ S.S. Gottlieb,¹ C. DeFilippi,¹ C. Drachenberg,¹ R. Poston,¹ J. Gammie,¹ J.M. Brown,¹ R.N. Pierson III,¹ ¹Surgery and Medicine, U. Maryland, Baltimore, MD

(138) Prospective Short-Term Pilot Study of Sirolimus as an Induction of Immunosuppression in Heart Transplant Recipients

M. Zakliczynski,¹ J. Nozynski,¹ J. Wojarski,¹ M. Zembala,¹ ¹Department of Cardiac Surgery & Transplantation, Silesian Centre for Heart Disease, Zabrze, Poland

(139) Sirolimus in Combination with Tacrolimus for Primary Immunosuppression after Orthotopic Heart Transplantation

M. Mueller,¹ B. Meiser,¹ J. Groetzner,¹ I. Kaczmarek,¹ F. Reisch,¹ F. Schuster,¹ P. Landwehr,¹ P. Ueberfuhr,¹ B. Reichart,¹ ¹Department of Cardiac Surgery, University of Munich, Klinikum Grosshadern, Munich, Bavaria, Germany

(140) Enhanced Clinical Utility of De Novo Cyclosporin C2 Monitoring after Lung Transplantation

J.M. Morton,¹ C.L. Aboyou,¹ M.A. Malouf,¹ A.R. Scott,¹ M.L. Plit,¹ A.R. Glanville,¹ ¹Lung Transplant Unit, St Vincent's Hospital, Sydney, NSW, Australia

(141) Optimal Immunosuppression Post Cardiac Transplantation: Clinical Outcomes of Long-Term Cyclosporine Monotherapy in a Large Patient Population

M.A. Rockx,¹ P.W. Pflugfelder,¹ W.J. Kostuk,¹ ¹Division of Cardiology, LHSC University Campus, London, ON, Canada

(142) Incidence of Non-Cellular (Humoral) Rejection Unchanged in the 1990 Decade Despite a Decrease in Cellular Rejection

G.A. Cogert,¹ S. Subherwal,¹ G. Wu,¹ J.K. Patel,¹ M. Espejo Vassilakis,¹ M.C. Fishbein,² J. Moriguchi,¹ H. Laks,³ J.A. Kobashigawa,¹ ¹Cardiology, The David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Pathology, The David Geffen School of Medicine at UCLA, Los Angeles, CA; ³Cardiothoracic Surgery, The David Geffen School of Medicine at UCLA, Los Angeles, CA

(143) New Combination of Immunosuppressive Therapy Decreases Acute Rejection in Lung Transplantation

S.M. Bhorade,¹ J. Villanueva,¹ A.M. Jordan,¹ A. Yu,¹ H. Kramer,² J. Leischner,³ W.T. Vigneswaran,⁴ E.R. Garrity,¹ ¹Department of Pulmonary and Critical Care, Loyola University Medical Center, Maywood, IL; ²Department of Epidemiology and Preventive Medicine, Loyola University Medical Center, Maywood, IL; ³Department of Internal Medicine, Loyola University Medical Center, Maywood, IL; ⁴Department of Cardiothoracic Surgery, Loyola University Medical Center, Maywood, IL

(144) Cyclosporin C2 Monitoring after Lung Transplantation (LT) in Cystic Fibrosis (CF) and Non CF Patients

L. Bodin,¹ D. Grenet,² F. Gonin,² N. Bernard,¹ M. Stern,² ¹Clinical Biology Unit, Hopital Foch, Suresnes, 92, France; ²Lung Transplant Unit, Hopital Foch, Suresnes, 92, France

(145) Activation of the Classic Complement Cascade Sequence in Patients Undergoing Lung Transplantation with and without Antithymocyte Globulin Induction: A Comparative Study

A. Pope-Harman,¹ C. Magro,² P. Ross, Jr.,³ M. Kelsey,¹ ¹Pulmonary and Critical Care Medicine, The Ohio State University, Columbus, OH; ²Pathology, The Ohio State University, Columbus, OH; ³Cardiovascular and Thoracic Surgery, The Ohio State University, Columbus, OH

(146) Immunosuppressive Effects of FK506 Inhalant on Acute Rejection in Lung Transplantation

A. Ingu,¹ M. Morikawa,¹ S. Ichimiya,² Y. Hirayama,³ K. Komatsu,¹ T. Abe,¹ ¹Thoracic and Cardiovascular Surgery, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan; ²Pathology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan; ³Immunology and Inflammation Medical Biology Research Laboratories, Kashima Institution, Osaka, Osaka, Japan

(147) Factors Influencing Mycophenolate Mofetil Drug Exposure in Thoracic Organ Transplant Recipients

N. Partovi,^{1,2} M.H.H. Ensom,² G. Fradet,⁵ A. Ignaszewski,⁴ R.D. Levy,³ ¹Pharmaceutical Sciences, Vancouver Hospital, Vancouver, BC, Canada; ²Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada; ³Medicine, Respiratory Division, St Pauls Hospital, Vancouver, BC, Canada; ⁴Medicine, Cardiology Division, St Pauls Hospital, Vancouver, BC, Canada; ⁵Cardiovascular Surgery, Vancouver Hospital, Vancouver, BC, Canada

(148) Ten Year Follow-Up of Recipients of a Kidney or Heart Transplant Who Received Induction Therapy with a Monoclonal Antibody Against the Interleukin-2 Receptor

M. Wabbiijn,¹ A. Balk,² R. van Domburg,² P. Vantrimpont,² I. van Riemsdijk,¹ C. Baan,¹ W. Weimar,¹ T. van Gelder,¹ ¹Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands; ²Cardiology, Erasmus Medical Center, Rotterdam, Netherlands

(149) Anti-CD25 Antibody (BASILIXIMAB) Therapy Is Not Superior to Anti-Thymocyte Globuline (ATG) for Immunosuppression Induction Following Heart Transplantation

S. Fischer,¹ M. Strüber,¹ B. Gohrbandt,¹ A. Simon,¹ C. Bara,¹ A. Haverich,¹ ¹Hanover Thoracic Organ Transplant Program, Hanover Medical School, Hanover, NS, Germany

(150) Is Acute Rejection Primary in the Development of Obliterative Bronchiolitis? A Retrospective Study of Daclizumab and Thymoglobulin

S. Gerhardt, J.V. Conte,¹ S.H. Allan,¹ M.C. Borja,¹ J.B. Orens,² S.C. Yang,¹ R.E. Girgis,² D.D. Yuh,¹ ¹Surgery, Johns Hopkins Medical Institutions, Baltimore, MD; ²Medicine, Johns Hopkins Medical Institutions, Baltimore, MD

(151) Azathioprine/Mycophenolate Conversion in the Management of Bronchiolitis Obliterans Syndrome (BOS) Following (HEART-)LUNG Transplantation

L.J. Dupont,¹ M. Delcroix,¹ J. Vanhaecke,² D. Van Raemdonck,³ G.M. Verleden,¹ ¹Respiratory Medicine, University Hospital Gasthuisberg, Leuven, Belgium; ²Cardiology, University Hospital Gasthuisberg, Leuven, Belgium; ³Thoracic Surgery, University Hospital Gasthuisberg, Leuven, Belgium

(152) A Comparison of the Efficacy of Standard Versus Intermittent Dosing of Rabbitt Anti-Thymocyte Globulin (RATG) for Induction of Heart Transplant Recipients

P.L. Shimamoto,¹ A.D. Barnes,¹ L.M. Tanagi,¹ ¹Pharmacy, University of Washington Medical Center, Seattle, WA

(153) Induction Therapy with Two Doses of Daclizumab in Heart Transplantation: A Prospective, Multi Centric Clinical Study. Interim Analysis

G. Rabago,¹ N. Manito,² L. Almenar,³ J.M. Arizón,⁴ E. Lage,⁵ J. Palomo,⁶ E. Roig,⁸ ¹Transplant Units from, Clinica Universitaria de Navarra; ²Hospital Belvitge; ³Hospital La Fe; ⁴Hospital Reina Sofia; ⁵Hospital Virgen del Rocío; ⁶Hospital Gregorio Marañón; ⁷Hospital Clinic, Spain

(154) Pre-Emptive Use of Oral Valgancyclovir in Cardiac Recipients

E. Devyatko,¹ A. Zuckermann,¹ M. Ruzicka,¹ A. Bohdjalian,¹ G. Wieselthaler,¹ M. Grimm,¹ ¹Department of Cardio-Thoracic Surgery, University Clinic of Vienna, Vienna, Austria

(155) Cyclosporin 2-Hr Post Dose Monitoring-A Potentially Valuable Tool for Optimising Immunosuppression after Heart Transplantation

S. Datta,¹ J. Hassan,¹ A. Machaal,¹ R. Martyszczyk,¹ A.K. Deiraniya,¹ N. Yonan,¹ ¹Cardiothoracic Transplant Unit, Wythenshawe Hospital, Manchester, United Kingdom

New Alternative Therapies to Transplantation

(156) Stem Cells Mobilization Treatment Removing Severe Congestive Heart Failure Patients from Heart Transplantation Indication- Preliminary Results

E.A. Bocchi,¹ G. Guimarães,¹ F. Bacal,¹ A. Mendroni,¹ D. Chamone,¹ V. Issa,¹ A.E. Filho,¹ M.C. Resende,¹ G. Bellotti,¹ J.F. Ramires,¹ Heart Institute (InCor), University of São Paulo Medical School, São Paulo, SP, Brazil

(157) Bone Marrow Mononuclear Cell Transplantation Improved Cardiac Function of Rat Doxorubicin-Induced Cardiomyopathy Model

M. Ishida,¹ S. Tomita,² T. Nakatani,³ S. Fukuhara,⁴ N. Nagaya,⁵ M. Hamamoto,¹ Y. Ohtsu,² C. Yutani,⁴ T. Yagihara,¹ K. Yamada,² S. Kitamura,¹ ¹Cardiovascular Surgery, National Cardiovascular Center, Suita, Osaka, Japan; ²Regenerative Medicine and Tissue Engineering; ³Organ Transplantation; ⁴Pathology; ⁵Cardiology

(158) Migration of Mesenchymal Progenitors to Heart Allograft: Evidence for Active Participation of Mesenchymal Stem Cells in Tissue Repair and Inadvertent Attribution to Graft Fibrosis

G.D. Wu,¹ J.A. Nolte,² Y.-S. Jin,¹ M.L. Barr,¹ V.A. Starnes,¹ D.V. Cramer,¹ ¹Cardiothoracic Surgery, Childrens Hospital Los Angeles, Los Angeles, CA; ²Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO

(159) Human Umbilical Cord Cells for Tissue Engineering of Trileaflet Heart Valves

A. Kadner,¹ G. Zund,¹ C. Breymann,² A. Fleischmann,¹ C.I. Guenter,¹ J.F. Visjager,³ C. Maurus,¹ M. Turina,¹ S.P. Hoerstrup,¹ ¹Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland; ²Obstetrics, University Hospital Zurich, Zurich, Switzerland; ³Biomaterials, Swiss Federal Institute of Technology, Zurich, Zurich, Switzerland

(160) Differentiation of Human Bone Marrow Mesenchymal Stem Cells into Airway Epithelia

V.G. Valentine,¹ J.K. Kolls,² D.C. Bertucci,² P.M. McFadden,¹ S.P. Kantrow,^{1,2} L. Seoane,¹ B.A. Bunnell,² D.J. Prockop,² G. Wang,² ¹Lung Transplantation, Ochsner Clinic Foundation, New Orleans, LA; ²Medicine, LSU Health Sciences Center, New Orleans, LA

(161) Efficiency of Retrograde Intracoronary Infusion for Cell Transplantation to the Heart

K. Suzuki,¹ B. Murtuza,¹ R.T. Smolenski,¹ M.H. Yacoub,¹ ¹Heart Science Centre, Harefield Hospital, Harefield, Middlesex, United Kingdom

Nursing/Social Services/Health Economics

(162) Depression and Neurocognitive Deficits Are Common Comorbid Conditions in Ambulatory Heart Failure Patients

J. Romanelli,¹ M.T. Allen,¹ R.C. Plotkin,² W.H. Shull, Jr.,² A. Kao,¹ ¹Medicine, University of Pennsylvania, Philadelphia, PA; ²Rehabilitation Medicine, University of Pennsylvania, Philadelphia, PA

(163) Functional Recovery of Heart Failure Patients in Cardiogenic Shock Treated with Paracorporeal Biventricular Support

C.N. Vogel,¹ B.L. Coleman,² L.J. Ernst,¹ T. Kleisli,² K.E. Magliato,² ¹Rehabilitation Medicine, Cedars-Sinai Medical Center, Los Angeles, CA; ²Cardiothoracic Surgery, Cedars-Sinai Medical Center, Los Angeles, CA

(164) How to Improve Organ Donation: The Results of the ISHLT/Fact Poll

A.R. Kherani,¹ M.C. Oz,¹ A. Rowe,² L. Roels,³ C.W. Crandall,⁴ L. Tomatis,⁵ J.B. Young,⁶ ¹Surgery, Columbia University, College of Physicians & Surgeons, New York, NY; ²International Society for Heart and Lung Transplantation, Addison, TX; ³Donor Action Foundation, Linden, Belgium; ⁴Palm Beach Cardiovascular, West Palm Beach, FL; ⁵Medical Affairs, Richard M. DeVos Family, Grand Rapids, MI; ⁶Cardiology, Cleveland Clinic Foundation, Cleveland, OH

(165) Patient Adherence at 5 to 6 Years after Heart Transplantation

A.J. Bellg,¹ K.L. Grady,² D.C. Naftel,³ B. Rybarczyk,² J. Young,⁴ D. Pelegrin,⁴ K. Patton-Schroeder,⁴ J. Kobashigawa,⁵ J. Chait,⁵ J. Kirklin,³ C. White-Williams,³ A. Heroux,² W. Piccione, Jr.,² ¹Cardiology, Appleton Heart Institute, Appleton, WI; ²Medicine, Rush University, Chicago, IL; ³Cardiothoracic Surgery, University of Alabama, Birmingham, AL; ⁴Cardiology, Cleveland Clinic Foundation, Cleveland, OH; ⁵Cardiothoracic Transplant, University of California, Los Angeles, CA

(166) Compliance Behaviors of Elderly Patients with Advanced Heart Failure

L.S. Evangelista,¹ L.V. Doering,¹ K. Dracup,² M.A. Hamilton,³ G.C. Fonarow,³ ¹School of Nursing, University of California, Los Angeles, Los Angeles, CA; ²School of Nursing, University of California, San Francisco, San Francisco, CA; ³School of Medicine, University of California, Los Angeles, Los Angeles, CA

(167) Health Related Quality of Life of Elderly Patients with End-Stage Heart Failure

L.V. Doering,¹ L.S. Evangelista,¹ K. Dracup,² M.A. Hamilton,³ G.C. Fonarow,³ ¹School of Nursing, University of California, Los Angeles, Los Angeles, CA; ²School of Nursing, University of California, San Francisco, San Francisco, CA; ³School of Medicine, University of California, Los Angeles, Los Angeles, CA

(168) Differential Vulnerability to Psychiatric Distress after Lung Vs. Heart Transplantation

M.A. Dew,¹ R.L. Kormos,² A.F. DiMartini,¹ J.M. Goycoolea,¹ J.D. Manzetti,² K.R. McCurry,² ¹Psychiatry, University of Pittsburgh; ²Surgery, University of Pittsburgh, School of Medicine & Medical Center, Pittsburgh

(169) Risk/Benefit-Based Lung Allocation Algorithms

S. Murray,^{1,2} J. Yu,² R.A. Wolfe,^{1,2} R. Merion,^{1,2} K. McCullough,² R. Bustami,² T. Egan,³ F. Grover,⁴ ¹SRTR, URREA, Ann Arbor, MI; ²U Michigan, Ann Arbor, MI; ³U North Carolina, Chapel Hill, NC; ⁴U Colorado, Denver, CO

(170) Profiling the Nonadherent Adolescent Heart Transplant Recipient

M.H. Freeman,¹ J.A. Moliterno,² K.L. Harker,³ D.A. Kahler,⁴ F.J. Fricker,⁵ K.O. Schowengerdt,⁵ S. Skoda-Smith,⁶ ¹Patient and Family Resources, Shands Hospital at the University of Florida, Gainesville, FL; ²Student, University of Florida, Gainesville, FL; ³Transplant Center, Shands at the University of Florida, Gainesville, FL; ⁴Pharmacy, Shands at the University of Florida, Gainesville, FL; ⁵Pediatric Cardiology, University of Florida, Gainesville, FL; ⁶Pediatric Immunology and Infectious Disease, University of Florida, Gainesville, FL

(171) Quality of Life and Left Ventricular Assist Devices: Differences between Implanted, Explanted and Transplanted Patients

C.N. Hallas,¹ J.C. Wray,¹ A. Sanchez,¹ C. Bowles,¹ N.R. Banner,¹ ¹Transplant Medicine, Harefield Hospital, Harefield, Middlesex, United Kingdom

(172) Do Older Heart Transplant Recipients Have a Normal Quality of Life?

A. Kao,¹ M.T. Allen,¹ M. Jessup,¹ ¹Medicine, University of Pennsylvania, Philadelphia, PA

(173) Resource Implications of ECMO as a Bridge to Paediatric Heart Transplant

P. Whitmore,¹ S. Nelligan,¹ A. Goldman,¹ M.E. Jones,¹ M. Burch,¹ ¹Cardiothoracic Services (CRACC), Great Ormond Street Hospital for Children, London, England, United Kingdom

(174) Aspects of Adherence to the Treatment Regimen Following Heart or Heart-Lung Transplantation in Young People

J.C. Wray,¹ S. Waters,² T. Sensky,² R.C. Radley-Smith,¹ ¹PSU, Harefield Hospital, Harefield, Middlesex, United Kingdom; ²Imperial College School of Medicine, London, United Kingdom

(175) A Community-Based Weight Management Program for Cardiac Transplant Recipients: Results of a Pilot Study
J.J. Salver,¹ M.P. Flattery,² P.L. Joyner,³ R.K. Elswick,⁴ ¹Adult Health Nursing, Virginia Commonwealth University School of Nursing, Richmond, VA; ²Cardiothoracic Nursing, Medical College of Virginia Hospitals of Virginia Commonwealth University, Richmond, VA; ³Nursing, McGuire Veterans Administration Medical Center, Richmond, VA; ⁴Biostatistics, Virginia Commonwealth University School of Medicine, Richmond, VA

(176) LVAD Driveline Infections in the Modern Era : Incidence Risk Factors and Strategies for Reduction
E.A. Stanford,¹ L.J. Carozza,¹ S. Winowich,¹ J.S. Sapirstein,¹ L.L. Shears,¹ R.L. Kormos,¹ ¹Department of Surgery, University of Pittsburgh, Pittsburgh, PA

(177) Adherence to Self-Monitoring Protocols after Lung Transplant
J.B. Rea,¹ C.M. Lawrence,¹ J.W. Curl,¹ K.G. Setliff,¹ R.D. Davis,² S.M. Palmer,³ ¹Advanced Practice Nursing, Duke University Health System, Durham, NC; ²Cardiothoracic Surgery, Duke University Health System, Durham, NC; ³Pulmonary and Critical Care Medicine, Duke University Health System, Durham, NC

(178) What Contributes to Emotional Distress in Female Heart Transplant Recipients?
I. Gerard,¹ L.V. Doering,¹ L. Evangelista,¹ K. Dracup,² J. Kobashigawa,³ ¹School of Nursing, University of California Los Angeles, Los Angeles, CA; ²School of Nursing, University of California San Francisco, San Francisco, CA; ³School of Medicine, University of California Los Angeles, Los Angeles, CA

(179) Rapid Assessment of Quality of Life in Patients with Advanced Heart Failure
B.L. Baird,¹ A.W. Velleca,¹ V.S. Erickson,¹ M.A. Woo,¹ J.K. Patel,¹ M.A. Hamilton,¹ J.A. Kobashigawa,¹ K.A. Dracup,² ¹Cardiology, The David Geffen School of Medicine at UCLA, Los Angeles, CA; ²UCSF School of Nursing, San Francisco, CA

Pediatrics

(180) Neutrophil Defensin Concentrations in Pediatric Lung Transplant Recipients
A. Faro,¹ L.T. Spencer,¹ G.A. Visner,¹ M. Brantley,² ¹Pediatrics, University of Florida, Gainesville, FL; ²Medicine, University of Florida, Gainesville, FL

(181) Hypogammaglobulinemia in Pediatric Lung Transplant Recipients Is Associated with Increase Mortality
M.T. De la Morena,¹ S. Pradhan,¹ S.C. Sweet,¹ P.M. Schuler,¹ E.N. Mendeloff,² C.B. Huddleston,² ¹Pediatrics, Washington University School of Medicine, St. Louis, MO, British Virgin Islands; ²Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO

(182) Impact of Donor Characteristics in Pediatric Heart Transplant Recipients
J.M. Lamour,¹ L.J. Addonizio,¹ S. Mital,¹ A. Wiesen,¹ D.T. Hsu,¹ ¹Pediatric Cardiology, Columbia University, New York, NY

(183) Coronary Ectasia in Pediatric Heart Transplant Recipients
B.D. Kaufman,¹ D.T. Hsu,¹ J.M. Lamour,¹ L.J. Addonizio,¹ ¹Pediatrics, College of Physicians and Surgeons, Columbia University, New York, NY

(184) Mycophenolate Mofetil Dose and Serum Level Correlation in Young Cardiac Transplant Patients
R.J. Gajarski,¹ D. Crowley,¹ M. Zamberlan,¹ K. Lake,³ ¹Department of Pediatrics, University of Michigan, C.S. Mott Children's Hospital, Ann Arbor, MI; ²Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI

(185) Mycophenolate Mofetil: Clinical Applications and Pharmacokinetic Monitoring in Pediatric Heart Transplant Recipients
A.I. Dipchand,¹ B.W. McCrindle,¹ L.J. West,¹ ¹Cardiology, Hospital for Sick Children, Toronto, ON, Canada

(186) PTLD in a Pediatric Heart Transplant Cohort Is Not Associated with Traditional Risk Factors
E. Pahl,¹ S.E. Crawford,¹ B.Z. Katz,¹ M.C. Kostyk,¹ E. Morgan,¹ C. Mavroudis,¹ C.L. Backer,¹ ¹Children's Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL

(187) Airborne Transfer of Pediatric Patients on Extracorporeal Membrane Oxygenator Support
W.P. Fiser,^{1,2} J.J. Drummond-Webb,^{1,2} M.I. Schmitz,^{1,2} S. Ullah,^{1,2} S.H. Van Devanter,^{1,2} C.W. Chipman,¹ L.L. Baker,¹ A.T. Yetman,^{1,2} ¹Pediatric and Congenital Cardiac Surgery, Arkansas Children's Hospital, Little Rock, AR; ²Department of Surgery, Division of Cardiothoracic Surgery, University of Arkansas for Medical Sciences, Little Rock, AR

(188) Tolerability of Carvedilol in Children with Severe Heart Failure Referred to a Transplantation Centre
K.A. Ford,¹ A. McMahon,¹ P.G. Rees,¹ M. Burch,¹ ¹Pharmacy and Cardiology, Great Ormond Street Hospital for Children, London, United Kingdom

(189) Carvedilol in Children with Cardiomyopathy: 2 Years Follow Up in a Single Institution
P. Rusconi,¹ O. Gómez-Marín,¹ M. Rossique-González,² J.R. Marin,¹ M. Lon-Young,¹ G.S. Wolff,¹ ¹Pediatrics, University of Miami School of Medicine, Miami, FL; ²Pharmacy, Jackson Memorial Hospital, Miami, FL

(190) Geometric Disproportion of Cardiac Structures Affects Atrioventricular Valve Insufficiency in Neonatal Cardiac Transplant
M. Asano,¹ L.L. Bailey,² R.E. Chinnock,² ¹Cardiovascular Surgery, Nagoya City University, Japan; ²Surgery and Pediatrics, Loma Linda University, CA

(191) Renal Growth after Cardiac Transplantation in Infants
A.E. Tsirka,¹ B.M. Chavers,¹ L. Kaeter,¹ C.E. Canter,² E.A. Braunlin,¹ ¹Pediatrics, Fairview University Hospital- University of Minnesota, Minneapolis, MN; ²Pediatrics, St Louis Children's Hospital- Washington University, St Louis, MO

(192) Normalization of Left Ventricular Size and Systolic Function after Diagnosis of Pediatric Dilated Cardiomyopathy
A.E. Tsirka,¹ S.A. Mandel,² S.C. Chen,³ S.E. Lipshultz,⁴ A.W. Strauss,⁵ C.E. Canter,⁶ ¹Pediatrics, University of Minnesota, Minneapolis, MN; ²Biostatistics, Washington University, St. Louis, MO; ³Pediatrics, St. Louis University, St. Louis, MO; ⁴Pediatrics, University of Rochester, Rochester, NY; ⁵Pediatrics, Vanderbilt University, Nashville, TN; ⁶Pediatrics, Washington University, St. Louis, MO

Pathology

(193) Changes in the Coronary Artery Adventitial Microvascular Density May be Involved in the Pathogenesis of Coronary Artery Vasculopathy
C. Atkinson,¹ S.C. Charman,³ H. Luckraz,² S. Rhind-Tutt,¹ J. Wallwork,² M. Goddard,¹ ¹Pathology Department, Papworth Hospital, Cambridge, Cambridgeshire, United Kingdom; ²Department of Surgery, Papworth Hospital, Cambridge, Cambridgeshire, United Kingdom; ³MRC Biostatistics Unit, MRC, Cambridge, Cambridgeshire, United Kingdom

(194) Late Cardiac Allograft Rejection ISHLT Grade \geq 3A Resolves Spontaneously and Is Not Subject to an ERA Effect
R. Klingenberg,¹ A. Koch,² Ph.A. Schnabel,³ F.U. Sack,² A. Remppis,¹ T.J. Dengler,¹ ¹Cardiology/Heart Transplant Center, University Hospital Heidelberg, Heidelberg, Germany; ²Cardiothoracic Surgery, University Hospital Heidelberg, Heidelberg, Germany; ³Pathology, University Hospital Heidelberg, Heidelberg, Germany

(195) iNOS and Peroxynitrite Formation during Acute Rejection after Human Heart Transplantation
E.J. Birks,¹ M.H. Yacoub,¹ A.E. Bishop,² M. Burke,¹ A. Khaghani,¹ J.M. Polak,² N.R. Banner,¹ ¹Harefield Research Foundation, RBH Trust, Harefield, Middlesex, United Kingdom; ²Histochemistry, Chelsea & Westminster Hospital, London, United Kingdom

(196) Assessment of the Phenotypic Profile and T Cell Clonality in Biopsies of Lung Allograft Rejection
A. Pope-Harman,¹ M. Srinivasan,² C. Magro,² P. Ross, Jr.,³ ¹Pulmonary and Critical Care Medicine, The Ohio State University, Columbus, OH; ²Pathology, The Ohio State University, Columbus, OH; ³Cardiovascular and Thoracic Surgery, The Ohio State University, Columbus, OH; ⁴Cardiothoracic Surgery, Ohio State University, Columbus, OH

(197) Cardiac Pathology in Porcine to Primate Heterotopic Xenografts (XG) Functioning for >60 Days
H.D. Tazelaar,¹ R.P. Frantz,¹ L.J. Olson,¹ R.C. Walker,¹ S.S. Teotia,¹ J.M. Risdahl,² G.W. Byrne,² J.S. Logan,² C.G. McGregor,¹ ¹Transplant Center, Mayo Clinic, Rochester, MN; ²Nextran, Princeton, NJ

(198) Autopsy Pathology (AP) in Primate Recipients of Heterotopic Xenografts (XG) Functioning for >60 Days
H.D. Tazelaar,¹ R.P. Frantz,¹ L.J. Olsen,¹ R.C. Walker,¹ S.S. Teotia,¹ J.M. Risdahl,² G.W. Byrne,² J.S. Logan,² C.G. McGregor,¹ ¹Transplant Center, Mayo Clinic, Rochester, MN; ²Nextran, Princeton, NJ

(199) Localization of TGF- β 1 and Type II Receptor in End Stage Emphysema of Lung Transplanted Patients
F. Calabrese,¹ B. Beghé,² F. Rea,³ F. Campigotto,² M. Loy,³ G. Turato,² S. Baraldo,² M. Saetta,² G. Thiene,¹ M. Valente,¹ ¹Department of Pathology, University of Padova, Padova, Italy; ²Department of Experimental Medicine, University of Padova, Padova, Italy; ³Department of Thoracic Surgery, University of Padova, Padova, Italy

(200) Causes of Death after Heart Transplantation and Risk Factor Analysis
A. Angelini,¹ D. Calzolari,² A.L.P. Caforio,² S. Piaserico,³ A. Gambino,⁴ A. Belloni Fortina,³ F. Tona,² S. Iliceto,² D. Casarotto,⁴ G. Thiene,¹ ¹Cardiac Pathology, University of Padua, Padua, PD, Italy; ²Cardiology, Department Exp Clinical Medicine,

University of Padua, Padua, PD, Italy; ³Dermatology, University of Padua, Padua, PD, Italy; ⁴Cardiac Surgery, University of Padua, Padua, PD, Italy

(201) Yield of Surveillance and Diagnostic Transbronchial Lung Biopsies (TBB) Performed Beyond One Year after Lung Transplantation

R. Wennström,¹ C. Kjellström,² G. Mårtensson,³ H. Scherstén,¹ F. Nilsson,¹ ¹Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden; ²Department of Pathology; ³Department of Pulmonary Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden

(202) Scoring of 2,788 Endomyocardial Biopsies Correlate Rejection to the Development of Transplant Coronary Artery Disease after Heart Transplantation

M. Espejo Vassilakis,¹ J.A. Kobashigawa,¹ S. Subherwal,¹ M.C. Fishbein,³ J.K. Patel,¹ J. Moriguchi,¹ S. Go,¹ P. Almeda,¹ H. Laks,² ¹Cardiology, The David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cardiothoracic Surgery, The David Geffen School of Medicine at UCLA, Los Angeles, CA; ³Pathology, The David Geffen School of Medicine at UCLA, Los Angeles, CA

(203) De Novo Alveolar Proteinosis in Lung Transplant Recipients

R. Bag,^{1,2,3} P.T. Cagle,^{1,2} T. Allen,¹ J. Abrams,³ A.E. Frost,^{1,2} ¹Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX; ²The Methodist Hospital, Houston, TX; ³St. Luke's Episcopal Hospital, Houston, TX

(204) Diagnostic Value and Safety of Endomyocardial Biopsy in Selected Patients with Heart Failure

W.O. Howe, J.C. Mendez, K. Malinowska, B.A. Pisani, R.C. Lichtenberg, J.A. Robinson, G.M. Mullen, Advanced Heart Failure/Heart Transplant Program, Loyola University Health System, Maywood, IL

**GENERAL POSTER SESSION 1
(Gardehalle 1)**

FRIDAY, APRIL 11, 2003

5:30 pm – 6:30 pm

Clinical Heart Transplantation

(277) Survival Benefit of Heart Transplantation in High Risk Donors and Recipients

H. Luckraz,¹ S.C. Charman,² L. Sharples,² J. Wallwork,¹ J. Parameshwar,¹ S.R. Large,¹ ¹Transplant Unit, Papworth Hospital, Cambridge, United Kingdom; ²MRC Biostatistics Unit, Cambridge, United Kingdom

(278) Interleukin-6 and Risk of Coronary Artery Disease and Graft Failure in Heart Transplant Recipients

C.A. Labarrere,¹ J.B. Lee,¹ S.J. Miller,¹ R.A. Siddiqui,¹ E.J. Brizendine,² D.E. Pitts,³ D.A. Hormuth,³ M.C. Deng,⁴ ¹Methodist Research Institute, Clarian Health Partners, Inc., Indianapolis, IN; ²Division of Biostatistics, Indiana University School of Medicine, Indianapolis, IN; ³Clarian Health Transplant Center, Clarian Health Partners, Inc., Indianapolis, IN; ⁴Heart Failure Center Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY

(279) Unexpected Role for HO-1 in the Clinical Heart Transplant Setting

C. Holweg,¹ A. Balk,² A. Maat,³ W. Weimar,¹ C. Baan,¹ ¹Internal Medicine, Erasmus MC, Rotterdam, Netherlands; ²Cardiology; ³Thoracic Surgery, Netherlands

(280) Is Low Frequency of Donor Specific Interleukin 10 (IL10) Producing Cells in Peripheral Blood (PB) of Heart Transplant Recipients Related to Graft Rejection?

E. Paschetto,¹ F. Meloni,¹ C. Pellegrini,² A. Marone Bianco,¹ A.M. D'Armini,² M. Morosini,¹ A. Fietta,¹ M. Viganò,² ¹Department Haemat. Pneumol. Sciences, University, Pavia, Italy; ²Cardiac Surgery Division, University-Hospital S. Matteo, Pavia, Italy

(281) Brain Natriuretic Peptide Predicts Rejection in Heart Transplant Recipients Independent of Pulmonary Capillary Wedge Pressure

A.H. Wu,¹ K.D. Aaronson,¹ D.B. Dyke,¹ T.M. Koelling,¹ ¹Department of Internal Medicine, University of Michigan, Ann Arbor, MI

(282) Cardiac Angiotensin II Receptors Predict Allograft Vasculopathy in Heart Transplant Recipients

A. McNeil, M. Yousufuddin, R.C. Starling, E.M. Tuzcu, S. Haji, N.B. Ratliff, D.J. Cooke, A. Abdo, P.M. McCarthy, J.B. Young, M.H. Yamani, Kaufman Center for Heart Failure, Cleveland Clinic Foundation, Cleveland, OH

(283) Preservation in Microvascular Endothelial Function Despite Epicardial Endothelial Dysfunction in Cardiac Transplant Recipients

S.S. Kushwaha,¹ S. Higano,¹ P. Chareonthaitawee,¹ A. Lerman,¹ ¹Cardiovascular Diseases, Mayo Clinic, Rochester, MN

(284) Which Heart Transplant Recipients Are Likely to Survive More Than 10 Years?

J. Segovia,¹ L. Alonso-Pulpón,¹ P. Ortiz,¹ R. Peraira,¹ E. Castedo,¹ R. Burgos,¹ A. Cañas,¹ J. Jiménez-Mazuecos,¹ L. Silva,¹ J. Ugarte,¹ ¹Cardiac Transplant Unit, Hospital Puerta de Hierro, Madrid, Spain

(285) Comparison of Survival by Allocation to Medical Therapy, Surgery or Heart Transplantation for Ischaemic Advanced Heart Failure

E. Lim,¹ Z. Ali,¹ A. Ali,¹ R. Motaleb-Zadeh,¹ C. Jackson,² S.L. Ong,¹ J. Halstead,¹ L. Sharples,² J. Parameshwar,¹ J. Wallwork,¹ S.R. Large,¹ ¹Transplant Unit, Papworth Hospital, Cambridge, United Kingdom; ²Biostatistics Unit, Medical Research Council, Cambridge, United Kingdom

(286) Therapy of Erectile Dysfunction by Sildenafil (Viagra) in Patients after Orthotopic Heart Transplantation

K.W. Deyerling,¹ G. Tenderich,¹ U. Schulz,¹ K. Minami,¹ R. Koerfer,¹ ¹Department of Thoracic and Cardiovascular Surgery, Heart Center North Rhine-Westphalia, Bad Oeynhausen, NRW, Germany

(287) Economic Evaluation of Everolimus Vs. Azathioprine as Part of Triple Immunosuppressive Therapy in a Phase III de novo Heart Transplant Trial

J.I. Radeva,¹ S.D. Reed,¹ Z. Kalo,² H. Pallos,² T.L. Kauf,¹ K.A. Schulman,¹ ¹Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Durham, NC; ²Novartis Pharma AG, Basel, Switzerland

(288) Idiopathic Dilated Cardiomyopathy a Major Predisposing Factor for Early Rejection: Relevance to Outcome

R.S. Warraich,¹ A. Pomerance,¹ A. Khaghani,¹ N.R. Banner,¹ M.H. Yacoub,¹ ¹Cardiothoracic Surgery and Transplant Medicine, National Heart and Lung Institute of Imperial College School of Medicine, Harefield Hospital, Middlesex, United Kingdom

(289) Identifying Optimal Heart Failure Patients for Forced Titration of Vasodilator Therapy Despite "Low" Initial Systolic Blood Pressures: A Cardiac Bioimpedance Study

M.T. Saltzberg,¹ N.J. Schwabauer,¹ ¹Heart Failure Program, Midwest Heart Specialists, Downers Grove, IL

(290) The Direct and Indirect Allogeneic Presentation Pathway during Acute Rejection after Human Cardiac Transplantation

N.M. van Besouw,¹ M. van Vliet,¹ A.H.M.M. Balk,² P.H. van der Meide,³ W. Weimar,¹ ¹Internal Medicine - Transplantation, Erasmus MC, Rotterdam, Netherlands; ²Cardiology, Erasmus MC, Rotterdam, Netherlands; ³Cytokine Biology Unit - CLAI, Utrecht University, Utrecht, Netherlands

(291) Effectivity of a T-Cell Adapted Induction-Therapy with Antithymocyte Globuline (ATG) Sangstad

A. Koch,¹ V. Daniel,³ T.J. Dengler,² S. Hagl,¹ F.U. Sack,¹ ¹Heart Surgery, University of Heidelberg, Heidelberg, Germany; ²Department of Cardiology, University of Heidelberg, Heidelberg, Germany; ³Department of Immunology, University of Heidelberg, Heidelberg, Germany

(292) Incidence and Outcome of Malignancies in Patients after Heart Transplantation

M. Ruzicka,¹ E. Devyatko,¹ A. Zuckermann,¹ A. Bohdjalian,¹ D. Dunkler,¹ K. Uenal,¹ G. Wieselthaler,¹ M. Grimm,¹ ¹Cardio-Thoracic Surgery, University of Vienna, Vienna, Austria

(293) Heart Transplant in Recipients Older Than 60 Years. Insights after More Than 10 Years of Follow-Up

J. Segovia,¹ L. Alonso-Pulpón,¹ R. Peraira,¹ P. Ortiz,¹ R. Fuentes,¹ R. Burgos,¹ A. Cañas,¹ L. Silva,¹ J. Ugarte,¹ ¹Cardiac Failure and Transplant Unit, Hospital Puerta de Hierro, Madrid, Spain

(294) Predictors and Outcomes of Acute Humoral Rejection Treated with Plasmapheresis in Heart Transplant Recipients

W.E. Uber,¹ S.L. Padgett,¹ A.B. VanBakel,² A.J. Crumbley,³ D.S. Feldman,² J.S. Ikonomidis,³ K.N. Simpson,¹ N.L. Pereira,² ¹Pharmacy, MUSC, Charleston, SC; ²Cardiology, MUSC, Charleston, SC; ³Cardiothoracic Surgery, MUSC, Charleston, SC

(295) The Impact of Induction Therapy and the Donor Specific Crossmatch on Outcome after Heart Transplantation

E. Devyatko,¹ A. Zuckermann,¹ D. Dunkler,¹ M. Ruzicka,¹ A. Bohdjalian,¹ G. Wieselthaler,¹ M. Grimm,¹ ¹Department of Cardio-Thoracic Surgery, University Clinic of Vienna, Vienna, Austria

(296) Elevated CXCR4 Levels on Peripheral Blood T-Cells in Heart Transplantation Patients

P. Athanassopoulos,¹ L.M.B. Vaessen,² W. Weimar,² A.H.M.M. Balk,³ A.P.W.M. Maat,¹ A.J.J.C. Bogers,¹ ¹Cardiothoracic Surgery, Erasmus M.C., Rotterdam; ²Internal Medicine, Erasmus M.C., Rotterdam; ³Cardiology, Erasmus M.C., Rotterdam, Netherlands

(297) Impact of BMI on Long-Term Survival after Heart Transplantation

H.J. Eisen,¹ S.A. Gowda,¹ D. Beltramo,¹ J. Manacchio,¹ J.P. Gaughan,¹ ¹Advanced Heart Failure and Transplant Center, Temple University School of Medicine, Philadelphia, PA

(298) The Change of Ultrasonic Tissue Characterization with Integrated Backscatter Is a Significant Marker To Diagnose Cardiac Allograft Vasculopathy

S. Nunoda,¹ S. Oinuma,¹ K. Shitakura,¹ M. Shinagawa,¹ Y. Kubo,¹ N. Hotta,¹ K. Ohtsuka,¹ S. Ohkawa,¹ ¹Department of Medicine, Tokyo Women's Medical University, Daini Hospital, Tokyo, Japan

(299) Impact of Post-Transplant Antibody in a Re-Examination of Humoral Rejection Diagnosis

S.K. Takemoto,¹ A. Gelbard,² G.W. Yuan,³ M.E. Vassilakis,⁴ P.J. Michaels,⁵ D.W. Gjertson,⁶ M.C. Fishbein,⁷ E.F. Reed,⁶ J.A. Kobashigawa,⁴ ¹Pathology and Surgery, David Geffen School of Medicine, UCLA, Los Angeles, CA; ²Tulane University, LA; ³Stanford University, Palo Alto, CA; ⁴Cardiology, David Geffen School of Medicine, UCLA, Los Angeles, CA; ⁵Pathology, Massachusetts General Hospital, Boston, MA; ⁶Immunogenetics Center, David Geffen School of Medicine, UCLA, Los Angeles, CA; ⁷Surgical Pathology, David Geffen School of Medicine, UCLA, Los Angeles, CA

(300) Enhanced Immune Response in CMV D+/R- Heart Transplant Patients Receiving Combined CMV Prophylaxis

N.E. Bonaros,¹ T. Watkins-Riedel,² E. Wolner,³ G. Laufer,³ A.A. Kocher,³ ¹Cardiac Surgery, University of Innsbruck, Innsbruck, Austria; ²Virology, University of Vienna, Vienna, Austria; ³Cardiothoracic Surgery, University of Vienna, Vienna, Austria

(301) Atrioventricular Orthotopic Heart Transplantation: Long Term Follow up of a Prospective Randomised Clinical Trial

P.C. Jansz,¹ J.I. Ferguson,¹ K.K. Dhital,¹ J. Wallwork,¹ S.R. Large,¹ ¹Transplant Unit, Papworth Hospital, Cambridge, Cambs, United Kingdom

(302) Tricuspid Regurgitation after Cardiac Transplantation: How Many Biopsies Are Too Many?

V. Nguyen,¹ R. Cecere,¹ M. Cantarovich,¹ N. Giannetti,¹ ¹Heart Failure and Transplant Center, McGill University Health Center, Montreal, QC, Canada

(303) Myocardial Velocity Patterns of Tissue Doppler Imaging in Pre-Terminal Heart Transplantation in Pediatric Patients

D.A. Fyfe,¹ R. Lewis,¹ W. Mahle,¹ G. Wu,¹ R.A. Vincent,¹ K. Kanter,² D. Ketcham,¹ ¹Non-Invasive Cardiology, Sibley Heart Center, Children's Healthcare of Atlanta, Atlanta, GA

(304) Clinical Predictors of Improvement in Ventricular Function in Non-Ischemic Dilated Cardiomyopathy

S. Ahmed,¹ A.D. Sniderman,¹ N. Giannetti,¹ ¹Cardiology, McGill University Health Center, Montreal, QC, Canada

(305) Equivalent Survival Despite Higher Risk Profile in African American Heart Transplant Recipients

D. Gupta,¹ M. Macha,¹ A.K. Singhal,¹ J.B. McClurken,¹ B.I. Goldman,² J.P. Gaughan,³ H.J. Eisen,⁴ S. Furukawa,¹ ¹Department of Cardiac and Thoracic Surgery, Temple University School of Medicine, Philadelphia, PA; ²Department of Pathology, Temple University School of Medicine, Philadelphia, PA; ³Department of Physiology and Biostatistics, Temple University School of Medicine, Philadelphia, PA; ⁴Department of Cardiology, Temple University School of Medicine, Philadelphia, PA

(306) Non-Invasive Monitoring of Acute Rejection in Heart Transplantation: A Reappraisal of Summated QRS Voltage Amplitude on ECG

A.L.P. Caforio,¹ G. Povoio,¹ F. Tona,¹ S. Piaserico,² D. Calzolari,¹ A. Belloni Fortina,² A. Gambino,³ A. Angelini,⁴ A. Peserico,² G. Thiene,⁴ D. Casarotto,³ S. Iliceto,¹ ¹Cardiology-Department Experimental Clinical Medicine, University of Padua, Padua, PD, Italy; ²Dermatology, University of Padua, Padua, PD, Italy; ³Cardiac Surgery, University of Padua, Padua, PD, Italy; ⁴Cardiac Pathology, University of Padua, Padua, PD, Italy

(307) Effect of Rapamycin on Anti-HLA Donor Antibody Formation in Patients with Transplant Coronary Artery Disease

S.P. Pinney,¹ S. Itescu,² E. Burke,² N.M. Edwards,² D.M. Mancini,¹ ¹Medicine, Columbia University, New York, NY; ²Surgery, Columbia University, New York, NY

(308) Statin Treatment Decreases QTC Interval Duration and Improves Survival in Heart Transplant Recipients

B. Vrtovec,¹ A.P. Yazdanbakhsh,¹ I. Stojanovic,¹ C.D. Thomas,¹ R. Radovancevic,¹ B. Radovancevic,¹ O.H. Frazier,¹ ¹Cardiopulmonary Transplantation, Texas Heart Institute, Houston, TX

(309) Impact of New Therapies on the Prevalence of Coronary Artery Disease in Heart Transplant Survivors: Stanford Experience

S.-Z. Gao,¹ M. Perlroth,¹ S. Hunt,¹ J. Schroeder,¹ ¹Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA

(310) Utility of B-Type Natriuretic Peptide in Cardiac Transplant Evaluation

G. Bhat,^{1,2} A. Jevans,² ¹Division of Cardiology, University of Louisville, Louisville, KY; ²Heart Failure/Cardiac Transplant Center, Jewish Hospital, Louisville, KY

(311) Dobutamine Stress Echocardiography Is Predictive of Events after Heart Transplantation

M.W. Pincus,¹ T. Nguyen,² A.M. Keogh,¹ C.S. Hayward,¹ M. Feneley,¹ P.S. Macdonald,¹ ¹Cardiac Transplant Department, St Vincent's Hospital, Sydney, NSW, Australia; ²Garvan Institute of Medical Research, Sydney, NSW, Australia

(312) Is the Alternate Waiting List Too High Risk? The Columbia-Presbyterian Experience

J.M. Chen,¹ K.M. Hammond,¹ A.R. Kherani,¹ J.M. Fal,¹ P.A. Mazzeo,¹ S.P. Pinney,¹ D.M. Mancini,¹ N.M. Edwards,¹ ¹Cardiothoracic Surgery and Cardiology, Columbia University College of Physicians & Surgeons, New York, NY

(313) Infectious Complications in Heart Transplantation Are Influenced by Ethnic Disparities in Immunoglobulin Expression

M.R. Mehra,¹ P.A. Uber,¹ C. Story,¹ R.L. Scott,¹ M.H. Park,¹ ¹Cardiomyopathy and Heart Transplantation Center, Ochsner Clinic Foundation, New Orleans, LA

(314) Post-Operative Obesity and Cachexia Are Risk Factors for Post Heart Transplant Morbidity and Mortality: A Multi-Institutional Study of Post-Operative Weight Change

K.L. Grady, D.C. Naftel, S. Pamboukian, O.H. Frazier, P. Hauptman, J. Herre, G. Torre, H. Eisen, F. Smart, R.C. Bourge, for the Cardiac Transplant Research Database(CTRD), ¹CTRD, University of Alabama at Birmingham, Birmingham, AL

(315) Microalbuminuria in Heart Transplant Patients: Association with the Development of Allograft Vasculopathy

M.A. Rockx,¹ P.W. Pflugfelder,¹ W.J. Kostuk,¹ ¹Division of Cardiology, LHSC University Campus, London, ON, Canada

(316) To Induce or Not To Induce: Current Assessment of Perioperative Immunosuppression Practices and Outcome in Heart Transplantation

R. Higgins, D.C. Naftel, B. Rayburn, L. Wagoner, R. Oren, K. Aaronson, L. Miller, R. Rodeheffer, M. Flattery, R.C. Bourge, for the Cardiac Transplant Research Database(CTRD), CTRD, University of Alabama at Birmingham, Birmingham, AL

(317) Pre-Operative Renal Function and Outcomes Following Orthotopic Heart Transplantation

J.N.K. Odum,¹ J. Wheat,¹ A. Osugi,¹ K. Mukherjee,¹ A. Alikhani,¹ R. Salehi-Rad,¹ S. Saleh,¹ J. Kobashigawa,¹ H. Laks,¹ UCLA Heart Transplant Team,¹ ¹Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA

(318) Are We Listing the Right Children for Heart Transplant at the Right Time? Are We Improving ?

J.J. O'Keefe,¹ S. Nelligan,¹ M. Elliott,¹ M. Burch,¹ ¹Cardiothoracic Services(CRACC), Great Ormond Street Hospital for Children, London, England, United Kingdom

(319) Does Statin Therapy Added to Calcium Channel Blocker Reduce Development of Transplant Coronary Artery Disease in Heart Transplant Survivors?

S.-Z. Gao,¹ S. Hunt,¹ M. Perlroth,¹ J. Schroeder,¹ ¹Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA

(320) Presence of a Positive PRA Adversely Predicts Both Short and Long Term Survival Following Heart Transplantation

B.S. Edwards,¹ R.P. Frantz,¹ S.S. Kushwaha,¹ R.J. Rodeheffer,¹ J.M. Wagner,¹ T.M. Sundt,¹ S.B. Moore,¹ J.A. Dearani,¹ C.G.A. McGregor,¹ R.C. Daly,¹ ¹William J von Liebig Transplant Center, Mayo Clinic, Rochester, MN

(321) Identification of MIP-1 α and VE-Cadherin as Important Markers of Acute Rejection Following Human Heart Transplantation

A.L.S. Roussoulieres,^{1,2} O. Raisky,³ L. Chalabreysse,⁴ G. Dureau,³ C. Cerutti,⁵ P. Boissonnat,¹ L. Sebbag,¹ J.-P. Gare,¹ J.-F. Obadia,³ J. Ninet,³ O. Bastien,¹ F. Thivolet-Bejui,⁴ J.L. McGregor,² ¹Department of Heart Transplantation, Hôpital Cardiologique Louis Pradel, Lyon, France; ²INSERM U331, Lyon, France; ³Department of Cardiac Surgery, Hôpital Cardiologique Louis Pradel, Lyon, France; ⁴Department of Pathology, Hôpital Cardiologique Louis Pradel, Lyon, France; ⁵Department of Physiology and Clinical Pharmacology, CNRS UMR 5014, Lyon, France

(322) Is Recrudescence Tobacco Exposure Following Heart Transplantation Associated with Expression of Atherothrombosis Risk Markers?

M.R. Mehra, P.A. Uber, D.D. Hicks, M.H. Park, R.L. Scott, Cardiomyopathy and Heart Transplantation Center, Ochsner Clinic Foundation, New Orleans, LA

(323) Implantable Cardioverter Defibrillators in Heart Transplant Patients at Risk for Sudden Death: Shocking News?

G.A. Cogert,¹ K. Shivkumar,¹ J.K. Patel,¹ I. Weiner,¹ J. Moriguchi,¹ M. Espejo Vassilakis,¹ H. Laks,² J.A. Kobashigawa,¹
¹Cardiology, The David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cardiothoracic Surgery, The David Geffen School of Medicine at UCLA, Los Angeles, CA

(324) Cardiac Transplantation for the Treatment of Adults with Congenital Heart Disease: A Single Center Experience

S.P. Pinney,¹ D.T. Hsu,² L.J. Addonizio,² M.S. Rosenbaum,¹ J.M. Chen,³ J.M. Quaegebeur,³ R.S. Mosca,³ N.M. Edwards,³ D.M. Mancini,¹ J.M. Lamour,² ¹Cardiology, Columbia University; ²Pediatric Cardiology, Columbia University; ³Cardiothoracic Surgery, Columbia University, New York, NY

(325) Early Initiation of Aerobic and Resistance Training Improves Peak Aerobic Power, Leg-Press Maximal Strength and Distance Walked in Six Minutes in Recent Cardiac Transplant Recipients

M. Haykowsky,¹ N. Eves,¹ L. Figgures,¹ M. Koller,¹ J. Burton,² W. Tymchak,² ¹Faculty of Rehabilitation Medicine, University of Alberta, Edmonton, AB, Canada; ²Division of Cardiology, University of Alberta, Edmonton, AB, Canada

Clinical Lung/Heart-Lung Transplantation

(326) The Right Ventricular Response to Pulmonary Hypertension Is Related to Left Ventricular Mass

T. Saba,¹ J. Foster,² M. Cockburn,² M. Cowan,² A. Peacock,¹ ¹Scottish Pulmonary Vascular Unit, Western Infirmary, Glasgow, Lanarkshire, United Kingdom; ²Department of Radiology, Western Infirmary, Glasgow, Lanarkshire, United Kingdom

(327) Two-Year Experience with Continuous Subcutaneous Treprostinil (Prostacyclin Stable Analogue) in Severe Pulmonary Hypertension Treatment

M.J. Ruiz-Cano,¹ P. Escribano,¹ M.A. Gomez-Sanchez,¹ M. Lazaro,¹ J.F. Delgado,¹ L. Cea-Calvo,¹ R. Tello de Meneses,¹ C. Saenz de la Calzada,¹ ¹Cardiology, Hospital Doce de Octubre, Madrid, Spain

(328) Recovery of Chronic Renal Impairment with Sirolimus after Lung Transplantation

F. Venuta, E. Mercadante, E.A. Rendina, S. Quattrucci, T. De Giacomo, G. Cimino, M. Ibrahim, G.F. Coloni, Thoracic Surgery, University of Rome "La Sapienza", Rome, Italy

(329) Multiple Combination Bactericidal Testing (MCBT) for Patients with Multiresistant Pseudomonas Aeruginosa Undergoing Lung Transplantation

A.R. Scott,¹ J.M. Morton,¹ C. Harbour,² B. Rose,² M.A. Malouf,¹ A.R. Glanville,¹ ¹The Lung Transplant Unit, St Vincent's Hospital, Sydney, NSW, Australia; ²The Infectious Diseases Department, Sydney University, Sydney, NSW, Australia

(330) How To Predict Forced Vital Capacity of the Recipient after Living-Donor Lobar Lung Transplantation

H. Date,¹ M. Aoe,¹ Y. Sano,¹ I. Nagahiro,¹ A. Andou,¹ H. Matsubara,² K. Goto,³ T. Tedoriya,⁴ N. Shimizu,¹ ¹Cancer and Thoracic Surgery, Okayama University Graduate School, Okayama, Japan; ²Cardiology, Okayama University Graduate School, Okayama, Japan; ³Anesthesiology and Resuscitology, Okayama University Graduate School, Okayama, Japan; ⁴Cardiovascular Surgery, Okayama University Graduate School, Okayama, Japan

(331) Routine Cytopathology Testing Is Unnecessary with Bronchoscopy Following Lung Transplantation

T.J. Wanner,¹ S.G. Gerhardt,² M. Borja,² R.E. Girgis,² J.V. Conte,³ S.C. Yang,⁴ J.B. Orens,² ¹School of Medicine, The Johns Hopkins Hospital; ²Division of Pulmonary and Critical Care Medicine; ³Division of Cardiac Surgery; ⁴Division of Thoracic Surgery, The Johns Hopkins Hospital, Baltimore, MD

(332) Oxygen Consumption Predicts Outcomes in Lung Transplant Candidates with Pulmonary Fibrosis

S.M. Kawut,¹ M.K. OShea,³ M.N. Bartels,¹ J.R. Sonett,² S.M. Arcasoy,¹ ¹Division of Pulmonary, Allergy, and Critical Care, Columbia University College of Physicians and Surgeons, New York, NY; ²Division of Cardiothoracic Surgery, Columbia University College of Physicians and Surgeons, New York, NY; ³Department of Surgery, Columbia University College of Physicians and Surgeons, New York, NY; ⁴Department of Rehabilitation Medicine, Columbia University College of Physicians and Surgeons, New York, NY

(333) Multi-Organ Transplantation: Is There a Protective Effect Against Acute and Chronic Rejection?

L. Pinderski,¹ J. Kirklin,² D. McGiffin,² R. Brown,² D. Naftel,² T. Smith,¹ R. Young,^{1,3} R. Bourge,¹ J. Tallaj,^{1,3} B. Rayburn,¹ R. Benza,¹ B. Foley,¹ G. Zorn,² K. Leon,¹ K. Wille,¹ M. Deierhoj,² J.F. George,² ¹Department of Medicine, University of Alabama at Birmingham, Birmingham, AL; ²Department of Surgery, University of Alabama at Birmingham, Birmingham, AL; ³Department of Medicine, Birmingham VA Medical Center, Birmingham, AL

(334) Accuracy of Exhaled Nitric Oxide (eNO) Measurements for the Diagnosis of Chronic Rejection (CR) after Lung Transplantation (LTx)

G.M. Verleden,¹ L.J. Dupont,¹ M. Delcroix,¹ D.E. Van Raemdonck,¹ the Leuven Lung Transplant Group,¹ ¹Lung Transplantation Unit, University Hospital Gasthuisberg, Leuven, Belgium

(335) Lung Transplantation in Recipients with Previous Lung Volume Reduction Surgery

C.L. Lau,¹ T.J. Guthrie,¹ C. Chaparro,² D. Hadjiliadis,² T. Waddell,² S. Keshavjee,² R.C. Fields,³ M.F. Yeatman,³ S.M. Palmer,³ R.D. Davis,³ J.D. Cooper,¹ E.P. Trulock,¹ G.A. Patterson,¹ B.F. Meyers,¹ ¹Washington University Lung Transplant Program, Washington University School of Medicine, St. Louis, MO; ²Toronto Lung Transplant Program, Toronto General Hospital, Toronto, ON, Canada; ³Duke Lung Transplant Program, Duke University Medical Center, Durham, NC

(336) Long Term Results of the Domino Procedure from Cystic Fibrosis Live Donors

D. Aravot,¹ K. Mcneal,¹ J. Dunning,¹ S. Tsui,¹ F. Wells,¹ S. Large,¹ J. Wallwork,¹ ¹Heart-Lung Transplant Unit, Papworth Hospital, Cambridge, United Kingdom

(337) Role of CMV Antigenemia Directed Preemptive Therapy with Ganciclovir for the Prevention of CMV Disease at 6 Months in Lung Transplant Recipients

S. Husain,¹ K.R. McCurry,² J.H. Dauber,³ R. Zomak,² P. Williams,¹ S. Kusne,¹ ¹Division of Infect Dis, University of Pitt Med Ctr, Pittsburgh, PA; ²Division of CT Surg; ³Division of Pulm Med, University of Pitt Med Ctr, Pittsburgh, PA

(338) Comparison of Quantitative PCR to Antigenemia for CMV Surveillance after Lung Transplantation

B.C. Cahill,^{1,2} J.A. Crompton,² S. Parker,² C.A. Sullivan,² D. Hillyard,³ D. Mohl,³ J. Admirand,³ S. Wood,³ K. Carroll,^{1,3} ¹Department of Medicine, University of Utah; ²Lung Transplant Program, University of Utah; ³ARUP, SLC, UT

(339) Therapy with Prostanoids and Transplantation in Patients with Primary Pulmonary Hypertension

M. Dandel,¹ D. Kemper,¹ Y. Weng,¹ H.B. Lehmkuhl,¹ M. Hummel,¹ R. Hetzer,¹ ¹Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Berlin, Germany

(340) Co-Localisation of MMP-9 (Gelatinase B) with Airway Neutrophils in Stable Lung Transplant Recipients - A Potential Role in the Bronchiolitis Obliterans Syndrome

I.A. Forrest,¹ C. Ward,¹ G. Pritchard,¹ T.E. Cawston,² A.D. Rowan,² P.A. Corris,¹ ¹Lung Biology and Transplantation, University of Newcastle and Freeman Hospital, Newcastle upon Tyne, United Kingdom; ²Department of Rheumatology, University of Newcastle, Newcastle upon Tyne, United Kingdom

(341) Antifungal Management after Lung Transplantation (TX): A Survey of 37 Transplant Centers

S. Dummer,¹ N. Lazariashvili,¹ J. Barnes,¹ M. Ninan,² A. Milstone,¹ ¹Medicine, Vanderbilt University, Nashville, TN; ²Surgery, Vanderbilt University, Nashville, TN

(342) Aerosolized Cyclosporine as an Alternative Immunosuppressant in Post Lung Transplant Lymphoproliferative Disease

S. Gilbert,¹ A.T. Iacono,² W.F. Grgurich,² J.H. Dauber,² B.A. Johnson,² T.E. Corcoran,² D.A. Smith,² J.G. Youssef,² C.A. Bermudez,¹ K.R. McCurry,¹ ¹Surgery, University of Pittsburgh, Pittsburgh, PA; ²Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA

(343) Double Lung Transplantation Via Median Sternotomy and with Cardiopulmonary Bypass Is Safe and without Adverse Clinical Outcome

K.K. Dhital,¹ P.C. Jansz,¹ J.I. Ferguson,¹ J. Dunning,¹ J. Wallwork,¹ S.R. Large,¹ ¹Transplant Unit, Papworth Hospital, Cambridge, Cambs, United Kingdom

(344) Health-Related Quality of Life Outcomes in Patients with Pulmonary Hypertension

S. Shafazand,¹ M.K. Gould,^{1,2} M.K. Goldstein,^{1,2} M.A. Hlatky,¹ R.L. Doyle,¹ ¹Department of Medicine, Stanford University, School of Medicine, Stanford, CA; ²Department of Medicine, VA Palo Alto Health Care System, Palo Alto, CA

(345) Oxygenation Improvement and Pulmonary Vasodilation with Nitric Oxide (NO) or Alprostadil Immediately after Lung Transplantation

P. Bulpa,¹ D. Pranger,¹ J. Jamart,² M. Gonzalez,¹ E. Installe,¹ P. Evrard,¹ ¹Intensive Care Medicine, Mont-Godinne University Hospital, Yvoir, Namur, Belgium; ²Department of Biostatistics, Mont-Godinne University Hospital, Yvoir, Namur, Belgium

(346) Increased Expression of CD40, B7-2, Interleukin-15 and Granzyme B in Bronchoalveolar Lavage Cells from Human Lung Transplant Recipients

T. Mohanakumar,¹ R. Shi,¹ A. Jaramillo,¹ N. Steward,¹ A. Aloush,¹ J. Yang,¹ E.P. Trulock,² M. Suthanthiran,³ G.A. Patterson,¹ ¹Department of Surgery, Washington University School of Medicine, St. Louis, MO; ²Department of Medicine, Washington

University School of Medicine, St. Louis, MO; ³Division of Nephrology, Weill Medical College of Cornell University, New York, NY

(347) Air Trapping in Heart-Lung Transplant Recipients: Variability of Anatomical Distribution and Extent on Sequential Expiratory Thin-Section CT

A.A. Bankier,¹ A. Van Muylem,² P. Scillia,³ V. De Maertelaer,⁴ P.A. Geveno,³ M. Estenne,² ¹Department of Radiology, University of Vienna, Vienna, Austria; ²Department of Chest Medicine, Erasme University Hospital, Brussels, Belgium; ³Department of Radiology, Erasme University Hospital, Brussels, Belgium; ⁴Institute of Interdisciplinary Research in Human and Molecular Biology, University of Brussels, Brussels, Belgium

(348) Specific Gene Expression Profile Associated with Ischemia-Reperfusion Injury during Lung Transplantation Identified by CDNA Microarray

M. Yamane,¹ S.M. Quadri,¹ L. Segall,¹ A. Dutly,¹ T.K. Waddell,¹ M. Liu,¹ S. Keshavjee,¹ ¹Thoracic Surgery Research Laboratory, Toronto General Research Institute, Toronto, ON, Canada

(349) Prevalence of Gastro-Esophageal Reflux Disease in Lung Transplant Candidates

F. D' Ovidio, T.K. Waddell, M. de Perrot, D. Hadjiliadis, L. Miller, L.G. Singer, A. Pierre, G. Darling, S. Keshavjee, Toronto Lung Transplant Program, University of Toronto, Toronto, ON, Canada

(350) Cost Analysis of Universal Prophylaxis Versus Preemptive Therapy for Cytomegalovirus

J.A. Crompton,³ K. Carroll,^{1,4} C.A. Sullivan,³ S. Parker,³ S.V. Karwande,² J. Stringham,² D.A. Bull,² B.C. Cahill,^{1,3} ¹Department of Medicine, University of Utah; ²Cardiothoracic Surgery, University of Utah; ³Lung Transplant Program, University of Utah; ⁴ARUP, Salt Lake City, UT

(351) Protective Mechanisms of Radical Scavengers Vitamins C&E in an In-Vivo Pig Model of Pulmonary Reperfusion Injury

F.M. Wagner,¹ K. Ploetze,² F. Schubert,² A.T. Weber,² S. Albrecht,³ H. Reichenspurner,¹ S. Schueler,² ¹CV-Surgery, University-Hospital Eppendorf, Hamburg, Germany; ²Cardiac Surgery, Cardiac Center, University of Dresden, Dresden, Germany; ³GYN & OB, University Hospital, Dresden, Dresden, Germany

(352) Perioperative Complications after Living-Donor Lobar Lung Transplantation

Y. Sano,¹ H. Date,¹ M. Aoe,¹ I. Nagahiro,¹ A. Andou,¹ K. Goto,² H. Matsubara,³ N. Shimizu,¹ ¹Department of Cancer and Thoracic Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama, Okayama, Japan; ²Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine and Dentistry, Okayama, Okayama, Japan; ³Department of Cardiology, Okayama University Graduate School of Medicine and Dentistry, Okayama, Okayama, Japan

(353) Inflammatory Markers in BAL and Breath Condensate Early and Late after Lung Transplantation

M. Hofer,¹ T. Rechsteiner,¹ R. Naef,¹ R. Speich,¹ A. Boehler,¹ ¹University Hospital Zurich, Division of Pulmonary Medicine and Lung Transplant Program, Zurich, ZH, Switzerland

(354) Reduced Size Lung Transplantation - Follow up on 27 Patients

G. Warnecke,¹ J. Niedermeyer,² B. Gohrbandt,¹ S. Fischer,¹ B. Lindenberg,¹ A.R. Simon,¹ A. Haverich,¹ M. Strueber,¹ ¹T&CV Surgery, Hannover Medical School, Hannover, Germany; ²Respiratory Medicine, Hannover Medical School, Hannover, Germany

(355) Lung Transplantation in Patients with Pulmonary Sarcoidosis

N. Milman,¹ M. Iversen,¹ J. Carlsen,¹ ¹Danish Lung Transplant Group, The Heart Centre, Department of Medicine B, Division of Lung Transplantation, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

(356) Prolonged Non-Invasive Ventilatory Support Prior to Pulmonary Transplantation Does Not Affect Postoperative Outcome

H. Castle,¹ P.M. Hopkins,¹ L. Sharples,¹ J. Wallwork,¹ ¹Transplant Unit, Papworth Hospital, Papworth Everard, Cambs, United Kingdom

(357) Cardiopulmonary Bypass Does Not Increase the Morbidity Associated with Lung Transplantation for Chronic Obstructive Airway Disease

P.C. Jansz,¹ J.I. Ferguson,¹ K.K. Dhital,¹ J. Dunning,¹ J. Wallwork,¹ S.R. Large,¹ ¹Transplant Unit, Papworth Hospital, Cambridge, Cambs, United Kingdom

(358) Surveillance Bronchoscopy (SB) in Lung Transplant Recipients (LTR): Risk Versus Benefit?

T.J. McWilliams,^{1,2} H.M. Whitford,^{1,2} S.M. Fowler,¹ A.T. Kotsimbos,¹ G.I. Snell,^{1,2} T.J. Williams,^{1,2} ¹Department of Respiratory Medicine, The Alfred Hospital, Melbourne, VIC, Australia; ²Department of Respiratory Medicine, Monash University, Melbourne, VIC, Australia

(359) Survival of Lung Transplant Recipients with Cystic Fibrosis (CF) Harboring Panresistant Bacteria Other Than B. Cepacia, Compared to Patients Harboring Sensitive Bacteria

D. Hadjiliadis,¹ M.P. Steele,² C. Chaparro,¹ L.G. Singer,¹ R.H. Messier,² T.K. Waddell,¹ M.A. Hutcheon,¹ R.D. Davis,² D.E. Tullis,³ S.M. Palmer,² S. Keshavjee,¹ ¹Toronto Lung Transplant Program, University of Toronto, Toronto, ON, Canada; ²Duke University Lung Transplant Program, Duke University, Durham, NC; ³Toronto Adult Cystic Fibrosis Program, University of Toronto, Toronto, ON, Canada

(360) Lung Transplant Recipients (LTR) Have Persistent Abnormalities in Bronchoalveolar Lavage(BAL) and Endobronchial Biopsy(EBB): Interim Results from a Study of RAD Vs Azathioprine(AZA)

B.J. Levvey,¹ L. Zheng,² B. Orsida,² T.C. Kotsimbos,¹ T.J. McWilliams,¹ H.M. Whitford,¹ E.H. Walters,² T.J. Williams,¹ G.I. Snell,¹ ¹Respiratory Medicine, The Alfred, Melbourne, Australia; ²Monash University, Melbourne, Australia

(361) Recovery of Right Ventricular Function Post Lung Transplantation in Patients with Long-Term Pulmonary Hypertension on Contemporary Vasodilator Therapy

J. Jimenez,¹ D. Fertel,² R. Servian,¹ S. Gerity,² J. Bauerlein,¹ M. Bilsker,¹ H. Willens,¹ S. Pham,³ S. Mallon,¹ ¹Cardiology, Jackson Memorial Medical Center, Miami, FL; ²Pulmonary and Critical Care, Jackson Memorial Medical Center, Miami, FL; ³Cardiothoracic Surgery, Jackson Memorial Medical Center, Miami, FL

(362) The Utility of CMV Hyper Immunoglobulin in the Treatment of CMV Mismatch Lung Transplant Recipients

M.A. Malouf,¹ J.L. Yorke,¹ A.R. Scott,¹ J. Morton,¹ T. Gay,¹ M. Plit,¹ A.R. Glanville,¹ ¹Lung Transplant Unit, St Vincent's Hospital, Sydney, New South Wales, Australia

(363) Intravenous Ribavirin : Effective Therapy for Respiratory Syncytial Virus (RSV) Infection after Lung Transplantation

A.R. Scott,¹ J.M. Morton,¹ M.L. Plit,¹ M.A. Malouf,¹ A.R. Glanville,¹ ¹The Lung Transplant Unit, St Vincent's Hospital, Sydney, NSW, Australia

(364) Pet Imaging of [18]-FDG as a Non-Invasive Indicator of Infection Versus Rejection in Lung Transplant Recipients

H.A. Jones,¹ T. Donovan,² M.J. Goddard,³ K. McNeil,³ C. Atkinson,³ J.C. Clark,² J.F. White,¹ E.R. Chilvers,¹ ¹Respiratory Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom; ²Wolfson Brain Imaging Centre, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom; ³Transplant Unit, Papworth Hospital, United Kingdom

(365) Correlation between Induced Sputum Neutrophil Percentage and Decline from Best Postoperative Baseline in FEV1, FEF25-75 and FEF50

D.J. Allen,² J.E. Fildes,¹ N. Yonan,¹ A.K. Deiraniya,¹ C.T. Leonard,² ¹Transplant Centre, Wythenshawe Hospital, Manchester, Lancashire, United Kingdom; ²North West Lung Centre, Wythenshawe Hospital, Manchester, Lancashire, United Kingdom

(366) Surgical Risk Factor Analysis in Lung Transplantation

L.C. Muller,¹ C. Geltner,² E. Ruttmann,¹ O. Chevtchik,¹ G. Laufer,¹ ¹Cardiac Surgery, University Hospital, Innsbruck, Austria; ²Pneumology, Hospital Natters, Innsbruck, Austria

(367) Is Invasive Fungal Disease in Lung Transplant Recipients Predictable?

M.L. Plit,¹ L.G. Singleton,¹ A. Scott,¹ S. Rainer,² M.A. Malouf,¹ A.R. Glanville,¹ ¹The Lung Transplant Unit, St Vincent's Hospital, Sydney, NSW, Australia; ²Anatomical Pathology, Sydpath St Vincent's Hospital, Sydney, NSW, Australia

(368) Survival of Lung Transplant Recipients with Bronchiolitis Obliterans Syndrome

V.G. Valentine,¹ M.T. Knower,¹ C. Eitmann,¹ D.M. Fuchs,¹ G.S. Dhillon,¹ L. Seoane,¹ D.E. Taylor, ¹Lung Transplantation, Ochsner Clinic Foundation, New Orleans, LA

(369) Inhaled Iloprost as a Bridge To Transplant in Advanced Pulmonary Fibrosis and Secondary Pulmonary Hypertension

E.D. Moloney,¹ A. Daly,² M. Kirwan,² J.C. Rendall,² N.N. Anthony,² S.P. Gaine,² J.J. Egan,² ¹Department of Intensive Care Medicine, Royal Brompton Hospital, London, United Kingdom; ²Heart-Lung Transplant Unit, Mater Misericordiae Hospital, Dublin, Ireland

(370) Abdominal-Pelvic Lymphoproliferative Disease after Lung Transplantation

Felix Fernandez, R.R. Hachem,¹ G.A. Patterson,¹ E.P. Trulock,¹ ¹Lung Transplant Program, Washington University School of Medicine, St Louis, MO

(371) Prediction of Maximal Lung Function in IPF and COPD Single Lung Transplant Recipients

S. Ahmad,¹ S.D. Barnett,² C. Norwalk,¹ N. Burton,¹ S.D. Nathan,¹ ¹Inova Transplant Center, Inova Fairfax Hospital, Falls Church, VA; ²Inova Heart Institute, Inova Fairfax Hospital, Falls Church, VA

Mechanical Circulatory Support

(372) Novacor Left Ventricular Assist Bridge to Transplant: No Sensitization or Excess Rejection as Compared to Unsupported Patients

D.A. Baran,¹ I.D. Galin,¹ R. Correa,¹ R. DeAsla,¹ P. Seissler,¹ M. Chan,¹ M.C. Courtney,¹ D. Spielvogel,¹ S.L. Lansman,¹ A.L. Gass,¹ ¹Zena and Michael Wiener Cardiovascular Institute, Mt. Sinai Hospital, New York, NY

(373) Changes in Collagen Content of the Myocardium by Unloading with a Cardiac Assist Device

J. Mueller,¹ H. Liang,¹ Y. Weng,¹ M. Pasic,¹ R. Pregla,¹ P. Fu,¹ G. Wallukat,² R. Hetzer,¹ ¹Cardiac Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; ²Max-Delbrueck-Zentrum, Berlin, Germany

(374) Plasma Neurohormonal Expression in LVAD Patients: Toward Hormone-Guided Therapeutic Assessment

L.O. Thompson,¹ M. Loebe,¹ C.A. Skrabal,¹ K.A. Youker,¹ G.P. Noon,¹ ¹Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX

(375) The Effect on Microvascular Function of Combined Mechanical Circulatory Support and Pharmacological Therapy during Induction of Myocardial Recovery

P. Tansley,¹ M. Yacoub,¹ O. Rimoldi,² E. Birks,¹ J. Hardy,¹ M. Hipkin,¹ C. Bowles,¹ D. Dutka,² P. Camici,² ¹National Heart Lung Institute, Harefield Hospital, Harefield, Middlesex, United Kingdom; ²MRC Clinical Sciences Centre, Hammersmith Hospital, London, United Kingdom

(376) Declining Adverse Event and Mortality Rates over Implant Duration with the Novacor LVAS: Implications for Destination Therapy

J.G. Rogers,¹ M.K. Pasque,¹ ¹Washington University School of Medicine, St. Louis, MO

(377) Reliability of the Novacor LVAS: Implications for Destination Therapy

U. Livi,¹ ¹Department of Cardiovascular Sciences, General Hospital S. Maria Della Misericordia, Udine, Italy

(378) Left Ventricular Mechanical Unloading Decreases Ischemic Susceptibility by Modulating Angiotensin II Type-2 Receptor Gene Expression in the Failing Heart after Myocardial Infarction

S. Horimoto,¹ H. Horimoto,¹ S. Mieno,¹ K. Nakahara,¹ Y. Nakai,¹ M. Yoshida,¹ S. Sasaki,¹ ¹Thoracic and Cardiovascular Surgery, Osaka Medical College, Takatsuki, Osaka, Japan

(379) Differences in Patients with Left Ventricular Assist Device between Dilated Cardiomyopathy and Dilated Phase Hypertrophic Cardiomyopathy

N. Fukushima,¹ Y. Miyamoto,¹ Y. Sawa,¹ G. Matsumiya,¹ O. Monta,¹ S. Takashima,² M. Hori,² R. Shirakura,¹ H. Matsuda,¹ ¹Department of Surgery, Osaka University, Suita, Osaka, Japan; ²Department of Medicine, Osaka University, Suita, Osaka, Japan

(380) The Contribution of Blood Product Transfusions to HLA Allosensitization in LVAD Recipients

S.G. Drakos,¹ J.C. Stringham,¹ J.W. Long,¹ T.C. Fuller,¹ K.E. Nelson,¹ J.M. Lindblom,¹ P.A. Meldrum,¹ E.M. Gilbert,¹ S.A. Moore,¹ D.G. Renlund,¹ ¹UTAH Cardiac Transplant Program, University of Utah School of Medicine and LDS Hospital, Salt Lake City, UT

(381) Differential Regulation of CA²⁺-Dependent ATPase-Activity in Left Ventricular Myocardium during Mechanical Circulatory Support

H. Milting,¹ A. Kassner,¹ D. Boethig,¹ R. Thieleczek,² H. Koegler,³ H.E. Meyer,² L. Arusoglu,¹ R. Koerfer,¹ A. El Banayosy,¹ ¹Clinic of Thoracic and Cardiovascular Surgery, Research Laboratory, Ruhr-University Bochum, Heart- and Diabetescenter NRW, Bad Oeynhausen, NRW, Germany; ²Institute of Physiological Chemistry I, Ruhr-University Bochum, Bochum, NRW, Germany; ³Department Cardiology & Pneumology, University Goettingen, Goettingen, NS, Germany

(382) The Hub-And-Spoke System in Treating Acute Cardiogenic Shock: Who Survives?

A.R. Kherani,¹ F.H. Cheema,¹ M.C. Oz,¹ V.K. Topkara,¹ D.A. Wilson,¹ A.F. Cheema,¹ M.J. Garrido,¹ J.A. Morgan,¹ D.W. Vigilance,¹ Y. Naka,¹ ¹Surgery, Columbia University College of Physicians & Surgeons, New York, NY

(383) Novel Application of Thoratec VAD as a Paracorporeal Total Artificial Heart

A. El-Banayosy,¹ L. Arusoglu,¹ M. Morshuis,¹ L. Kizner,¹ R. Koerfer,¹ ¹Cardiac Surgery, Heart Center NRW, Bad Oeynhausen, Germany

(384) Mechanical Circulatory Support of 22 Patients with the Original Uncoated Debaquey VAD

M.J. Wilhelm,¹ D. Hammel,¹ C. Schmid,¹ T.D. Tjan,¹ M. Rothenburger,¹ A. Rhode,¹ T. Kaan,¹ C. Vahlhaus,² C. Schmidt,³ H.H. Scheld,¹ ¹Department of Thoracic and Cardiovascular Surgery, University of Muenster, Muenster, Germany; ²Department of Cardiology, University of Muenster, Muenster, Germany; ³Department of Anesthesiology and Operative Intensive Care, University of Muenster, Muenster, Germany

(385) A New Technique for Assessing Myocardial Improvement Using Pressure-Volume Loops during Mechanical Circulatory Assistance

K.A. Kadipasaoglu,¹ M. Ferrari,¹ M. Croitoru,¹ T.J. Myers,¹ I.D. Gregoric,¹ B. Radovancevic,¹ O.H. Frazier,¹ Cardiovascular Research, Texas Heart Institute, Houston, TX

(386) Effect of Mechanical Unloading of Left Ventricle on Right Ventricular Remodeling

J.C. Osorio,¹ A. Kherani,¹ R.J. Mosca,¹ J.M. Quaegebeur,¹ M.C. Oz,¹ L.J. Addonizio,¹ S. Mital,¹ J. Fal,¹ ¹Pediatrics & Cardiothoracic Surgery, Columbia University, New York, NY

(387) Ito and Ir Potassium Channel (K+) Expression and Regulation during Severe Left Ventricular Dysfunction (LVD) and Ventricular Unloading

S. Maybaum,¹ X. Qu,¹ A. Magnano,¹ J. Fal,² A. Kherani,² P. Mazzeo,² D. Mancini,¹ M. Oz,² Y. Naka,² H. Skopicki,¹ ¹Medicine, Columbia University, NY, NY; ²Surgery, Columbia University, NY, NY

(388) Incidence of Right Ventricular Failure and the Role of Concomitant Coronary Revascularization during LVAD Implantation

S.J. Park,¹ S. Huerd,¹ B. Fogelson,¹ R. Segurola,¹ W. Hays,¹ S. Ormaza,¹ L.W. Miller,² ¹Surgery, University of Minnesota, Minneapolis, MN; ²Medicine, University of Minnesota, Minneapolis, MN

(389) Screening Sacle for Predicting Outcomes in High-Risk Potential Heart Transplant Candidates under Extracorporeal Membrane Oxygenation

Y.S. Chen,¹ H.Y. Yu,¹ J.C. Chen,¹ W.J. Ko,¹ S.C. Huang,¹ F.Y. Lin,¹ S.S. Wang,¹ ¹Department of Surgery, National Taiwan University Hospital, Taipei

(390) Initial Clinical Experience with the Thoratec IVAD: A Versatile Implantable Uni- or Bi-Ventricular Assist Device

S. Tsui,¹ M. Slaughter,² J. Hill,³ N. Burton,⁴ R. Körfer,⁵ ¹Department of Cardiothoracic Surgery, Papworth Hospital, Cambridge, United Kingdom; ²Department of Cardiothoracic Surgery, Christ Hospital and Medical Center, Chicago, IL; ³Department of Cardiothoracic Surgery, California Pacific Medical Center, San Francisco, CA; ⁴Department of Cardiothoracic Surgery, Inova Fairfax Hospital, Falls Church, VA; ⁵Department of Cardiothoracic Surgery, Heart Center NRW, Bad Oeynhausen, Germany

(391) Perioperative Use of Neseritide in Heart Failure Patients Undergoing Implantation of Left Ventricular Assist Device

B. Radovancevic,¹ B. Vrtovec,¹ A.P. Yazdanbakhsh,¹ P.A. Odegaard,² C.D. Thomas,¹ R.M. Delgado,¹ O.H. Frazier,¹ ¹Cardiopulmonary Transplantation, Texas Heart Institute, Houston, TX; ²Transplant Service, St. Luke's Episcopal Hospital, Houston, TX

(392) Outcomes from 100 Patients Treated with Implantable LVAD Therapy: Are We Ready for Destination Therapy?

I.A. Smolens,¹ H.J. Patel,¹ S. Wright,¹ D.B. Dyke,² K.D. Aaronson,² E.D. Pagani,¹ ¹Section of Cardiac Surgery, University of Michigan, Ann Arbor, MI; ²Division of Cardiology, University of Michigan, Ann Arbor, MI

(393) The Risk of Thromboembolism with the Novacor Left Ventricular Assist Device

J.G. Rogers,¹ G.A. Ewald,¹ C.M. Hanselman,¹ K.S. Shelton,¹ M.K. Pasque,² ¹Cardiology, Washington University School of Medicine, St. Louis, MO; ²Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO

(394) Serious Abdominal Complications of Intra-Peritoneal Placement of Left Ventricular Assist Devices

P. Tansley,¹ E. Birks,¹ P. McDonald,¹ M. Hipkin,¹ J. Hardy,¹ C. Bowles,¹ N. Banner,¹ A. Khaghani,¹ M. Yacoub,¹ ¹Cardiothoracic Surgery, Harefield Hospital, Harefield, Middlesex, United Kingdom

(395) Cardiac Rhythm during and after Explantation of Left Ventricular Assist Devices (LVAD) Using the Harefield Recovery Programme

J. Hardy,¹ P. Tansley,¹ E. Birks,¹ M. Hipkin,¹ A. Khaghani,¹ N. Banner,¹ M. Yacoub,¹ ¹Cardiothoracic Surgery, Harefield Hospital, Harefield, Middlesex, United Kingdom

(396) Proteomic Analysis of Changes in "Total" Protein Expression during Bridge to Clinical Recovery Using Left Ventricular Assist Devices (LVADs)

M.J. Dunn,¹ J. Weekes,¹ E.J. Birks,¹ P.D. Tansley,¹ A. Khaghani,¹ N.R. Banner,¹ M.H. Yacoub,¹ ¹Cardiothoracic Surgery, Royal Brompton and Harefield Hospital, Harefield, Middlesex, United Kingdom

(397) Cerebral Hyperperfusion Syndrome Following LVAD Implantation

A.J. Boyle,¹ S.J. Park,¹ M.M. Colvin-Adams,¹ K.K. Liao,¹ S.M. Ormaza,¹ J.M. Thompson,¹ L.W. Miller,¹ ¹Cardiology, University of Minnesota, Minneapolis, MN

(398) Cytoskeletal Protein 4.1 Isoforms, Newly Discovered in Heart, Are Differentially Overexpressed in the Myocardium of Patients with Deteriorating Heart Failure

E.J. Birks,¹ P.M. Taylor-Harris,² L. Felkin,¹ A.M. Maggs,² R. Franklin,¹ N.R. Banner,¹ A. Khaghani,¹ P. Barton,¹ A. Baines,² J.C. Pinder,² M.H. Yacoub,¹ ¹Harefield Research Foundation, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom; ²Randall Centre for Molecular Mechanisms of Cell Function, Guys Campus, Kings College London, London, United Kingdom

(399) Bridge to Heart Transplant with the Continuous Axial Flow DeBakey VAD

M. Lanfranconi,¹ C.F. Russo,¹ T. Colombo,¹ E. Ribera,¹ G. Bruschi,¹ M. Frigerio,² E. Vitali,¹ ¹Cardiac Surgery Division, "A De Gasperis" Department Ospedale Niguarda Cà-Granda, Milano, Italy; ²Cardiac Failure & Heart Transplant Program, "A De Gasperis" Department Ospedale Niguarda Cà-Granda, Milano, Italy

(400) Significant Reduction in Major LVAD Device Failures: Comparison of the Heartmate[®] VE and XVE LVAS

F.D. Pagani,¹ H.J. Patel,¹ S. Wright,¹ B.D. Dyke,² K.D. Aaronson,² ¹Section of Cardiac Surgery, University of Michigan, Ann Arbor, MI; ²Division of Cardiology, University of Michigan, Ann Arbor, MI

(401) Readmission Following Discharge on LVAD: Implications for Permanent Support

M.K. Banbury,¹ K.J. Hoercher,¹ P.M. McCarthy,¹ J.L. Navia,¹ N.G. Smedira,¹ ¹The Kaufman Center for Heart Failure, The Cleveland Clinic Foundation, Cleveland, OH

(402) Prior HLA Allosensitization Predisposes Patients to Become and Remain Highly Sensitized after LVAD Implantation

S.G. Drakos,¹ J.W. Long,¹ J.C. Stringham,¹ T.C. Fuller,¹ M.E. Hagan,¹ K.E. Nelson,¹ S.A. Moore,¹ E.M. Gilbert,¹ D.G. Renlund,¹ ¹UTAH Cardiac Transplant Program, University of Utah School of Medicine and LDS Hospital, Salt Lake City, UT

(403) Predictors of Poor RV Function Following LVAD Implantation

A.J. Boyle,¹ S.J. Park,¹ M.M. Colvin-Adams,¹ S.M. Ormaza,¹ K.K. Liao,¹ J.M. Thompson,¹ L.W. Miller,¹ ¹Cardiology, University of Minnesota, Minneapolis, MN

(404) Pre-Operative Predictors of Outcome after VAD: Can We Predict Survivors?

J. Harding,¹ L.R. Goldberg,¹ M.L. O'Hara,² M.A. Acker,² M.L. Jessup,¹ ¹Cardiovascular Division - Heart Failure/Transplant, University of Pennsylvania, Philadelphia, PA; ²Cardiothoracic Surgery Division, University of Pennsylvania, Philadelphia, PA

(405) Natriuretic Peptides as Predictors of Clinical Course in Patients with End-Stage Heart Failure

E.V. Potapov,¹ F.D. Wagner,¹ F.K. Hennig,¹ C. Müller,² H. Lehmkuhl,¹ R. Sodan,¹ H. Hausmann,¹ B.A. Nasser,¹ R. Hetzer,¹ ¹Thoracic and Cardiovascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; ²Clinical Chemistry, Charité, Humboldt University, Berlin, Germany

(406) Improved Overall Outcome with the Micromed DeBakey LVAD as Bridge To Transplant

S. Salzberg,¹ M. Lachat,¹ A. Kadner,¹ G. Zuend,¹ M. Turina,¹ ¹Cardiovascular Surgery, University Hospital Zurich, Zurich, Switzerland

(407) Managing Patients with Left Ventricular Assist Device at Home, Results with 37 Patient-Years of Experience

R. Khodaverdian,¹ K.E. Nelson,¹ B.L. Porter,¹ A.J. Powers,¹ T.F. Nielson,¹ J.W. Long,¹ ¹Utah Artificial Heart Program, LDS Hospital, Salt Lake City, UT

(408) Mechanical Support for Isolated RV Failure in Post-Cardiotomy Patients

N. Moazami,¹ M.K. Pasque,¹ M.R. Moon,¹ R.L. Herren,¹ M.S. Bailey,¹ J.S. Lawton,¹ R.J. Damiano,¹ ¹Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO

(409) Bridge to Cardiac Transplantation: Comparison of LVAD Versus Inotropic Support

S.D. Moffatt,¹ P. Demers,¹ M. Chan,² P.E. Oyer,¹ B.A. Reitz,¹ R.C. Robbins,¹ ¹Cardiothoracic Surgery, Stanford University, Stanford, CA; ²Cardiovascular Medicine, Stanford University, Stanford, CA

EXHIBIT BOOTH LOCATIONS

VORSAAL

Roche
SangStat
Scanlan International, Inc.

PLATZL

Micromed Technology, Inc.

ANTEKAMMER

Fujisawa

SEITENGALERIE

Actelion Pharmaceuticals
Asanus Medicintechnik GmbH
Medical Insight Research
Novartis
Thoratec Corporation
Vitrolife

MARMORSAAL

Acorn Cardiovascular Inc.
Arrow International
Berlin Heart AG
Terumo Europe NV
World Heart Corporation

WINTERGARTEN

Biotest Pharma GmbH

EXHIBITING COMPANY INFORMATION

Acorn Cardiovascular, Inc.

601 Campus Drive, St. Paul, MN 55112
Phone: 651-286-4859 | Fax: 651-286-4855
Contact: Laura Von Holtum

Actelion Pharmaceuticals

Schönblickstrasse 3, Meggen 6045 Switzerland
Phone: 41-41-377-5342 | Fax: 41-41-377-5334
Contact: Sabine Stotz

Arrow International

Hill & George Avenue, Reading, PA 19610
Phone: 610-378-1606 | Fax: 610-478-3184
Contact: Sue Prutzman

ASANUS Medizintechnik GmbH

Gewerbepark 2, Neuhasen ob Eck D78579, Germany
Phone: 49-7467-9479 12 | Fax: 49-7467-9474 50
Contact: Herr Schorer

Berlin Heart AG

Wiesenweg 10, Berlin 10825, Germany
Phone: 49-30-8187-2678 | Fax: 49-30-8187-22-2678
Contact: Pia-Maria Goemer

Biotest Pharma GmbH

Landsteinerstr 5, Dreieich 63303, Germany
Phone: 49-6103-801-462 | Fax: 49-6103-801-880
Contact: Wilhelm Schneider

Elsevier Science Inc.
360 Park Avenue South, New York, NY 10010
Phone: 212-633-3923 | Fax: 212-633-3913

Fujisawa GmbH
Neumarkter Strasse 61, D-81673 Munich Germany
Phone: +49 89 45 44 2175 | Fax: +49 89 45 44 2030
Contact: Martin Hess

ISHLT Registry and MCSD Database
c/o TII/UNOS, 700 N. 4th Street, Richmond, VA 23218
Phone: 804-782-4922 | Fax: 804-782-4809
Contact: Denise Wise

The ISHLT Transplant Registry and mechanical Circulatory Device Database collect worldwide transplant and assist device data. Data are utilized for scientific study to increase the body of knowledge regarding thoracic transplantation and cardiac device management. This year's exhibit will feature online availability of center-specific analysis for review by ISHLT members who represent the centers submitting the data. In addition, ISHLT members can view data entry screens for the MCSD Database and receive information on how to provide data to the transplant and device databases.

Medical Insight Research
c/o Putnam Associates
25 Burlington Mall Rd, 65th Floor, Burlington, MA 01803
Phone: 781-273-5480 | Fax: 781-273-5484
Contact: Nicolaas Kelder

MicroMed Technology, Inc.
8965 Interchange Drive, Houston, TX 77054
Phone: 713-838-9210 | Fax: 713-838-9214
Contact: Tammy Pitts

Novartis
Transplantation and Immunology
WSJ 210.4.33, Lichtstrasse 35, CH-4002 Basel, Switzerland
Phone: 41-61-324-8342/5329 | Fax: 41-61-324-9630
Contact: Gerard Cooney

Roche
PBC, Bldg. 74/4-O, 4070 Basel, Switzerland
Phone: + 41-61-688 71 26 | Fax: + 41-61-688 14 09
Contact: Nils Meyer

SangStat
58, avenue Debourg, B.P. 7055, F-69348 Lyon cedex 07 France
Phone: 33 437 28 16 49 | Fax: 33 437 28 16 95
Contact: Corinne Madec

Scanlan International, Inc.
One Scanlan Plaza, St. Paul, MN 55107
Phone: 651-298-0997 | Fax: 651-298-0018
Contact: Jennifer Cobian

Terumo Europe N.V.
Siemensstrasse 1, Borken 46325 Germany
Phone: 49-2861-808-208 | Fax: 49-2861-605-010
Contact: Ingrid Craninckx

Thoratec Corporation
6035 Stoneridge Drive, Pleasanton, CA 94568
Phone: 925-734-4003 | Fax: 925-847-8574
Contact: Gina Crabb

Vitrolife

Molndalsvagen 30, Goteborg 41263 Sweden
Phone: 46-31-721-80-00 | Fax: 46-31-721-80-95
Contact: Beatrice Mikaelsson

World Heart Corp.

1 Laser Street, Ottawa, ON, K2E 7V1 Canada
Phone: 613-226-4278 | Fax: 613-723-8522
Contact: Jennifer Poulson

FUTURE ISHLT MEETINGS

NOVEMBER 8 - 9, 2003 (TENT.)

FALL EDUCATION MEETING

immediately preceding the American Heart Association Meeting
Orlando, FL

APRIL 21 - 24, 2004

ISHLT 24TH ANNUAL MEETING AND SCIENTIFIC SESSIONS

San Francisco, California

APRIL 6 - 9, 2005

ISHLT 25TH ANNUAL MEETING AND SCIENTIFIC SESSIONS

Philadelphia, PA